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Prevention of mother-to-child transmission (PMTCT) services were established in Cape Town 
during 1999, and antiretroviral treatment (ART) services for pregnant women with advanced 
stage HIV were implemented in 2004. This thesis uses a mixed-methods approach to evaluate 
these services between 2005 and 2008, and describes the challenges to PMTCT programme 
coverage in this setting.  
Five chapters, each submitted for publication, are presented. The first paper presents results 
from a cross-sectional study utilizing cord blood surveillance to ascertain PMTCT programme 
coverage in 2007-2008. Cord blood analysis showed that 58% of HV-infected women received 
standard of care treatment according to guidelines. Missed opportunities for intervention were 
found at different stages of the PMTCT care pathway, including failure to test for HIV and sub-
optimal regimen adherence during labour. Discrepancies between documented coverage and 
cord blood coverage suggested a need for strengthened routine data collection and reporting. 
The second and third papers examine ART initiation in eligible women accessing antenatal 
services in 2005 and 2008. Three service models are described, defined by the proximity of the 
antenatal service to the ART service. In these retrospective cohorts, data showed that uptake of 
ART in pregnancy increased from 51% in 2005 to 52% in 2008. In 2005, there was no difference 
in uptake between service models. However, the ‘integrated’ service with outreach staff 
providing ART in the antenatal facility initiated significantly more women in 2008. In both 
papers, late antenatal presentation was associated with failed coverage. The fourth paper 
describes HIV-infected women and service providers’ perceptions of challenges to ART initiation 
in pregnancy, and the final paper discusses women’s experience of HIV-positive pregnancy and 
motherhood. Paper 4 suggests that a triple emotional burden of pregnancy, HIV-positive 
diagnosis and the requirement to start lifelong therapy, impacts on ART uptake, while Paper 5 
suggests that considerable emotional work is undertaken by these women to maintain their 
social identities as mothers. The thesis concludes that PMTCT coverage remains sub-optimal in 
this setting. Novel approaches to service delivery which focus on missed opportunities for 
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Chapter 1 — Introduction 
1.1 Background 
Antiretroviral (ARV) regimens administered to pregnant women and exposed infants during 
pregnancy and postpartum have been shown to be highly effective in the prevention of 
mother-to-child transmission of HIV (PMTCT) and the preservation of maternal health.1-7 
Paediatric AIDS has been virtually eliminated in resource-rich settings, yet children account 
for one in six new HIV infections in sub-Saharan Africa daily, the majority of these 
infections being attributable to mother-to-child transmission (MTCT).8  
The epidemiology of HIV in children reflects the burden of disease in women, and 
AIDS is the leading cause of death among women of reproductive age worldwide.9 HIV has 
contributed to considerable increases in maternal mortality in sub-Saharan Africa, and has 
hampered the progress towards meeting Millennium Development Goal (MDG) 5, which 
aims to improve maternal health.10,11 HIV-infected women experience greater morbidity and 
mortality than uninfected women,12 and initiation of antiretroviral treatment in women 
during pregnancy may be both lifesaving for women, and impact on the reduction of vertical 
transmission.13 
Prevention of mother-to-child (PMTCT) programmes have been implemented across 
Africa, where the highest proportion of HIV-infected pregnant women live.11,14 Yet, 
compared to resource-rich settings and the rapid scale-up of national antiretroviral therapy 
(ART) programmes in countries with a high burden of disease, progress in the expansion and 
coverage of PMTCT programmes has for the most part lagged behind expected targets, 
despite reports that 70% of HIV-infected pregnant women in these settings access antenatal 
services at least once in pregnancy.15 Service- and patient-related factors such as poor service 











up, limit the public health effectiveness and impact of these programmes.16 Programme 
estimates of global PMTCT coverage in 2009 indicated that 53% of HIV-infected pregnant 
women and 35% of exposed infants received antiretroviral drugs.17 
Improved approaches to health system delivery of PMTCT programmes and the use 
of safer and more acceptable treatment regimens with proven effectiveness have been 
promoted over the past decade.18 While some ground has been gained in attenuating the 
impact of HIV infection in children through improved PMTCT programme effectiveness, 
antiretroviral prophylaxis in pregnancy and postpartum is of little therapeutic benefit to 
mothers, particularly in women with advanced stage disease. Children of mothers who have 
died of AIDS have a 3- to 4-fold increased risk of mortality, regardless of HIV status.19,20 A 
recent shift in focus from simple pregnancy-based prophylactic interventions to reduce 
vertical transmission, first demonstrated in the 1990s, to the recognition of the importance 
of maternal health situated in models of family-based care has resulted in the more 
comprehensive PMTCT strategy found in current international guidelines.21 Not only does 
this approach focus on prevention of paediatric infection, it also incorporates additional 
elements to target the primary prevention of HIV in women of reproductive age, the 
prevention of unintended pregnancy in HIV-infected women, and the identification of 
women who require treatment for their own health, emphasising the need to link them and 
their families to HIV treatment and care services.22  
Historically, PMTCT programme interventions in the field have concentrated primarily 
on the third and fourth elements of the strategy, focusing on women who are identified as 
HIV-infected and already pregnant.23 While these approaches have been shown to drastically 
decrease paediatric infection in resource-constrained settings and improve maternal and child 
health, challenges remain in the implementation of PMTCT programmes in health systems 











pregnant women who require a continuum of care in the context of maternal and child 
health services.24,25  
In the WHO’s commitment to global PMTCT scale-up, integration and the forging of 
service linkages has been earmarked as an area of focus to promote stronger maternal, infant 
and child and reproductive health programmes.21 Pregnancy is a critical time for identifying 
HIV infection in women for prevention of MTCT, but antenatal services can also identify a 
cohort of women with advanced stage disease and facilitate opportunities to link them to 
lifelong antiretroviral treatment (ART).24,26 Thus, within PMTCT programmes there is the 
potential to integrate prevention and treatment, two areas of service delivery that are 
frequently independently defined.27 Furthermore, recent scientific developments have led to 
the use of extended ART regimen combinations for maternal treatment and/or mother-
infant prophylaxis, to cover the breastfeeding period in order to mitigate postpartum 
transmission and to increase programme effectiveness by lowering late postpartum 
transmission rick, and providing women with a broader range of infant feeding options.1,28-30  
1.2 Rationale 
This thesis is situated within a larger body of operational research which evaluates the 
effectiveness of PMTCT programmes in resource-constrained settings. The population 
under study is drawn from HIV-infected pregnant women attending antenatal services in 
Cape Town, South Africa, and the research concentrates on PMTCT and ART treatment 
services for HIV-infected pregnant women within a broader social context of pregnancy and 
motherhood. Operational research into programme implementation is useful on a local level 
because it can provide context-specific evidence on the gaps and weaknesses which may 
affect service uptake and programme effectiveness. As a result, programmatic improvement 
can be effected by addressing missed opportunities that are identified through service-based 











availability of ART services for women in pregnancy within the Cape Town service setting. 
Furthermore, the challenges faced by HIV-infected women in initiating ART during 
pregnancy have not been investigated in this population. Overall, there is a paucity of 
research which documents the lived experience of HIV-positive motherhood in resource-
constrained settings. 
Historically, PMTCT programmes have highlighted the weaknesses of health services 
in resource-constrained settings but at the same time, have presented an opportunity for 
health systems strengthening.9 The starting premise of this thesis is based upon the argument 
made elsewhere15,23,25-27that the transfer of scientific progress in PMTCT research to 
resource-constrained settings has not been optimized, and a gap remains between efficacy of 
PMTCT interventions and the operational effectiveness of these programmes. Within ten 
years of publication of the first trial results that demonstrated the efficacy of PMTCT 
regimens in 1994, MTCT had been virtually eliminated in well-resourced countries.27 In the 
United States and the United Kingdom, the early identification of HIV-infected women in 
pregnancy through universal opt-out HIV screening; the administration of effective 
antiretroviral regimens to women who require it for their own health or for prophylaxis; the 
use of caesarean section and the complete avoidance of breastfeeding through the use of safe 
replacement feeding, has led to vertical transmission rates of 1-2%.31 A call has been made 
for resource-constrained settings to work towards the virtual elimination of paediatric 
HIV.32,33 Yet PMTCT programmes in these contexts continue to lag behind in their 
coverage, due to a higher burden of disease, poor health system infrastructure, cost 
implications a lack of service integration as well as social and structural factors which 












The aim of this thesis is twofold. First, it documents and evaluates the coverage of the 
PMTCT programme in terms of prophylactic interventions and ART for women in Cape 
Town who require it for their own health during pregnancy. In the context of this thesis, 
coverage is defined as the proportion of the at-risk population who successfully access and 
utilize the intervention, excluding those not accessing antenatal care, or accessing antenatal 
care privately or outside the public health setting. Second, the thesis investigates the barriers 
to maternal ART initiation in pregnancy and describes the experience of HIV-positive 
motherhood. The real-world population effects of a programme are a product of 
intervention efficacy and coverage, and hence effectiveness is synonymous with programme 
impact. While this thesis does not address PMTCT outcomes directly, through the synthesis 
of these findings, it draws inferences on factors which may compromise programme 
effectiveness. Five research questions are employed to achieve these aims: 
 What proportion of HIV-infected pregnant women who access antenatal care 
in Cape Town are identified by services as requiring PMTCT interventions, 
and receive standard of care regimens by delivery? 
 What proportion of women who present at antenatal services and are 
subsequently identified as eligible to initiate lifelong ART, have started 
treatment by the time they deliver?  
 Is there a difference between selected service models for delivering ART to 
HIV-infected pregnant women with advanced disease in Cape Town, and have 
there been changes in ART coverage within these service models since the 
inception of the programme? 
 What are the perceived challenges which compromise ART initiation by HIV-











 How do HIV-infected women - pregnant and 6-month postpartum - 
experience HIV-infection during pregnancy, and furthermore, how do they 
manage HIV-positive motherhood? 
Based on the synthesis of the findings of this thesis, the concluding chapter discusses why 
programme coverage in this setting is suboptimal and makes recommendations for future 
service improvement. 
1.4 Outline 
A mixed methods approach has been applied to answer these research questions. Three 
research projects were undertaken to collect primary data used in this thesis (Table 1.1).  
 
Table 1.1 Summary of research projects, their outcomes and primary 
methodology, used in the preparation of the thesis 
 
The first entailed cord blood surveillance in the Western Cape, which formed a sub-study to 
the PEARL Study, conducted in four African countries between 2007 and 2010.35  The 
PEARL Study was a two-part evaluation of the effectiveness of PMTCT services at both the 
community and facility level. The second comprised two evaluations of ART initiation in 






Cross sectional survey 
using clinical folders and 
cord blood specimens
Retrospective cohort study 
using service registers and 
folders
Retrospective cohort study 
using service registers and 
folders
Service delivery approaches for 
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three different service delivery models in Cape Town services in 2005 and 2008. The third 
was a qualitative study among health care providers and HIV-infected pregnant or 
postpartum women, which investigated the barriers to ART initiation in pregnancy and the 
experience of HIV-positive motherhood. 
The projects’ outcomes, which pertain to retrospective service data from 2005 to the 
end of 2008, are reported in five self-contained chapters that have been prepared for 
publication during the period of registration for the PhD. Chapter 2 reviews the literature 
and places the research within the broader context of PMTCT implementation research. The 
first research project is described in Chapter 3, and concerns the evaluation of PMTCT 
programme coverage. This chapter entails an analysis of a cord blood surveillance exercise at 
three Cape Town antenatal services during 2007-2008. Overall coverage is analysed and 
comparisons are drawn between the documentation of interventions dispensed and their 
presence in cord blood. Through the analysis of the PMTCT cascade, missed opportunities 
for prevention are identified.  
The second research project is described in Chapters 4 and 5, and concerns ART 
initiation in Cape Town. These two chapters present an evaluation of ART initiation among 
eligible pregnant women during the early stages of the programme in 2005, and in a follow-
up study conducted in 2008. Three service delivery models are compared in terms of the 
proportion of eligible women who initiate ART before delivery, in order to provide insight 
on the optimal model for ART provision for pregnant women within Cape Town health 
services.  
While these two projects present quantitative service-related, data, the third project 
qualitatively examines the challenges to initiating ART in pregnancy and women’s lived 
experience of HIV infection, pregnancy and motherhood. Chapters 5 and 6, which are based 
on the results of this project, present the results of in-depth interviews with service providers 











factors that compromise treatment coverage, Chapter 5 examines the barriers to ART 
initiation described by women who were identified as eligible for lifelong treatment in 
pregnancy. Chapter 6 explores women’s perceptions of HIV infection in pregnancy, and 
how women manage HIV-positive motherhood. Since much evidence on the experience of 
HIV-positive motherhood emanates from resource-rich settings, this chapter uses developed 
country discourse to compare and contrast the experiences of HIV-positive mothers in the 
context of the South African HIV epidemic. 
The final chapter synthesises the results from the three research projects into an 
account of factors that influence PMTCT programme effectiveness in this setting. 
Conclusions are drawn about programme coverage, which according to the data presented in 
the thesis, is suboptimal. While these results are in keeping with findings from other African 
settings discussed in the literature review, the possible reasons for compromised programme 
effectiveness, and proposed interventions for improvement, are discussed in the context of 
both the evidence presented in each paper and current international trends in PMTCT. The 











Chapter 2— The development of PMTCT programmes: a 
literature review 
This review establishes the background to, and the conceptual framework for, this thesis. It 
covers the development of PMTCT interventions and the successes and failures resulting 
from their implementation in field settings over the past 20 years. Specific evidence 
pertaining to the establishment and expansion of the South African PMTCT programme is 
presented in order to provide the context for the rest of the thesis. While this thesis does not 
cover the impact of infant feeding on MTCT, the final part of the review focuses on current 
international scientific trends that address postpartum transmission, and are emerging as 
increasingly important challenges. These scientific advancements, which provide the basis for 
future operations research, are discussed in the concluding chapter of this thesis. 
This literature review is structured around themes which are pertinent to the empirical 
research conducted in the ensuing chapters. In order to lay the ground work for the rest of 
this thesis, Section 2.1 of this literature review provides an account of the first decade of 
PMTCT progamme implementation. After briefly outlining the risk factors for MTCT, this 
section describes the transfer of evidence from clinical trials to the field, and the evidence for 
early successes and failures of simple drug regimens introduced to resource-poor contexts. 
Since this thesis concerns a South African setting, evidence from sub-Saharan Africa is 
afforded particular weight here. 
Sections 2.2 and 2.3 follow chronologically from Section 2.1, by documenting the 
emergence of ART for pregnant women in resource-poor contexts. The idea of service 
linkage between ART and antenatal care is introduced in Section 2.3 and early evidence for 
the feasibility of integrated ART and antenatal services is discussed. The published literature 











This section provides the background for the content of Chapters 4 and 5 of the thesis, 
which evaluate different service delivery models for ART initiation in pregnancy, these 
models varying in terms of the proximity of antenatal care to ART services. 
While the abovementioned sections situate the thesis within a broader context of 
PMTCT programme development, Section 2.4 reviews the literature on challenges to 
PMTCT coverage and ART initiation. This section covers cross-cutting themes pertinent to 
all the chapters, including late antenatal presentation (Chapters 4, 5 and 6); reluctance to test 
for HIV in pregnancy, leading to unknown HIV status (Chapter 3); psychosocial aspects of 
HIV-positive pregnancy and motherhood (Chapter 7) and challenges to the initiation of 
ART and adherence during pregnancy and postpartum (Chapter 6). Other themes, including 
access and service-related barriers to PMTCT and counselling and testing in the peripartum 
are also discussed as important barriers to PMTCT coverage, however, are only indirectly 
associated with the empirical research in this thesis. 
Section 2.5 provides the background to the research setting of this thesis, through the 
documentation of the PMTCT programme from inception in 1999 to 2011 in the Western 
Cape and other parts of South Africa. This provides local context for the data presented in 
this thesis, which range from 2005 to 2008. Section 2.5 also documents evidence of poor 
routine data collection within the PMTCT programme which compromises the reporting of 
programme progress. 
Although beyond the scope of this thesis, infant feeding is emerging as an important 
challenge to prevention of postpartum vertical transmission. Section 2.6 covers some of the 
major findings from postpartum prevention studies and interventions reported around 2009, 
which have shaped the current WHO PMTCT guidelines (2010).36 The presentation of this 
evidence leads into Section 2.7, which focuses on the call for the elimination of paediatric 
HIV and current PMTCT policy in South Africa. Section 2.8 concludes with a synthesis of 











2.1 Prevention of mother-to-child transmission: the first decade 
2.1.1 Risk factors for MTCT 
MTCT accounts for the majority of paediatric infections worldwide, and can occur during 
pregnancy, labour and delivery or postpartum during breastfeeding.37 In non-breastfeeding 
populations, transmission risk ranges between 15-30% , this risk being increased to 20-45% 
in breastfeeding populations.9 Other host characteristics include maternal immune factors, 
including neutralising antibodies; breast milk immune factors and fetal or newborn immune 
response.38,39 Genetic factors such as the foetal HLA type and maternal-foetal HLA 
concordance may increase risk of MTCT, due to limited effectiveness of the foetal immune 
response against maternal HIV.39 Certain viral characteristics have been associated with 
transmission, and one or very few viral variants are reported more commonly than multiple 
variants in infected infants. The evidence on HIV subtype differences in vertical 
transmission, however, is mixed.39  
There is a strong relationship between high maternal viral load, low CD4 cell count 
and elevated transmission risk.40 Perinatal MTCT risk can be reduced to around 2% with the 
use of antiretroviral regimens and the complete avoidance of breastfeeding.3,4,7,41 Elective 
caesarean section and the avoidance of prolonged rupture of membranes have also been 
shown to reduce transmission risk.42,43 Recent evidence supporting the use of antiretrovirals 
administered to mothers and/or infants in the postpartum period can reduce the risk of 
MTCT to 5% in breastfeeding populations.44 
2.1.2 Evidence from clinical trials 
In 1994, the ground-breaking Pediatric AIDS Clinical Trials Group (PACTG) protocol 076 
demonstrated marked reductions in vertical transmission through the administration of 
antepartum azidothymidine (AZT) from 14 weeks gestation, intrapartum and to the newborn 











weeks in non-breastfeeding women.2 In the United States and other well-resourced 
countries, immediate changes were made to public health policy to implement this 
intervention, frequently in conjunction with caesarean section.45 The complexity and cost of 
this regimen prevented its wide-spread use in Africa until results from trials in Thailand and, 
later, Côte d’Ivoire demonstrated the efficacy of shorter course oral AZT , which targeted 
the antenatal and peripartum period, reducing transmission risk by around 50% and 44% 
respectively.46,47 To account for breastfeeding populations, DITRAME/ANRS 0049a 
reported a reduced MTCT risk of 38% in Burkina Faso and Côte d’Ivoire at 6 months 
postpartum,48 while later the addition of lamivudine (3TC) to increase antiviral potency in 
combination with AZT to mother ante-, peri- and postpartum to the mother and infant 
demonstrated a reduction in transmission risk of 61% at six weeks.49 However, little impact 
was found for AZT on transmission risk during breastfeeding.27 
Around the same time, the efficacy of single dose nevirapine (sdNVP) was 
demonstrated in a breastfeeding population in Uganda.50 Based on the assumption that a 
single dose intervention targeted at the neonate and ingested by the mother at the onset of 
labour, followed by an infant dose within 72 hours of delivery, would be sufficient to reduce 
vertical transmission risk, HIVNET 012 reported a 47% efficacy between 14 -16 weeks.51 As 
a nonnucleoside reverse-transcriptase inhibitor (NNTRI) with a long half-life, sdNVP was 
deemed simple to administer and inexpensive to use in resource-constrained settings and it 
was heralded as a breakthrough for PMTCT where medical infrastructure is inadequate, not 
least because sdNVP could be used in breastfeeding populations with poor access to 
antenatal care.9,18 However, protection was not sustained in breast feeding populations with 
infections being reported from 56 days to 18 months follow up.51,52 As the fifth trial to be 
reported among breastfeeding populations, the South African Intrapartum Nevirapine Trial 
(SAINT) compared regimens from the PETRA and HIVNET trials, notably multiple dose 











2000, in order to take into consideration local context and country-level programme capacity, 
the WHO and UNAIDS recommended three options for PMTCT including short course 
AZT or AZT/LMD, sdNVP and exclusive breastfeeding with early weaning in resource-
constrained settings, depending on feasibility, efficacy, acceptability and cost.54  
2.1.3 Field effectiveness of early PMTCT programmes in resource-
constrained settings 
These successes paved the way for a series of pilot projects for the provision of PMTCT 
services in resource-constrained countries.18,55 In 2001, targets of reducing the proportion of 
vertically infected children by 20% by 2005 and by 50% by 2010 were set by the United 
Nations General Assembly in the Declaration of Commitment on HIV/AIDS.56 
UNAIDS/UNICEF, WHO and the World Bank launched projects focusing on short course 
AZT in Botswana, Burundi, Cote d'Ivoire, Honduras, India, Kenya, Rwanda, Tanzania, 
Uganda, Zambia, and Zimbabwe. United Nations agencies and global funding initiatives, 
such as the Global Fund and PEPFAR , as well as pharmaceutical companies supported the 
expansion of sdNVP interventions.57 These efforts were also supported from as early as 1999 
in 11 countries in sub-Saharan Africa, Russia and Thailand by the Elizabeth Glazer Pediatric 
AIDS Foundation’s (EGPAF, through support of the Gates Foundation and other private 
donors) “Call to Action”.14,58,59 With the goal of expanding access to PMTCT programmes in 
these settings, EGPAF projects focussed on the integration of PMTCT within existing 
maternal and child health services, the training and re-deployment of staff to deliver the 
services, and the promotion of new cadres of staff such as lay health workers, community 
workers and traditional birth attendants to assist with programme strengthening. To assist 
with programme uptake, these countries also applied different counselling and testing 
approaches incorporating opt-out counselling and rapid HIV testing. Choice of ARV 
regimen was determined by country on the basis of large scale feasibility and cost, with most 











2.1.4 Early evidence of missed opportunities for PMTCT coverage 
Optimal PMTCT programme coverage is reliant on the completion of a series of 
interventions through pregnancy and after birth, including access of antenatal/PMTCT 
services; offer and acceptance of HIV testing and if HIV-infected, receipt and ingestion of  
antiretrovirals before, during and after delivery and through breastfeeding. This sequence of 
steps is known as the PMTCT cascade.60 After 2000, several African countries published 
early results from evaluations of their PMTCT pilot programmes. These reports highlighted 
some of the successes and also several challenges in early programme implementation, which 
were later to be found in other settings to lead to suboptimal programme coverage. For 
example, in Zambia, the feasibility and cost effectiveness of sdNVP as demonstrated in the 
first year of programme operations (2001), with a 72% HIV testing uptake and 57% and 
40% of women and babies receiving NVP respectively, leading to a PMTCT rate of 65 
children per 1 000 identified infected mothers.61 Lower uptake was reported in Zimbabwe, 
where despite universal testing uptake, the first pilot programme demonstrated that only 
74% of women returned to collect their test results and 24% of infected women and children 
received sdNVP.62 Return for HIV test results and low uptake of peripartum AZT were also 
a challenge in Côte d’Ivoire. In Abidjan, 80% of women opted to undergo testing and 71% 
of HIV-negative women returned for their results. Fewer infected women (60%) returned 
for their results and 64% of women received AZT up to delivery.63 Another effectiveness 
study in Abidjan (ANRS 1201/1202 Ditrame Plus), commencing in 2000, suggested uptake 
among one third of women who had been identified for a dual regimen package in 
pregnancy.64 These reports were among the first to reveal missed opportunities for 
prevention and service gaps which led to suboptimal PMTCT programme coverage. 
Field efficacy of MTCT was reported to vary widely across settings as the first 
outcomes from these early field studies were released. In Kenya, a perinatal transmission rate 











in effect from 21%.65 Another effectiveness study in this country which compared the 
sdNVP regimen from HIVNET 021 to the Thailand study comprising AZT from 36 weeks 
and during labour, reported higher MTCT among those who received sdNVP (22%) versus 
those who received the AZT protocol (9%).66 In a prospective cohort of two clinics in 
Lusaka, Zambia, the 6-week transmission rate was reported to be 11%.67 In Cameroon, an 
early effectiveness study of NVP reported 10% of children infected with HIV at 6 to 8 
weeks, similar to the results found in the SAINT trial NVP arm.53,68 
Operational issues that emerged as challenges in these settings included the need to 
adjust patient flow and accommodate nurse training in PMTCT for the purpose of scale-up 
and integrating PMTCT within antenatal services. Adequate staffing and district level 
support were seen to be integral to programme expansion, and community mobilization 
demonstrated increased service coverage in Zimbabwe.69 Patient adherence was a challenge 
in Zambia and Kenya, with the latter country reporting that male partner notification and 
partner support increased adherence in pregnancy.66,67 Most countries reported challenges to 
testing and the return for HIV results, even in the context of rapid testing, citing stigma and 
fear of partner abuse as contributory reasons.23,61,63 In Côte d’Ivoire, poor uptake in the 
ANRS 1201/1202 Ditrame Plus study was associated with lower educational level and living 
with a partner. The authors suggested that more community awareness could assist women 
with a better understanding of the PMTCT programme as well as create wider awareness of 
the benefits of HIV testing and programme uptake among women and their families.64 
2.1.5 The emergence of drug resistance 
Although not covered in this thesis, drug resistance induced by short course regimens 
resulting in incomplete suppression of HIV, was a widespread concern from 2000. This 
shaped much of the literature on PMTCT and became an issue for policy change. It was 











reducing vertical transmission was also a limitation, particularly among women with 
advanced-stage disease who had high plasma HIV RNA levels and low CD4+ cell counts.70 
Both HIVNET 01250 and the SAINT53 trials showed rapid selection of NVP-resistant HIV 
after one and two doses of NVP for up to 18 months and 13 months postpartum 
respectively in both women and children.71-75 Resistance was not limited to NVP, but was 
also reported for other short course regimens that did not fully suppress HIV, including 3TC 
and AZT, the probability of resistance increasing with higher plasma HIV RNA levels and 
regimen duration.76,77  
At the time, scientists considered whether resistance was clinically meaningful and if 
so, what the implications of antiviral agents for exposed women in subsequent pregnancies 
would be. Also, little was known about the management of women who required NNRTI-
based highly active antiretroviral (HAART, referred to here as ART) regimens for their own 
health post sdNVP exposure, and the consequences thereof.27,78 Evidence from the results of 
the Perinatal HIV prevention Trials group (PHPT-2) trial in Thailand by Lallemant et al., 
which demonstrated that the use of sdNVP to mother and infant in addition to short course 
AZT (from 28 weeks) led to an 80% reduction in transmission in formula-fed infants at one 
month.79 This marked the b ginning of a second generation of less expensive, feasible 
combination regimens for resource-constrained contexts.80 However, in subsequent follow-
up analyses of these data, Jourdain et al. confirmed that women who had previous exposure 
to sdNVP were less likely to attain virologic suppression (<50 copies/ml) than those who 
were NVP naïve. Nevertheless clinical improvements and CD4 cell counts were comparable 
in the two groups.81 Again, resistance from intrapartum dosing was notably more prevalent 
among women with high plasma HIV-1 RNA levels and low CD4 cell counts, who would 
have benefited from ART in pregnancy. This fuelled further debate around strategies to 
optimize the benefits of PMTCT for women who required prophylaxis as well as those who 











Critics of the PMTCT programme voiced concerns about the lack of attention paid to 
maternal health outcomes in light of the increasing maternal mortality attributed to AIDS 
and argued that the focus of PMTCT needed to be extended beyond the prophylactic benefit 
to the foetus. It was highlighted that women had little access to antiretroviral therapy for 
themselves, and that child outcomes were prioritised over maternal health and survival.83,84 
There was need to seek affordable and safer combination regimens which could be used in 
resource-poor settings.85 
2.1.6 The introduction of combination drug regimens for PMTCT in Africa  
Since the release of the PACTG 076 results, evidence from other trials and observational 
cohorts demonstrated that antiretroviral agents including ART, together with caesarean 
section delivery, lowered MTCT risk to around 2%.3,4,7,86 Guidelines recommending extended 
duration of ART in pregnancy combined with caesarean section and the avoidance of 
breastfeeding had been implemented rapidly in the United States, Europe and Brazil for all 
women.80,87-89 The combined use of these prolonged, effective regimens and the rapid 
mobilization of public health services; the availability of good sanitation and the cultural 
acceptability of replacement feeding contributed to dramatic decreases in MTCT reported 
around 2002-04 in these settings.19,90  
By contrast, the widening gap between resource-rich and resource-poor contexts was 
conspicuous: while there were 124 new infections among children under 13 years in the 
United States in 2005,91 at the same time vertical transmission in low and middle-income 
countries was increasing unabated, with an estimated 1800 infants becoming infected per 
day.92 While sdNVP reduced MTCT, scientists argued that there was a ‘moral imperative’ to 
improve MTCT rates in resource-constrained settings.78  
By the late 1990s, triple-drug regimens were already widely available as prophylaxis for 











resource-constrained settings required sufficient service reach and delivery to be effective. 
Since 2001, unprecedented public health mobilization towards stemming the HIV epidemic 
has occurred. While countries were committed to reducing the proportion of infected infants 
by 20% by 2005, in 2005 only 7 out of 71 countries were on track to meet this target.94 
 In 2004, revised guidelines for resource-constrained settings were published by the 
WHO in response to new scientific evidence on regimen safety and efficacy which were to 
be implemented in the context of the scale-up of PMTCT programmes.95 Several clinical 
approaches were described in these guidelines: women who did not have indications for 
ART were to receive either AZT from 28 weeks of pregnancy together with sd NVP during 
delivery and sdNVP and a week of AZT for the infant. Recognizing that combination 
regimens could be burdensome on both services and pregnant women and hence neither 
feasible nor acceptable, these guidelines made provision for alternative regimens based on 
AZT alone, short-course AZT/3TC or sdNVP alone.95 The importance of maternal health 
in resource-constrained settings was highlighted, and for the first time, it was recommended 
that women who required treatment for their own health were to receive it during 
pregnancy.95 
With the efficacy of the second generation PMTCT regimens for resource-constrained 
settings involving short course combination treatments clearly demonstrated in the PHPT-2 
trial,79 study results from Côte d’Ivoire and Botswana showed further reduction in 
transmission rates, suggesting that reducing MTCT to below 5% in Africa was possible.80 
Dual regimens were shown to be effective in a trial in Côte d’Ivoire. In this study, 
maternal AZT from 36 weeks and infant dose for 1 week postpartum, as well as sdNVP to 
mother and infant peripartum led to a transmission rate of 6.5% (95% CI: 3.9-9.1%) at 6 
weeks, a 72% reduction in transmission risk when compared to AZT alone. Importantly, 
however, this study reported that although ART regimens were not widely available for 











eligible women: 23% with AZT alone, 13% for AZT and sdNVP, and 9% for AZT, 3TC 
and sdNVP. While these results were not statistically significant, the authors reported that 
the dual regimen was particularly effective in settings where access to ART was not available, 
yet they expressed concern over the residual transmission risk among these women for 
whom ART would be more effective.96  
More promising findings were reported in Botswana around the same time. In this 
study, women were randomized to receive sdNVP or placebo in labour in addition to AZT 
from 34 weeks gestation (all infants received sdNPV and AZT for one month). One-month 
transmission rates of 4.3% (95% CI: ±2.3%) were reported for the intervention and 3.7% 
(95% CI: ±2.2%) in the placebo arm, although these results were not statistically different. In 
2002 while the trial was underway, ART was introduced for women with advanced disease 
(CD4 cell count ≤200 cells/µ/L) in Botswana, and 2.8% of women on ART transmitted 
HIV to their infants.97 For the first time, vertical transmission rates below 5% had been 
demonstrated in Africa.  
2.2 The emergence of ART for pregnant women in resource-
constrained settings 
During a technical consultation concerning the drafting of the 2004 WHO guidelines, which 
recommended treatment for women with indications for ART in pregnancy for the first 
time,95 it was acknowledged that antenatal services provided an opportunity to identify and 
link women with advanced stage disease to lifelong ART treatment and care, preventing 
residual vertical transmission at the same time.98 Yet these recommendations, based on 
successes in Europe and America, were proposed for programmes which were already 
burdened with poor uptake of simple regimens. There was virtually no evidence at this time 
to suggest the efficacy or safety of ART in resource-poor contexts and there was concern for 
the feasibility of ART initiation in pregnancy, given the challenges associated with PMTCT 











ART had been shown to be effective in Brazil where it had been used since 1998,89 however, 
the first results of ART use in a resource-constrained African setting were reported from 
Côte d’Ivoire among women on the MTCT-Plus Programme. Early results showed that of 
69 live births to women who started ART at 30 weeks gestation, there was one case of 
MTCT.99  
Around this time, the Drug Resource Enhancement against AIDS and Malnutrition 
(DREAM) programme, run in several African countries, enrolled women on triple regimens, 
regardless of CD4 cell count threshold during pregnancy, continuing for 6 months 
postpartum for prevention and lifelong therapy for women with advanced stage disease.100 
DREAM in Mozambique demonstrated strong programme uptake and 80% completion of 
the treatment protocol and transmission rates in Mozambican (across all CD4 cell counts) to 
be 3%.101 Limitations of this study may have contributed to this favourable outcome: the 
sample size was small (n=985) and selection bias may have occurred as selected Mozambican 
facilities were used. 
The preliminary evidence from the MTCT-Plus programme in Côte d’Ivoire was 
released around the time of the Abuja Call to Action in December 2005, which underscored 
the move towards the elimination of HIV in infants and young children.102 Following this, 
the WHO released revised recommendations for PMTCT in 2006. The purpose of these 
guidelines was to align PMTCT programmes with increasing international commitment to 
universal access to HIV prevention, treatment and care.103 The guidelines comprised a two-
tier strategy for the provision of standardized regimens as described in the 2004 guidelines. 
However, a public health approach was stressed within the context of human and financial 
resource constraints. The primary focus of the updated guidelines was the integration and 
streamlining of PMTCT within maternal and child health services to increase service 
utilization and broaden the reach of PMCT programmes. Not only were PMTCT 











HIV services for lifelong ART were seen as critical for increasing programme 
effectiveness.104 
2.3 Integrating ART for pregnant women within antenatal services  
Within PMTCT programmes there is the potential to integrate prevention and treatment, 
two areas of service delivery that are frequently independently defined.27 Pregnancy provides 
a valuable but time-limited opportunity for identifying HIV infection in women for the 
purpose of prevention of MTCT. Yet antenatal services can also identify a cohort of women 
with advanced stage disease and facilitate opportunities to link them to lifelong treatment 
and care.24,26 The treatment and care of pregnant women with advanced stage disease, as well 
as the extension of these services to their families has been incorporated in PMTCT strategy 
since 2002,105 this being further entrenched in the 2006 WHO PMTCT guidelines. In the 
WHO’s 2010 commitment to global PMTCT scale-up, integration and the forging of service 
linkages has been earmarked as an ongoing area of focus to promote maternal, infant and 
child and reproductive health programme strengthening.21  
2.3.1 The development of linkages between antenatal and ART services 
Service linkage is a term often used loosely and interchangeably with the term ‘integration’106 
and more recently, it also extends to the concept of ‘continuum of care’, which refers to the 
promotion of linked services to minimise patient attrition. In this thesis, the investigation of 
service linkages is central to the analysis of Chapters 4 and 5, where service models for ART 
initiation in pregnancy are discussed, and the question regarding the optimal model of service 
delivery is posed. 
Service linkage across different programmes in primary health care settings was first 
applied to the management of the elderly107 and then expanded to include among others, the 
integration of sexual and reproductive health services for women in maternal health care and 











to the need for disease control through existing mainstream services for women.108,109 The 
rationale behind integration is to meet a broader range of client needs and to have greater 
population reach, thus improving the efficiency and effectiveness of health service 
delivery.110 Since the ideology behind service linkage is very much the same, there is little 
consensus on the definition and interpretation of integrated versus linked services and hence 
the use of these terms varies within the literature.111 
The literature on service integration concedes that service linkages can be successful in 
terms of outcomes and impact under certain conditions, yet in some instances it is neither 
feasible nor beneficial.112 The latter is frequently attributed to incompatibility between policy 
and service levels: if policy guidelines are drawn up at an administrative level within a 
verticalised management framework (i.e. with separate programme directorates), the 
implementation of integrated programmes at the service level may be compromised. 
Similarly, separate funding streams for discrete programmes can add complexity to integrated 
service implementation. Health care provider training or experience, capacity and attitudes 
will influence success of integration, as will patients’ level of understanding and attitudes 
towards disease.109 
The integration of services to manage maternal and child health and services to treat 
HIV illustrates the potential effectiveness of a comprehensive service delivery approach 
through a continuum of care from the time of preconception through to postpartum and 
beyond. From as early as 2002, a four-prong strategy for PMTCT was devised to incorporate 
the prevention of primary infection of women of reproductive age; the prevention of 
unintended pregnancies among women living with HIV; the prevention of MTCT and the 
provision of appropriate treatment, care and support for HIV-infected mothers and their 
children and families.105 The third and fourth prongs are the focus of most programmes in 
the field and programme reporting, due to the complexity of monitoring and reporting on 











As described above, evidence from early field effectiveness studies suggested that PMTCT 
interventions using simple short course regimens in resource-constrained countries could be 
successfully integrated into antenatal services. PMTCT guidelines were easily incorporated 
into antenatal service delivery and had the potential for widespread coverage. Both PMTCT 
and antenatal services involved care of mothers and infants and sufficient cross-over in skills 
between staff at primary health care level.114 Antenatal services across sub-Saharan Africa 
were well attended and sdNVP and short course regimens which were limited to pregnancy 
and the peripartum were simple to administer by nurses or midwives. In particular, sdNVP 
did not require multiple antenatal visits nor laboratory monitoring and could be initiated in 
labour.80 While these simple combination regimens were shown to be feasible in resource-
constrained settings, researchers raised concerns about residual transmission attributable to 
women who required ART for their own health.96 Furthermore, sdNVP may have been more 
complex programmatically in rural areas with fewer infrastructural and staff resources to 
ensure complete coverage. There was growing recognition of the missed opportunity to 
address the health concerns of these women in the context of antenatal care, among whom 
the greatest impact of MTCT prevention could be achieved.83,115 
2.3.2 Antenatal services as a gateway to lifelong maternal ART 
HIV care and treatment services for women with advanced stage disease have more often 
been established as stand-alone services, which could threaten the continuity of care during 
pregnancy, postpartum and beyond in these women. As a result, scientists have suggested 
that the aim of a comprehensive approach to PMTCT programmes - that is, to combine 
prevention and treatment of HIV - may be compromised.24 Pregnancy is episodic, requiring 
progression from antenatal services to delivery services and postnatal baby care. In contrast, 
HIV requires ongoing longterm care. Given the separate administration of services, in some 











expertise, it has been suggested that programme linkages to forge a continuum of care, rather 
than integration of services may be less complex to engineer.24 
With the efficacy of PMTCT regimens proven and early evidence that ART initiation 
in resource-constrained contexts was feasible and effective, the focus of efforts to strengthen 
and scale up PMTCT programmes has moved to operations and implementation research 
since the release of the 2006 WHO PMTCT guidelines.104 There was new interest in 
appropriate models of care which facilitate ART initiation through linkages to care in eligible 
pregnant women, despite poor health services infrastructure and other challenges in 
resource-constrained contexts.116 It was this interest in models of care which provided the 
rationale to undertake the research presented in Chapters 4 and 5, in order to shed light on 
different approaches in a South African setting. 
Several demonstration projects were initiated to test the acceptability and feasibility of 
providing much needed ART to women who were identified as eligible in pregnancy. 
MTCT-Plus (referred to above) was developed as a multi-country five-year demonstration 
project in 2003 which took established PMTCT services one step further by building on the 
existing programme and providing treatment and care packages.26 In addition to supplying 
short course prophylaxis, MTCT-Plus provided ART and treatment for opportunistic 
infections to women with advanced stage disease, family planning, and psychosocial and 
nutritional support. This was one of the first projects to test the implementation of ART 
services for pregnant women in multiple settings and it served as a model for future PMTCT 
programmes.117 Emphasising linkage to care, the objective of the MTCT-Plus model was to 
incorporate a family-based care approach that recognised the opportunity to link women and 
their partners and children to HIV services. The model focus was on a multi-disciplinary 
team approach, which provided staff at various levels of service to manage patients. The 











Using PMTCT services as a gateway to lifelong treatment of women was extended in the 
MTCT –Plus programme, which placed the HIV-infected pregnant woman in the pivotal 
role of facilitating the testing and treatment of family members.118 MTCT-Plus also 
developed support structures for women and their families in the form of community 
outreach, a treatment ‘buddy’ system for adherence support and support groups for 
psychological wellbeing. In services poorly resourced with data monitoring and evaluation 
tools, MTCT-Plus designed and implemented monitoring systems for patients in care.24,26 
Country outcomes from the MPTCT-Plus programme suggested successful MTCT 
prevention, with a 12-month transmission rate in Côte d’Ivoire of 2.3% among women who 
initiated ART in pregnancy versus 16.1% in women who received short course regimens.119 
MTCT-Plus demonstrated the effectiveness of the two-tier approach, advocated by the 
WHO, and offered dual therapy to women who did not require treatment for their own 
health. Reporting on data from Côte d’Ivoire between 2003 and 2005, overall transmission at 
4 weeks was 2.2% (95% CI: 0.3-4.2%) and cumulative transmission at 12 months was 5.7% 
(95% CI: 2.5-9.0%) in the MTCT-Plus cohort. Infant HIV-free survival was 95.7% (95% 
CI:1.7-7.0%). These findings were most promising, and suggested that the two-tier approach 
in a resource-constrained setting was feasible, safe and highly effective.120 
Two further papers produced from the MTCT-Plus cohorts highlighted both 
successes and challenges of the programme. In Côte d’Ivoire, around half of women enrolled 
in the programme disclosed their HIV status to their partners, 30% of whom came forward 
to be tested. Of the men who were found to be HIV-infected, 78% enrolled in the 
programme, while 10% of exposed children were brought for HIV testing.118  
Another two studies from the MTCT-Plus consortium reported adherence to ART 
declining over time among women who had initiated in pregnancy in Uganda, and poor 
adherence 12 months after initiation among women who had received short course PMTCT 











to adherence highlighted the need to enhance long-term continuum of care strategies – often 
not required in other primary health care packages – in order to improve patient retention 
and health outcomes.115 
In building on this evidence-base, further research from other countries on different 
approaches to offering ART to HIV-infected pregnant women emerged. In Zambia, Killam 
et al. showed that an intervention which provided an integrated ART service once to twice 
weekly within the antenatal service, doubled the uptake of ART within 60 days of delivery, 
compared to uptake among pregnant women accessing separate antenatal and ART services 
(32% in the intervention group versus 14% in the control group). Interestingly, the 
intervention did not have any effect on the time to initiation, which was at least 10 weeks for 
both groups. Furthermore, retention in care measured at 90 days was not significantly 
different between the two groups (87.8% in the intervention group versus 91.3% in the 
control group).123 
In Rwanda, two models of care were evaluated in the context of guideline change from 
single drug regimens to dual and triple therapy between 2006 and 2008. The results showed 
that women who attended antenatal sites which offered an integrated, full package of care 
including dual therapy and ART were almost twice as likely to be enrolled in ART services, 
compared to women who attended stand-alone antenatal and ART services. However, there 
were no significant differences between the two models in terms of initiation of ART, which 
was 83% between 2007 and 2008 overall. This suggests that the integrated service may have 
assisted with treatment referral, but it failed to demonstrate an effect on treatment uptake. 
The authors note that several innovative interventions may have contributed to the high 
uptake of ART. These included focused psychosocial support; the presence of patient 
escorts to ensure that referral to ART services occurred; and a patient tracking system 
utilized by social workers to trace defaulting pregnant women. These interventions were 











Another study evaluated a delivery model to forge linkages between ANC and ART services 
in Johannesburg, South Africa. This intervention placed health workers from the ART 
service once per week in the ANC to identify and assist ART eligible pregnant women with 
referral to participating ART services. Adherence counselling and treatment preparation took 
place within the ANC before referral. The results of this before-after study found that the 
median time to treatment initiation was reduced from 56 days (prior to the intervention) to 
37 days after the intervention was implemented. Although the coverage of ART in 
pregnancy was not reported for the period prior to the intervention, ART initiation in 
eligible women was 75.4% during the intervention.125  
While these studies demonstrate the feasibility of integrating ART within ANC 
services, their results also suggest challenges to rapid uptake of interventions before delivery 
and suboptimal treatment coverage of ART in pregnancy. This is consistent with an 
observational study in Botswana that showed that 37% of women who were eligible for ART 
in pregnancy initiated treatment. Women who presented at ANC services at 20 weeks 
gestation or more were less likely to initiate ART. Although the authors do not describe the 
procedures of referral of women from ANC to ART services, they suggest that referral 
between services may have contributed to low uptake.126  
A South African study reported that late presentation was a challenge to timely ART 
initiation in an integrated service in pregnancy, with the mean gestational age of initiation 
being 27 weeks. High postpartum loss to follow up was also suspected at this service.127 
Pregnancy provides a limited period to optimize treatment initiation, and the risk of vertical 
transmission in utero and the peripartum is decreased with every week of antenatal ART.128 
These findings suggest that in spite of service linkages or integration, barriers to optimal 











2.4 Challenges to PMTCT uptake and ART initiation in pregnancy 
The results of the abovementioned studies illustrate what has been an ongoing concern for 
the past decade, notably a potential ‘efficacy-effectiveness’ gap between the successes of 
PMTCT trials in reducing MTCT and the limited impact of these programmes in operational 
settings, particularly in resource-constrained contexts.19,27 While the risk factors for MTCT 
are universal, women in resource-constrained settings may not have access to interventions 
available to their Western counterparts, for example, sophisticated drug regimens, caesarean 
section or safe alternatives to breastfeeding.60 Despite this, simplified drug regimens have 
proven to be feasible and as effective in the field, and it is programme coverage - which 
impacts on effectiveness – that has emerged as an ongoing health systems challenge. 
Progress towards universal coverage of PMTCT programmes has been made; however, it has 
occurred at a slow pace. In 2009, it was estimated that 26% of HIV-infected women received 
an HIV test, an increase from 7% in 2005. Only half of these women were assessed for ART 
eligibility in the same year and 53% (range: 40%-79%) of HIV-infected women received 
antiretrovirals in pregnancy for PMTCT, an increase from 15% (12%-18%) in 2005.17  
It has been suggested that poor PMTCT coverage may be neither due to a lack of 
political will nor the absence of technical support alone, because even settings with mature 
services continue to fall short of universal coverage. It is more likely a result of a 
combination of barriers which include service and patient driven factors that impact on the 
uptake of both PMTCT programmes and initiation of lifelong ART in pregnancy.23 Much 
research into the reasons for suboptimal PMTCT programme coverage is concerned with 
evaluating the attrition at each step of the PMTCT cascade, which comprises a sequence of 
events required to deliver antiretroviral interventions to HIV-infected women and their 
exposed children. HIV counselling, testing and CD4 cell count testing is required to identify 
women for the administration of appropriate and opportune treatment during antenatal care, 











late postpartum ART, if tested and found to be infected. Modelling exercises have shown 
that even 5% attrition at each step of the cascade compounds sufficiently to result in 86% 
antiretroviral coverage, this proportion falling dramatically with successively lower coverage 
of each step of the cascade.129 The success of each consecutive step of the cascade is 
dependent on the coverage of the previous step. To illustrate, an HIV-infected woman who 
is unaware of her status may access comprehensive and high quality antenatal services, yet 
remain at risk of MTCT and avoidable death as a result of undiagnosed HIV.114 Hence each 
aspect of the PMTCT package of interventions is integral to ensuring uptake and missed 
opportunities at any step will negatively impact on coverage. It is under these conditions that 
mothers are lost to care and that the proven efficacy from trial conditions cannot be realised 
in operational settings.129 
Many studies have investigated the reasons for poor coverage of PMTCT 
programmes. Most of this research is setting specific and while lessons can be learned from 
these evaluations, they may not be broadly applicable. This is because variation in the burden 
of maternal HIV disease, health service capacity, HIV awareness and community attitudes 
and social context may influence programme success. Yet, through local level health system 
evaluation, insights can be gained into the inherent patient- and service-related factors which 
contribute to programme success or failure.23 Much of this literature reports on challenges to 
PMTCT programme coverage without distinguishing between the specific barriers to short 
course and lifelong drug regimen uptake. This is likely due to the fact that all HIV-infected 
women begin at the antenatal clinic where their status is identified, hence there is 
commonality in the first few steps of the PMTCT cascade regardless of CD4 cell count. 












2.4.1 Access and service-related barriers 
Coverage of PMTCT services can be compromised in settings where antenatal care is either 
difficult to access or where there is insufficient infrastructure to provide PMTCT 
interventions. After initiating several pilot programmes in resource-constrained settings, 
PMTCT services were expanded to many countries in Africa due to aid from the Elizabeth 
Glazer Pediatric AIDS Foundation (EGPAF), the US President’s Emergency Fund for 
AIDS Relief (PEPFAR) and other organizations including the Bill and Melinda Gates 
Foundation.14 Service coverage increased over time and by 2006, 108 countries representing 
99% of women with HIV in low and middle-income countries were reporting on PMTCT 
programme data, suggesting substantial progress in scale-up of services.130 However, HIV 
counselling and testing coverage for pregnant women was reported to be 35% in sub-
Saharan Africa in 2009.17 Service-level challenges to the access of PMTCT programmes 
include poor health service infrastructure, limited service capacity, staffing shortages, 
competing health priorities and lack of prioritization of maternal and child health services, all 
of which compromise service delivery.34,131-135  
2.4.2 Late antenatal presentation 
Many women in sub-Saharan Africa, including South Africa, present at late gestational age 
for antenatal care 136-140 and there may be little time for women who are diagnosed with HIV 
in pregnancy to consider the effect that a lifelong chronic illness may have on motherhood. 
Late presentation in pregnancy is a prevalent theme in Chapters 4 and 5, where it is shown to 
impact on ART initiation directly, as well as suboptimal duration of ART prior to delivery. 
This finding is re-iterated by service providers in Chapter 7. 
  Late entry into antenatal care is a barrier to effective PMTCT coverage because it 
limits the opportunity for timely uptake of treatment. As already mentioned, late 











pregnancy. Early evidence also reported that women who presented late in pregnancy were 
more likely to be HIV-infected, 141 and fewer antenatal care visits have been shown to predict 
poorer postnatal care seeking behaviour.142,143  
The WHO antenatal care guidelines recommend a minimum of four antenatal visits 
for women in resource-constrained settings. Research into the preferences and behaviour of 
women seeking antenatal care has provided some insight into the factors that influence late 
presentation, although these factors vary between settings. In a review of factors affecting 
the utilization of antenatal care in resource-constrained settings, Simkhada et al. suggested 
that earlier antenatal care access was reported in different studies to be associated with being 
married, educated or of a higher socio-economic status, while multiparous women were on 
occasion less likely to seek early antenatal care. The authors reported a possible association 
between age and parity: older women of low parity may seek earlier antenatal care.144 In a 
study of South African women, qualitative data indicated that access to antenatal care was 
compromised due to the travel required. Needing to be convinced of a pregnancy through 
physical symptoms was also an important motivator for seeking antenatal care.139 
2.4.3 Reluctance to test for HIV during pregnancy 
The cord blood surveillance paper presented as Chapter 3 finds that unknown HIV status 
through the failure to test in pregnancy is a contributory factor to missed opportunities for 
PMTCT coverage. The emotional cost of screening tests has been well documented and 
screening uptake has been shown to be successful if patients believe that the benefits of 
testing outweigh the risks.145 This has been reported in industrialized countries with strong 
health systems which have sufficient resources to offer HIV-infected women.146 However, 
questions concerning informed consent for HIV testing in the context of pregnancy were 
raised in the early stages of PMTCT programme implementation. Voluntary counselling and 











and reproductive health programmes for individuals seeking HIV testing.147 Hence it is 
thought that antenatal HIV testing may be perceived differently from selective HIV 
screening conducted in mainstream HIV services in that the former may be strongly 
motivated by the desire to protect the unborn child.23  
Debates emerged around the appropriateness of incorporating HIV testing as a routine 
component of antenatal screening,148 particularly at a time when the introduction of routine 
HIV testing in pregnancy in the USA and other resource-rich countries early on in the HIV 
epidemic demonstrated substantial success in the identification of HIV-infected women for 
treatment.149 Despite this, the benefits of knowledge of HIV status outweigh the risks in light 
of the efficacy of drugs to treat infection and calls to re-evaluate HIV testing models in 
pregnancy in order to facilitate greater uptake of PMTCT have been made.147  
In contrast, however, routine testing has been slower to be implemented in most parts 
of Africa, where historically voluntary counselling and testing (VCT), or opt-in approaches 
have been adopted. Despite this, studies have provided evidence of routine testing 
acceptability and impact on increased PMTCT coverage in countries including Botswana, 
Zimbabwe, and Malawi.14,146,150,151 In South Africa, opt-in counselling approaches (VCT) were 
used in PMTCT guidelines with a policy shift to provider-initiated counselling and testing 
(PICT) ‘opt-out’ approach in 2009-10.152 One study from Mpumalanga has reported 
increased testing coverage in pregnancy with the introduction of PICT, where testing 
coverage increased from 69% in 2007/08 to 81% in 2009. Common reasons for not testing 
included knowing one’s status already, fear of stigma, concerns around provider 
confidentiality.153 
Testing in pregnancy is advantageous because it creates awareness of HIV risk in HIV 
negative women, who consequently may be better equipped to manage sexual risk during 
pregnancy and postpartum. An HIV-positive diagnosis in pregnancy may assist with the 











decisions around disclosure and infant feeding options and care as well as providing an 
opportunity to seek early treatment.154 Women who acquire awareness about PMTCT prior 
to pregnancy, or who have tested previously, are more likely to accept testing in 
pregnancy.155-157 In several countries, barriers to uptake of testing were found to include fear 
of an HIV-positive test result.113,158-161 Other reasons for test refusal among Côte d’Ivoirian 
women include requiring permission from their partners to test or wanting to make a 
decision later at home on whether to undergo testing.159 In some settings, being married has 
increased the likelihood of uptake of testing.157 Reports on the acceptability of VCT among 
Nigerian pregnant women were favourable. Fears of stigmatization due to lack of 
confidentiality in disclosure of the test result were a barrier to uptake in this study, this also 
being found in a study of Ghanaian women.162,163 In Sudan, older women, primigravids and 
women of Muslim faith were more likely to follow through with an HIV test after initially 
agreeing to it. Authors suggested that possible barriers to uptake included service fees and 
long waiting times in this setting.164  
Concern about disclosure of HIV status is a well-documented challenge to testing 
uptake in pregnancy, and is linked to the perceived stigma associated with infection. 
Disclosure of HIV status is advocated by both the WHO and CDC as a means to decrease 
anxiety, garner social support and to decrease risk of transmission through uptake of 
preventive interventions and behavioural change. Disclosure may also facilitate partner 
testing and access to family-based HIV care. 165 In a review of rates and barriers to disclosure 
in pregnancy, Medley et al. document that fear of abandonment, discrimination and rejection 
by partners or family members were the most commonly cited barriers to disclosure of HIV 
status in pregnancy. Fear of partner rejection was of particular concern to women who were 
economically dependent on their partners.147 A recent study of women from Tshwane, South 











and to raise transmission risk awareness within their intimate relationships. Few women 
experienced adversity as a result of disclosure, as has been documented elsewhere. 147,166 
2.4.4 Counselling and testing in the peripartum 
The barriers cited above underscore complex factors which may result in a woman 
completing a pregnancy without the knowledge of her HIV status, consequently leading to a 
missed opportunity for antenatal PMTCT intervention. Missed opportunities for treatment 
further extend to those women who either have few antenatal visits, hence minimizing the 
opportunity for offering HIV counselling and testing, and those who present for the first 
time in labour. The proposal for implementation of counselling and testing for women who 
present in labour with no or few antenatal care visits, or for women with undocumented 
HIV at the time of delivery was raised in the USA soon after the guidelines for dispensing 
AZT for PMTCT were implemented in the late 1990s. Drawing comparisons with congenital 
syphilis transmission, it was thought that women with minimal or no antenatal care would be 
the most likely to transmit HIV.167 This was confirmed in results from the Mother-Infant 
Rapid Intervention at Delivery (MIRIAD) Study, which showed that more than 60% of the 
women who had tested HIV-positive in labour had received no antenatal care and that 75% 
of HIV-positive women had attended 3 or fewer antenatal visits. This study demonstrated 
the acceptability and feasibility of perinatal consent and rapid testing, and also highlighted 
the need to support women from marginalized groups who for economic or psychosocial 
reasons did not access early antenatal care.168,169 Testing in labour wards was recommended 
for implementation by the CDC in 2004 and set the example for resource-constrained 
settings to follow suit with rapid point-of-care testing in labour wards.170,171 Testing in labour 
or during delivery is also considered important in the management of women who 
seroconvert in pregnancy. These women are a high risk of MTCT, as incident infection is 











HIV-negative status, these women will most likely not receive nor follow interventions to 
reduce MTCT risk.  
The field effectiveness of testing in labour in resource-constrained settings was 
recently demonstrated in a study in Swaziland, the results of which showed significant 
differences in the uptake of testing during delivery and prophylaxis coverage among women 
who attended health facilities where nurses had received training in an intervention to 
identify and offer testing women in labour with unknown or negative HIV status.173 
Seroconversion in this study was 4% among women who had tested HIV-negative earlier in 
pregnancy and 15% of all HIV-positive specimens were attributed to women whose HIV 
status was unknown at time of arrival. In a South African study, 66% of women accepted 
intrapartum HIV testing and all women who were found to be HIV-infected accepted 
prophylaxis before delivery.174 While this suggests the feasibility of peripartum testing in this 
setting and current guidelines recommend the testing of women in latent labour, there are no 
data to support evidence of feasibility and acceptability in routine service provision. 
In South Africa, reported rates of seroconversion in pregnancy vary. In Chapter 3, the 
cord blood surveillance study shows that a small proportion of women (0.7%) were found to 
have seroconverted in pregnancy. Around the start of the millennium, seroconversion at 
Chris Hani Baragwanath Hospital was reported as 5% 175 and 2% in KwaZulu-Natal.176 
However, in a small study in the Western Cape, no seroconversion was found in a sample of 
532 pregnant women.177 Moodley et al. documented in a cross-sectional study nested within a 
PMTCT programme that the incidence of HIV was four times as high in HIV-negative 
women who retested between 36-40 weeks gestation than found in a survey of the general 
population.178 This underscores the importance of repeat testing in late pregnancy. Repeat 
testing has been advocated for any subsequent visit of women who refused a test at a 











pregnancy since 2008, however, it is not known how well repeat testing is utilized in 
services.178  
2.4.5 Psychosocial aspects of HIV-positive pregnancy and motherhood 
It is well documented that women undergo severe emotional stress when receiving an HIV-
positive test result.179 Furthermore, pregnancy is a life event accompanied by hormonal 
changes. As with HIV diagnosis, these changes may place women at heightened risk of 
depression.180 It has been reported from African settings that HIV-infected women suffer 
greater levels of psychological distress than non-infected women during pregnancy181 hence 
women who are diagnosed with HIV during pregnancy may be more at risk of depressive 
and somatic illness than women of known HIV status who become pregnant.182 A high 
background prevalence of depressive disorders associated with unplanned pregnancy and 
poor socio-economic circumstances has been documented among South African rural 
women enrolling for PMTCT services, regardless of HIV status.183 Hence it is possible that a 
woman diagnosed HIV-positive in pregnancy takes on a further emotional burden regarding 
the acceptance of her illness and the need to protect her child when she may already be 
experiencing psychological distress.  
In most parts of Africa, motherhood is highly valued, this being true in South Africa 
where childbearing is considered the norm among married and co-habiting couples.184-186. 
Motherhood carries heavy social meaning, with reproduction being a strong component of 
the female role and social identity. 187,188 Yet the social construction of maternal identity is 
thought to be determined by greater political processes.189 High social value is attached to 
pregnancy, yet HIV is associated with stigma and deviance.190,191 As a result, it has been 
suggested that HIV-infected women are at risk of negative attitudes towards motherhood, as 
a result of the internalized conflict between social constructs of motherhood and the stigma 











social stereotype of the deviant or ‘bad’ mother – as a mother who fails to protect her child 
from danger.193 Hence discourse on HIV-positive motherhood suggests that HIV infection 
places these mothers in a ‘double-bind’ such that while social expectations dictate 
reproduction, so society condemns HIV-positive motherhood.190,191 This paradox is often 
observed in the decision-making processes of HIV-infected pregnant women and mothers. 
Frequently their anxiety concerning the avoidance of vertical transmission during pregnancy 
and in the postpartum entails counterbalancing the social risks of HIV infection with the 
benefits of motherhood for these women.194 This is explored in Chapter 7, where the lived 
experience of HIV-positive motherhood is documented in the Cape Town setting. This 
chapter also describes a typology of ‘work’ associated with the preservation of maternal 
identity – that of a ‘good’ and protecting mother.195-197  
2.4.6 Challenges to the initiation of ART and regimen adherence during 
pregnancy and postpartum 
Acceptance, treatment initiation and adherence to antiretroviral regimens in pregnancy are 
crucial to maximise viral suppression in order to reduce the risk of MTCT. There is little 
evidence which describes the specific challenges to treatment initiation in pregnant women 
who are eligible for ART, and this theme is examined in detail in Chapter 6 through a 
qualitative study of service providers and ART-eligible pregnant or 6 months postpartum 
women. The findings of this study suggest that women often presented late in pregnancy, as 
discussed previously, and they experienced stages of denial and acceptance of diagnosis, 
which delayed treatment initiation. Fear of treatment side effects and difficulty in accepting 
lifelong treatment are also pertinent themes documented in Chapter 6. Results from a 
qualitative study among pregnant women accessing ART in Uganda suggest both logistics, 
service-related factors and psychosocial challenges impact on ART initiation in pregnancy. 
Poor service access due to transport or financial restraints; long waiting times at the services; 











highlighted as barriers to treatment initiation.198 A study from Soweto, South Africa, among 
non-pregnant, ART-eligible adults suggested that ART refusal was associated with feelings of 
wellbeing, despite these patients meeting the criteria to initiate ART.199  
Most studies which examine the behavioural aspects of adherence to lifelong ART for 
the benefit of individual health do so in non-pregnant populations. This research commonly 
reports adherence as a series of thresholds of complete adherence (100%), and incomplete 
adherence (≤95%).200 A small body of research specifically focuses on adherence to short 
course regimens during pregnancy in resource-constrained settings. In a study from the 
United States, adherence to ART during pregnancy was 65%, this dropping in subsequent 
postpartum months, including among women who were on lifelong ART. Factors associated 
with adherence in the previous 4 days included less advanced disease, favourable mood and 
the absence of marijuana use.201  
Botswanan women attending services in Francistown recalled missing doses of AZT 
due to being away from home, running out of treatment or forgetting to take it on time. 
Some mentioned that they prioritized other activities and some avoided taking treatment due 
to fear of side effects, while others suggested that they did not have food to take with the 
treatment.131 In an effectiveness study based in Lusaka, Zambia, it was reported that 57% of 
women who tested HIV-positive at participating antenatal services were documented to have 
acquired a NVP tablet.61 In a study of Zimbabwean women in Bindura, non-adherence to sd-
NVP and infant NVP was associated with lack of maternal secondary education and home 
delivery, while increased maternal adherence was associated with previous maternal PMTCT 
exposure and taking the NPV tablet home. A limitation of this study is recall bias because it 
was based on self-reported behaviours.202 Evidence from sub-Saharan Africa suggests that 
supportive male partner involvement in pregnancy is associated with improved adherence to 











currently being investigated and promoted as an intervention in resource-constrained 
settings.204 
2.5 Prevention of mother-to-child transmission in South Africa 
2.5.1 The development of PMTCT services in the Western Cape Province, 
1999 
The first South African antenatal prevalence survey was conducted in 1990, the results of 
which showed that HIV seroprevalence among women attending antenatal services was 
0.8%.205 In 1993, the National AIDS Coalition of South Africa was formed and by 1994 this 
body had drafted the first National AIDS Plan, which included a recommendation for 
voluntary counselling and testing (VCT) of pregnant women at antenatal clinics and the 
provision of prophylaxis.206 However, progress in implementation of the plan in the first four 
years was slow.207 In 1998, antenatal seroprevalence had increased to 22.8%,208 and a rise in 
infant mortality was attributed to the increase in MTCT.209 In the same year, in response to 
evidence from the Thailand46 trial on the efficacy of AZT, the Gauteng Department of 
Health proposed the implementation of PMTCT programmes at five pilot sites. However, 
support for these sites was withdrawn by government soon after, for reasons of 
affordability.210,211 
Future progress on the use of AZT in pregnancy was for the most part thwarted in the 
majority of provinces by government until 2008, when it was incorporated in national 
PMTCT guidelines as a part of new recommendations for dual regimens and triple therapy 
for pregnant women, replacing the sdNVP regimen which had been implemented since the 
commencement of the National PMTCT Pilot Programme in 2001-2002.212,213 
The time line of the development of the PMTCT programme in the Western Cape 
province (from which the data for this thesis are drawn), is illustrated in Figure 2.1. The 











the flagship PMTCT programme was implemented in two midwife obstetric units (MOUs) 
in Khayelitsha, outside Cape Town. Provision was made for VCT services within the MOU, 
AZT dispensation and follow up services in nine postnatal clinics which provided formula 
milk for those who elected to replacement feed.214,215 By 2004, the PMTCT programme had 
been expanded throughout the Western Cape as a nurse-driven service which offered dual 
therapy, as well as CD4 count testing to determine women with indications for HAART and 
PCR testing for infants at 14 weeks. 
At this stage, VCT coverage was 96% and seroprevalence was 11.8% by 2004.216 The 
field efficacy of the programme was tested in 2003-2004 among 535 mother-infant pairs. The 
study reported PMTCT coverage to be 77% with the MTCT rate being 8.8%. The results of 
this study demonstrated the feasibility and effectiveness of the PMTCT programme in this 
setting.217 As a partnership between the Provincial Government of the Western Cape 
(PGWC) and Médecins Sans Frontières (MSF), three primary health care (PHC) sites were 
set up in Khayelitsha in 2000 to offer HIV services and ART was made available to those 
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Experience gleaned from the implementation of the PMTCT programme in the Western 
Cape paved the way for the development of ART services for adults and children in this 
province. As with the PMTCT programme, the ART services relied on partnerships and the 
outsourcing of counselling to the NGO sector. Starting with an ART site administered by 
MSF in 2001 in Khayelitsha, more sites were set up in Khayelitsha, Langa, Gugulethu and a 
number of secondary and tertiary facilities by 2003. The ART programme was rolled out in 
earnest following the government’s commitment to the national provision of ART in 
2004.214,215 In the same year, the Western Cape PMTCT protocols were redrafted to include 
referral of pregnant women who were identified as ART-eligible to ART sites.214 Satellite 
clinics were set up within the MOU or in close proximity to the MOU to facilitate referral.219  
Also in 2004, McCord hospital in KwaZulu-Natal implemented the WHO guidelines 
of 2004, with financial assistance from EGPAF. Dual regimens for prophylaxis and ART for 
maternal health were made available for women accessing services. Data from an 18-month 
observational cohort in this setting reflected 91% testing coverage with 26% of women 
eligible for ART according to CD4 cell count result. Of the 97% of women who received 
ARV regimens, 44% received ART (including short course ART among 60% of women who 
had a CD4 cell count >200 cells/µL). Overall transmission at 6 weeks was low at 2.9%, 
being highest among women who received sdNVP (8.2%) and lowest among those who 
received ART (1.8%). This evidence demonstrated the operational effectiveness of more 
complex regimens in this setting, yet the outcomes are subject to some limitations. Since 
McCord is a fee-paying hospital, there may have been selection bias in terms of the socio-
economic and educational status of those enrolled in the cohort. Women may choose to 
refer elsewhere to free services closer to home, impacting on the loss to follow up, which 











2.5.2 Slow progress in national PMTCT programme scale-up, 1999-2007 
While the Western Cape had scaled up PMTCT services and other isolated sites within South 
Africa were implementing policy guidelines which were on a par with the 2004 WHO 
recommendations for resource-poor settings, other provinces lagged behind. In 2001, the 
Department of Health acted on the evidence from the HIVNET 012 study and implemented 
PMTCT programmes in 18 pilot sites across South Africa. With two sites in each province, 
the intervention comprised voluntary HIV counselling and testing to all women presenting 
for their first antenatal visit and sdNVP for women and their infants intrapartum. 
Replacement feeding in the form of free formula milk was offered for 6 months and children 
were offered testing at 12 months.221 An evaluation of the pilots reported that approximately 
9% of pregnant women made use of the PMTCT services at the pilot sites in 2001 and 2002 
respectively and the HIV testing uptake rate among these women increased from 51% in 
2001 to 56% in 2002. National scale-up commenced after a judgment passed by the 
Constitutional Court in July 2002,210 ordering that the government make NVP universally 
available to HIV-infected pregnant women. The first national PMTCT programme offered 
voluntary counselling and testing in antenatal services, with NVP to mother and child per 
HIVNET 012, as well as free infant formula for 6 months postpartum, co-trimoxazole for 
infants up until 12 months, by which time HIV testing was offered to determine infection 
status.222  
In 2000, the government had estimated that 75 000 children were born with HIV in 
South Africa, given the antenatal prevalence of 24%.211,223 During the early years of the 
PMTCT programme, there were limited national routine data on programme outcomes, due 
to the slow roll-out of the programme.224 Early outcomes from the national pilot programme 
reported a total of 1907 infants born to HIV-infected mothers and transmission was 
documented as 18%. However, due to 50% attrition in this sample, this rate was an 











‘snapshot’ evidence of effectiveness at the time within operational settings.225 Results from a 
programme at Coronation Hospital in Johannesburg in 2003 reported 15% consent to HIV 
testing and high sdNVP uptake rates (>95%) at delivery. Transmission rates were 8.7% at 6 
weeks and 8.9% at 3 months, with more than 70% of children lost to follow up by 4 
months.222  
Another study conducted between 2002-2004 documented late postpartum 
transmission in children at 36 weeks from three sites in the Western Cape, KwaZulu-Natal 
and Eastern Cape. Cumulative transmission or death by 36 weeks was 16% (95% CI: 10-
23%); 26% (21-32%) and 35% (28-43%), with maternal viral load being the most significant 
risk factor of HIV transmission or death, followed by low birth weight and breastfeeding. 
Furthermore, the authors attributed high transmission to poor health system performance, 
cautioning that any future availability of dual and triple therapy for pregnant women could 
be compromised by operational challenges.226 Evidence from the Eastern Cape between 
2003 -2004 highlighted these operational challenges, suggesting a lack of PMTCT integration 
with antenatal services; poor management systems including a dearth of monitoring tools to 
evaluate effectiveness; a lack of infrastructure and limited support structures and supervision 
for staff contributed to poor coverage of the programme. Community stigma, traditional 
postpartum birth customs and cost of transport to facilities were patient-related barriers 
which prevented programme uptake.227 At the same time in the Western Cape, interviews of 
staff at different levels of health service provision elicited similar responses regarding 
operational barriers to the uptake of PMTCT services. Limited training opportunities for 
counsellors and staff; poor co-ordination and staff shortages were highlighted as service-
related barriers, while stigma, lack of knowledge, fear of denial and disclosure were cited as 
patient-related barriers to care.228 
In 2005, 240 000 children under 15 years of age were estimated to be HIV-infected in 











be 30.2% for the same year.230 South Africa was reported to be one of ten countries to 
account for two-thirds of all vertical transmission in 2005.94 In the previous year, the 
Minister of Health declared during the International AIDS Conference in Bangkok that 
despite the South African Medicine Control Council’s recommendation for the use of dual 
therapy, sdNVP would continue to be provided in public health sector facilities.231 Limited 
data on the coverage and impact of the PMTCT programme were available. In one South 
African study at this time, it was estimated that the risk of vertical transmission ranged 
between 19.4% (formula only and exclusively breast fed infants) and 26.1% (mixed feeding 
practices) at 6 months postpartum.232  
By 2006, the Department of Health reported that an estimated 302 000 pregnant 
women were HIV-positive. With 85% antenatal service coverage, it was reported that 73% 
of women were identified and enrolled on the PMTCT programme.233 Yet sdNVP was still 
the only drug available for use throughout most of South Africa, despite the 2006 WHO 
recommendation of dual regimens and ART for eligible HIV-infected pregnant women.104 It 
became clear that while maternity and obstetric services were succeeding in providing 
appropriate ante- and perinatal care on many levels, the suboptimal management of HIV in 
pregnancy was regarded as a significant failure by these services to manage the epidemic and 
HIV was a major threat to maternal and infant survival.234 According to the Saving Mothers 
Report for 2002-2004, the gains made in reducing maternal mortality through the 
management of several direct causes of maternal death such as hypertension and abortion 
were reversed due to the rise in non-pregnancy related infections, including HIV.235 HIV-
infected pregnant women in South Africa were more likely than their HIV-negative 
counterparts to develop pregnancy complications and experience adverse outcomes, 
including anaemia, pregnancy-induced hypertension, lower maternal weight, urinary tract 
infections, premature delivery and in utero growth restriction.236 Guidelines on the 











Antiretroviral therapy scale-up had begun in 2004, and approximately 190 000 South 
Africans were receiving treatment by the end of 2005.238 However, it was estimated that less 
than 10% of pregnant women were receiving ART and 14% of women were receiving 
prophylaxis through the PMTCT programme.237 While antenatal services provided VCT for 
the identification of HIV-infected women, integration of ART services within maternity care 
was uncommon. A major challenge to initiation in pregnancy was the verticalisation of 
programmes, with poor linkage between maternal services and ART services.237,239 
With sparse routine data available on the PMTCT programme, there was an overriding 
concern about the significant numbers of HIV-infected children admitted to South African 
health facilities.240 In KwaZulu-Natal, cumulative PMTCT effectiveness was measured 
among infants in combination with reported maternal sdNVP ingestion. The MTCT rate at 
4-8 weeks was 20% (95% CI: 17-23%), leading to an HIV prevalence of 7% in infants 
around 6 weeks, suggesting poor coverage of the PMTCT programme.241 These poor 
outcomes were ascribed to a failure to adopt more successful scientific approaches to 
PMTCT, as well as a failure to address programme weaknesses. Furthermore, while sdNVP 
may have initially provided the impetus for PMTCT programme expansion in the late 1990s, 
it was argued that its impact on vertical transmission was clearly no longer having sufficient 
effect.242 
At the time, another evaluation from KwaZulu-Natal suggested suboptimal PMTCT 
service coverage, with high attrition at each step of the PMTCT cascade. A hospital audit of 
data from women recently postpartum in 2007 reported that 84% of women had had access 
to testing, of whom 91% accepted. Antenatal NVP was dispensed to 87% of identified HIV-
infected women and 76% were administered sdNVP in labour. Documentation of CD4 cell 
count testing was found in 45% of women, of whom only 46% received their results. Of the 











2.5.3 2008 and beyond: International policy translated into improved 
national PMTCT strategy 
By 2007, the Interagency Task Team (IATT) on Prevention of HIV Infection in Pregnant 
Women, Mothers and their Children, comprising world experts, scientific and funding 
bodies as well as national role players, reported on strategies to improve the scale-up and 
implementation of PMTCT in resource-constrained environments. In order to strengthen 
PMTCT programmes, IATT called for increased governmental leadership and accountability; 
the delivery of a standard package of care; the use of provider-initiated testing and 
counselling in antenatal and postnatal services; the institutionalization of longitudinal care for 
mothers and children, increasing the linkages between and access to ART for eligible 
pregnant women and their families; strengthening infant feeding support and nutrition in the 
context of HIV care; forging links between PMTCT services and sexual and reproductive 
health services and developing community-based links and empowerment.15  
By 2006, the WHO had released updated guidelines recommending ART initiation in 
women with stage 4 disease, irrespective of CD4 cell count; women in stage 1 or 2 with CD4 
cell counts of <200 cells/µL and women with stage 3 disease and CD4 cell counts of 200-
350 µ/L, as well as AZT prophylaxis from 28 weeks’ gestation and sdNVP during delivery.103 
While adopting selected recommendations set by IATT and the WHO guidelines of 2006, 
South Africa released new PMTCT guidelines in early 2008 - the first revision since 2003 - 
which included the addition of AZT from 28 weeks’ gestation to the standard sdNVP 
package; ART for women with stage 3 or 4 disease and/or a CD4 cell count ≤200 cells/µL. 
Formula milk continued to be offered at no cost to HIV-infected women attending PMTCT 
services for 6 months, as per the original guidelines, and exclusive breastfeeding for 6 
months was also to be encouraged.212 Although acknowledged to be a long-awaited 
improvement on the 2003 guidelines, the new guidelines were criticized by experts and civil 











and advocating a low threshold for initiating ART. Furthermore, the failure to address the 
poor linkages between antenatal and ART services was cited as an ongoing barrier to women 
who needed ART in pregnancy, this being compounded by the prerequisite that doctors, and 
not nurses or midwives, initiate and prescribe treatment.244 
Evidence from South African settings which reported on the effectiveness and 
feasibility of ART initiation in antenatal contexts, as well as the service-related challenges to 
implementation at this time has been discussed above in context of the implementation of 
service integration.125,127 In these evaluations, which demonstrated that initiating ART in 
pregnancy was possible, coverage in ART-eligible women was cited as an ongoing challenge. 
Included in this thesis is a publication which suggests that during the first years of ART 
availability within Cape Town antenatal services, overall coverage in women eligible for 
treatment was 51%. Facilities which provided ART within the MOU were not significantly 
more likely to initiate women than facilities which referred women to separate ART services 
(Chapter 3).245 While coverage improved slightly in a follow-up study, the integrated 
approach to care did demonstrate more favourable coverage (Chapter 4).  
As reported nearly a decade beforehand, uptake of PMTCT interventions rather than 
the efficacy of the drugs themselves, remained a crucial factor which influenced programme 
effectiveness. Evidence from the PEARL cord blood surveillance study in four African 
countries (2007-2008), which measured perinatal uptake of NVP prophylaxis in mothers and 
infants reports that country-adjusted coverage (evidence of NVP in cord blood and record 
of direct observation of infant administration) was 51%. Failed coverage was associated with 
fewer antenatal visits (1 or fewer) and younger maternal age (20-25 years), while one in four 
women who were dispensed sdNVP did not ingest it.35 Even in light of more complex 
protocols, optimizing coverage remained an ongoing challenge: in a sub-analysis of this 











standard of care regimens (defined as AZT and sdNVP or LMD, indicating ART), this being 
lower than reported in accompanying service data (Chapter 2).  
2.5.4 Continued challenges: the reporting of South African PMTCT 
coverage through routine data 
Despite these suboptimal results, coverage of ARVs for prophylaxis and maternal health 
estimates provided by UNICEF,UNAIDS and the WHO for sub-Saharan Africa continued 
to improve each year from 35% (95% CI: 29-44%) in 2007 to 45% (37-57%) in 2008 and 
53% in 2009.11,17 Increases in the availability of routine data, including disaggregated data 
were noted, and 35% of women who tested HIV-positive were reported to have been 
assessed for ART, either according to CD4 cell count testing or clinical staging.11  
By December 2009, routine data from South Africa reported by the WHO were 
suggesting a testing rate greater than 95% in antenatal services and antiretroviral intervention 
coverage greater than 80%.17 The annual report by the National Department of Health of the 
same year reported HIV testing rates of 92%, with 91% of infants receiving sdNVP and 77% 
of women eligible for ART being initiated in pregnancy. This report, however, acknowledged 
that data collection of dual therapy regimens was compromised and no coverage figures 
could be produced. An estimated 56% of infants were tested for HIV, but the transmission 
rate was not published.246  
Few evaluations on the reporting of routine programme data for PMTCT exist, 
however, Mate et al. reported poor accuracy and completeness in these data from 316 
services KwaZulu-Natal in 2007.247 Their findings suggested huge variations in the quality of 
the data collected between the sites. Overall, data elements were only reported 50% of the 
time, and they were reported accurately only 12% of the time.247 Similar inconsistencies have 
been found in other published reports of PMTCT routine data,248,249 and the cord blood 











part the discrepancy between documented dispensation of PMTCT regimens and exposure 
to regimens as found in the cord blood results. 
Another limitation of routine data is that they fail to account for the true services 
coverage by excluding women of unknown HIV status who do not test in pregnancy, as well 
as those who may be documented as receiving PMTCT interventions, but who fail to ingest 
them.35,61 This weakness provides the rationale for cord blood surveillance, as described in 
Chapter 3. 
Laboratory data may offer an alternative source for data on PMTCT effectiveness. 
Data from the National Health Laboratory Services reported an estimated 5.8% transmission 
rate at 2 months of age. Yet a limitation of these data is that they were based on early infant 
diagnosis coverage of 45%.250 
At the same time the Western Cape reported that 85% of women presenting in 
antenatal services tested for HIV. Documented sdNVP uptake was 98% among women 
presenting in labour, and 22% of HIV-infected women delivering in facilities were on ART. 
However, this does not indicate the proportion of those who were eligible for ART who 
received it. Vertical transmission was reported to have decreased from 4.5% in 2008-2009 to 
3.6% in 2009-2010 among children identified on the PMTCT programme.251 
Impressive decreases in early vertical transmission were confirmed in mid-2011, when 
the Medical Research Council released preliminary results of a national facility-based HIV 
prevalence survey among infants between the ages of 4-8 weeks. Early vertical transmission 
ranged between 6.2% (4.5-6.9%) in Mpumalanga and 3.3% in the Western Cape (2.9-4.1%). 
Selection bias in the study may have arisen through the exclusion of hospitals where acute 
cases of HIV are more likely to present and recall bias and social desirability bias may have 











2.6  Transmission through infant feeding 
While gains were being made in perinatal prevention, it was acknowledged that infant 
feeding transmission was becoming one of the most difficult aspects of PMTCT strategy 
faced by scientists, clinicians and HIV-infected mothers in resource-constrained settings. 253 
Ante- and intrapartum regimens targeted perinatal transmission, but subsequent high risk of 
postnatal transmission remained a challenge.28 Exclusive breastfeeding for the first six 
months of life is advocated for all infants for optimal growth and development, as well as for 
infant health and the immunological benefits of protection against childhood illness.254 In 
resource-constrained settings, breastfeeding practices, incorporating exclusive and mixed 
feeding, may account for up to between one third to one half of late postpartum 
transmission.9 In a meta-analysis of individual patient data, 42% of HIV-infected infants 
were reported as HIV-infected at or after four weeks of age.255 While transmission risk is 
constant throughout the breastfeeding period, length of exposure has been associated with 
elevated risk.256 Women who have recently seroconverted are at twice the risk of vertical 
transmission due to high viral load.172 
In resource-rich settings, complete avoidance of breastfeeding is recommended and 
attained through safe formula feeding. This has also been achieved in several less-resourced 
settings, including Brazil, Thailand and parts of Africa where there is sufficient infrastructure 
and support to promote affordable, feasible, acceptable, safe and sustainable replacement 
feeding, as recommended by the WHO in 2004.98,242,257 Updated feeding guidelines 
recommended exclusive breastfeeding for HIV-infected women in the absence of safe 
replacement alternatives, for the first six months of life.258 These were based on evidence 
regarding the challenges to replacement feeding include poor access to safe water supplies or 
formula and low acceptability of replacement feeding due to stigma.34 It is argued that in 
poorly-resourced countries, the reductions in MTCT afforded by formula feeding are 











in no net benefit of replacement feeding. Hence prevention strategies to modify 
breastfeeding practices have been examined over recent years to make them safer.253  
Exclusive breastfeeding has been shown in different country settings to be feasible, 
and is associated with lowered risk of vertical transmission compared to mixed feeding 
practices.232,259-264 While this suggests that exclusive breastfeeding may provide a promising 
alternative to replacement feeding for women in resource-constrained settings, these studies 
have shown that it does not eliminate transmission risk.34 Evidence from trial and 
observational settings from 2006 onwards has reported that the use of extended 
antiretroviral prophylaxis in infants substantially reduces the risk of postpartum MTCT in 
breastfeeding populations, with early postnatal infection rates ranging between 0.8% and 
2.5% and 0.8%-4.4% for late postnatal transmission (4-6 weeks to 6-9 months) where data 
collected and were comparable.1,34,265-269 Furthermore, maternal ART administered during 
breastfeeding has also shown promising results. Early postnatal transmission rates from 
studies assessing the effectiveness of maternal ART reported early postnatal transmission 
ranging between 0% and 5% (4-6 weeks).270-274 Late postnatal transmission in these maternal 
studies, as well as the DREAM and the Breastfeeding, Antiretroviral and Nutrition (BAN) 
study were also under 5%.1,100 The BAN study demonstrated a seven month transmission 
rate of 6.4% in the control arm, 3.8% in the maternal ART arm and 1.8% in the infant NVP 
arm. The difference between the maternal and infant interventions was not significant, and 
the study was not powered to detect this difference.1 
Several limitations to this evidence were noted particularly with respect to the variation 
between studies in duration of antenatal and postnatal regimen exposure, the rates of 
exclusive breastfeeding and the duration of feeding practices, the availability of the data 
available on perinatal vertical transmission, as well as the different CD4 cell count thresholds 
at which maternal regimens were administered.28 Maternal ART was administered at 











resistance and the safety of repeated courses of ART in subsequent pregnancies in women 
not requiring ART for their own health.253,275 However, these studies yet again underscored 
the importance of lifelong ART as the most critical component of managing maternal health 
and preventing MTCT, showing the greatest impact in women with advanced disease who 
were on ART in pregnancy.253,276 
2.7 Towards the elimination of paediatric HIV 
Following the successful outcomes of these studies, the call for the global elimination of 
paediatric HIV was made in 2009 and PMTCT recommendations were revised in order to 
reflect the promotion of more effective programme interventions between 2009 and 
2010.21,44 The primary approach to these guidelines was again a two-tiered strategy 
comprising prophylaxis for PMTCT and lifelong ART for women who required it for their 
own health. However, the rationale behind the changes was to ensure a higher proportion of 
women received treatment for their own health from earlier in pregnancy, in order to 
optimise maternal and children outcomes. The need for a continuum of care between 
antenatal and postnatal services was emphasised to underscore the need to address  MTCT 
transmission through breastfeeding.21 
A number of priority areas for revision included recommendations for earlier 
prophylactic treatment starting in pregnancy at 14 weeks gestation, as well as earlier initiation 
of ART in eligible pregnant women. Furthermore, extended mother or infant regimens to 
cover the period of breastfeeding to reduce postpartum transmission were recommended.44 
Based on the variations in combination therapy used in the postpartum studies, several 
treatment options were included in these guidelines which could be adapted to different 
service settings. Maternal ART was recommended for women with clinical indications of 
advanced disease or a CD4 cell count of ≤350 cells/µL. In addition, infants of mothers on 











Two options for women who did not require ART for their own health were proposed, to be 
chosen at country level according to feasibility, acceptability, safety and cost. Option A 
recommended twice daily AZT from 14 weeks gestation, with the addition of sdNVP in 
labour and twice daily AZT and LMD for 7 days postpartum to prevent resistance. Daily 
administration of NVP to infant who are breastfeeding was recommended from birth to one 
week after cessation of breastfeeding, or for a minimum of 4-6 weeks if breastfeeding is 
stopped before 6 weeks. In non-breastfeeding populations, the same antenatal regimens were 
recommended with infant NVP or sdNVP and twice daily AZT, to be administered for 4-6 
weeks postpartum. Option B advocated ART for pregnant women who did not require it for 
their own health, from 14 weeks gestation until delivery, or until a week post-cessation of 
breastfeeding, coupled with NVP or twice daily AZT to the infant until 4-6 weeks of age.21  
Other important changes to these recommendations included the move away from 
more toxic triple therapy regimens towards the use of safer, fixed-dose regimens. The 
expansion of laboratory settings for the monitoring of CD4 cell counts was also emphasised. 
Furthermore, with the introduction of extended prophylaxis during the postpartum, 
countries were urged to assess infant feeding in the context of optimising infant survival.21  
Concern was expressed for the capacity of middle- and low-income countries to 
implement the new guidelines rapidly in light of resource constraints and competing health 
priorities and the need for supported scale-up was highlighted.277 Following the release of the 
guidelines, the WHO’s PMTCT strategy for 2010-201521 underscored the importance of 
country-level leadership, much like the IATT report of 2007.15 Furthermore, emphasis was 
placed on the quality of care for women and children and the integration of maternal and 
child services; HIV treatment and care and sexual and reproductive health services within a 
strengthened health system that made appropriate provision for performance measurement.21  
In the most recent developments towards the virtual elimination of paediatric HIV by 











among children by 2015 and keeping their mothers alive, 2011-2015” was devised through a 
consultative process between UNAIDS, country leaders and a high level task team.278 The 
Plan targets middle- and low- income countries, with the intention to assist with the 
mobilization of efforts towards the virtual elimination of MTCT.  There is particular focus 
on the 22 countries with the highest estimate of HIV-infected pregnant women, of which 
South Africa is one. Based on the premise that although treatment coverage has improved 
over recent years, the report suggests that a substantial proportion of women still do not 
receive required interventions due to missed opportunities within services. The report poses 
country-level challenges for increased leadership and accountability through better 
management of resources and services as well as the development of appropriate monitoring 
and evaluation systems to assess progress. The Plan advocates for the revitalization of 
national strategies to address the epidemic as well as the strengthening of linkages between 
maternal and child health services and ART services, enhanced supply of human resources 
and increased community involvement through improved communication.278 
The National Department of Health revised the 2008 PMTCT guidelines to 
incorporate the WHO recommendations of 2010, using Option A for women who did not 
require treatment for their own health.279 In support of baby-friendly initiatives in health 
services, the Department of Health has recommended the withdrawal of free formula milk 
from all public health facilities. The proposal to increase the support of mothers who wish to 
breast feed will included the supply of community health promoters and promotion of 
workplace feeding support as well as tighter regulation of the sale of breast milk substitutes, 
in an attempt to promote exclusive breastfeeding within the context of the revised 2010 
guidelines.280 These changes have been received with mixed reactions, which are centred 
around the debate concerning which options have the maximum impact on child survival 











Recent policy development in Malawi incorporates “Option B-Plus”, which allows for 
lifelong universal ART for all HIV-infected pregnant women. This initiative was instigated in 
order to overcome obstacles in CD4 cell count testing, due to limited resources, and to 
increase PMTCT coverage in the context of prolonged breastfeeding and high fertility rates. 
Additional benefits are expected: early ART initiation will reduce the burden of opportunistic 
infection, sexual transmission of HIV and the risk of drug resistance through treatment 
interruption.283 Besides the considerable gains to be made in programme coverage and 
prevention of vertical transmission, model estimates suggest that huge reductions in maternal 
mortality in sub-Saharan Africa could be achieved if universal maternal ART were 
implemented in sub-Saharan Africa. 284 Based on these benefits, this approach should be 
considered for future incorporation into South African PMTCT policy, yet implementation 
would require considerable planning around the optimal approaches to delivering universal 
ART to pregnant women. 
2.8 Conclusion 
This literature review has presented the scientific development of PMTCT programmes and 
how they have been translated into clinical practice in operational settings. While factors 
including political will, ample resources and low HIV antenatal prevalence have ensured the 
success of these programmes in resource-rich settings, the same is not true for resource-
constrained settings, which continue to carry the largest burden of paediatric HIV.  
In South Africa, as with other middle- and low- income countries, challenges to 
PMTCT programme strengthening are multiple, encompassing both patient- and service-
related factors. The delay in the implementation of new and more effective regimens has 
proved to be a critical factor which has compromised effectiveness in the past. Furthermore, 
the poor integration of ART services within maternal health is an ongoing challenge to 











in the context of Cape Town services providing PMTCT and ART for pregnant women 
between 2005 and 2008. 
Weaknesses in programme monitoring have been identified across resource-
constrained contexts. This is true for South Africa where historically assessment of the 
PMTCT programme was based on sparse data and much of the evidence on PMTCT 
progress was reliant on isolated research projects which were not necessarily generalizable. 
Furthermore, there is evidence to suggest that routine data need to be interpreted in light of 
challenges to accuracy and completeness, as well as their capacity to reflect true coverage 
among women of unknown status. This is discussed in light of the findings in Chapter 3. 
Despite these challenges, service-based research since 2008 has suggested 
improvements in programme coverage and early PMTCT outcomes, possibly attributable to 
the changes to PMTCT guidelines in 2008 and the scale-up of services. Updated guidelines 
from 2010 may address late postpartum vertical transmission, however, little is known at this 
stage of their effectiveness in the South African context.  
As discussed, there is an international shift in focus towards treatment for prevention, 
and an increasing proportion of HIV-infected pregnant women will be eligible to initiate 
ART at earlier stages in pregnancy. Of the small body of literature on the psychosocial issues 
concerning HIV diagnosis, treatment initiation in pregnancy and women’s perceptions of 
HIV-positive motherhood, most evidence pertains to resource-rich contexts where it is 
possible that different social and structural forces are at play. Chapters 6 and 7 examine HIV 
diagnosis, the barriers to treatment initiation and women’s views on HIV-positive 
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Background   
The effectiveness of prevention of mother-to-child of HIV (PMTCT) programmes 
depends on the successful coverage of a series of interventions through 
pregnancy, intrapartum and postpartum. Routine monitoring systems based on 
service data and limited to women on the PMTCT programme may overestimate 
intervention coverage at multiple points along this cascade. 
Methods  
Cord blood specimens with individually linked anonymous demographic and 
pregnancy data were collected from three delivery services in the Western Cape 
Province, South Africa, and screened for HIV. Seropositive specimens were 
tested for the presence of antiretrovirals. Comparisons were drawn between 
documented service data and cord blood findings for HIV seroprevalence and 
antenatal antiretroviral coverage. 
Results  
A total of 3 034 specimens were tested for HIV, 507 (16.7%) of which were 
HIV seropositive. Of these, 470 (92.7%) were tested for the presence of 
antiretrovirals, of whom 58.1% had evidence of a standard of care maternal 
antiretroviral regimen, and 73.6% some form of antenatal antiretroviral 
prophylaxis. Cord blood antiretroviral coverage was lower than that reported by 
service data. Incomplete antenatal HIV testing accounted for an estimated 
46.2% of missed opportunities for transmission reduction. 
Discussion  
Even in this well-resourced setting, HIV screening and ensuring antenatal 
compliance with prescribed regimens were the most immediate priorities for 
reducing vertical transmission. Cord blood surveillance offers a unique 
opportunity to explore missed opportunities using methods not currently 














Mother-to-child transmission of HIV (MTCT) remains the primary route of HIV infection 
in children. Transmission risk can be dramatically reduced through the use of ante-, intra-, 
and postpartum antiretroviral (ARV) regimens.7 Recent reports of declining infant mortality 
in South Africa may be due in part to the effectiveness of the PMTCT programme and 
survival of infected mothers on ART.285,286 Yet antenatal seroprevalence remains high, having 
increased to 30.2% in 2010,287 from 29.3% in 2008, when this study was conducted.288 New 
national prevention of mother-to-child transmission (PMTCT) guidelines based on 2010 
WHO recommendations36,279 are being implemented throughout public health services and 
preliminary results from a recent national survey suggest that early MTCT may currently be 
as low as 3.5%.252 The elimination of paediatric HIV, however, still requires committed and 
sustained efforts to achieve high PMTCT programme coverage and a continuum of care that 
also identifies women at risk of incident infection in pregnancy and postpartum vertical 
transmission.17,34,114,289  
The effectiveness of PMTCT programmes is contingent on a cascade of critical steps 
which include HIV testing in pregnancy and the provision of, and adherence to, antepartum, 
intrapartum and postpartum ARV regimens.60 Epidemiological modelling of programme 
effectiveness has shown that the use of more effective ARV drug combinations could have 
limited impact on transmission if adequate service coverage of all the steps of the PMTCT 
programme is not achieved.129 This highlights the importance of identifying and reducing the 
missed opportunities in programme coverage.  
Effective monitoring and evaluation of PMTCT programmes is hence crucial for the 
identification of missed opportunities in service delivery along the PMTCT cascade. Since 
2001, PMTCT programme coverage in South Africa has been reported through indicators 











quality of data due to incomplete and inaccurate reporting.247,249 In addition, these data reflect 
coverage in women attending antenatal care and further document dispensing of PMTCT 
prophylaxis rather than actual ingestion.290 
In 2007, the PEARL (PMTCT Effectiveness in Africa: Research and Linkages to Care) 
study consortium explored a new approach to the evaluation of PMTCT programme 
coverage through cord blood surveillance of HIV status and nevirapine (NVP) concentration 
in four African countries.35 The study was expanded in the Western Cape Province of South 
Africa to document the effective administration of azidothymidine (AZT) and combined 
antiretroviral therapy (cART), which were at the time available as standard of care to HIV-
infected women with CD4 cell counts above and below 200 cells/µl respectively. Our aim 
was to describe true standard of care PMTCT coverage using cord blood surveillance of HIV 
infection and the presence of ARVs. We further sought to compare these outcomes to 
programme reporting and examine missed opportunities for preventing vertical transmission 
in the Western Cape PMTCT programme,219,291,292 which started in 2002 and was considered 
at the time to be effective based on routine reporting.219 
3.2 Setting 
HIV prevalence in the Western Cape among pregnant women 15-40 years was 16.1% in 
2008, ranging between subdistricts from 9.3% to 17.9%.288 Two delivery services in the 
metropolitan area and one rural area were randomly selected from 32 sub-districts in the 
province. 
At the time of this study, PMTCT services were integrated into primary health care 
antenatal services, with the exception of cART provision to eligible women, which was 
provided by a separate programme within the same facility at the antenatal service at all three 
sites. At the first antenatal visit all women received group HIV counselling followed by 











requested. In 2007-8, the standard of care for HIV-infected pregnant women with a CD4 
cell count >200 cells/µl comprised AZT from 28 weeks gestation in combination with single 
dose NVP to the mother and exposed infant at time of delivery, and three-hourly AZT 
during labour to the mother. If a woman had a CD4 cell count ≤200 cells/µl she was 
referred to a separate service to initiate cART.212 Vertical transmission proportions according 
to these treatment guidelines were reported to be 3.5% among infants who were tested 
around 6 weeks in immunisation services in 2009 in the Western Cape.251 
3.3 Methods 
The study methodology has been described in detail elsewhere.35 To ascertain cord blood 
HIV seroprevalence and ARV coverage, consecutive umbilical cord blood specimens were 
drawn at the study sites between December 2007 and May 2008.  A sample size was 
calculated for the four country study, whereby the number of specimens required was 
ascertained based upon an assumed PMTCT programme coverage of 55% (95% CI 0.52-
0.58). An estimated target of 800 specimens was required from each country, however, in 
order to make this sample size a function of HIV seroprevalence, this specimen target was 
divided by the estimated seroprevelance of each country at the time of the study.35 In some 
sites there were more deliveries and the study was completed within 6 weeks whereas in 
others completion took up to 6 months to complete. Anonymous HIV prevalence testing 
was performed, using a rapid immunoassay (Determine HIV1/2, Abbott Laboratories, 
Chicago, Illinois). High performance liquid chromatography and tandem mass spectrometry 
were used to extract and qualitatively detect the presence of maternal NVP, AZT and 
lamivudine (3TC) on all seropositive specimens.293 In order to draw comparisons between 
cord blood outcomes and PMTCT programme reporting, linked anonymous surveillance 
data were extracted from patient-held antenatal records and service registers at the time of 











obstetric data and recorded maternal and infant PMTCT regimen administration (Appendix 
1) 
The primary study outcomes were maternal HIV seroprevalence and ARV coverage, 
defined as the proportion of women who had at least NVP and AZT or cART (ascertained 
through the presence of 3TC) detected in cord blood specimens at delivery. Cord blood HIV 
seroprevalence and ARV coverage were then compared with HIV seroprevalence and ARV 
coverage data extracted from service records. In the service data, standard of care was 
assumed to be any documentation of AZT in combination with single dose NVP, or cART, 
regardless of duration. A series of proportions for each step of the PMTCT cascade was 
constructed from the extracted services data and cord blood specimen results. Kappa 
statistics were calculated to measure the agreement beyond chance between the presence of 
antiretrovirals in the cord blood and reported antiretroviral provision. Maternal-infant 
coverage was also determined through combined cord blood ARV coverage and 
documented administration of infant NVP and/or AZT from service records. Twin 
deliveries were treated as singleton deliveries for the purposes of analysis, as each set of 
HIV-exposed twins (n=4) received the same infant prophylaxis. Factors associated with 
PMTCT coverage were determined using a multivariable logistic regression model. The 
modelled impact of missed opportunities for maternal prophylaxis was assessed by assuming 
differential vertical transmission based on standard of care interventions,212 sub-optimal 
prophylaxis, no prophylaxis and seroconversion during pregnancy. Model estimates were 
based on assumed probabilities of 0.04 (AZT and NVP), 0.02 (cART), 0.12 (NVP only), 0.07 
(AZT only), 0.20 (no intervention) and 0.35 (seroconversion) reported by Johnson et al. in a 
model for paediatric HIV in this setting.294 
Ethical approval was granted by the institutional review boards of the United States 
Centers for Disease Control and Prevention; the Health Sciences Faculty Human Research 











Government of the Western Cape and the University of Alabama at Birmingham (Appendix 
2). 
3.4 Results 
Between December 2007 and May 2008, 3109 women delivered at the 3 sites and 3065 
(98.6%) cord blood specimens were collected.  
Figure 3.1 Cord blood specimen collection cascade, 2007-08 
 
Specimens were not collected from women who delivered before arrival or in 
instances where it was not possible to retrieve blood from the umbilical cord (cord snapped 
or unhealthy), or accidental specimen spillage. In total, 3034 specimens (97.6%) were tested 
3109 Documented deliveries
44 Specimens not collected
3065 98.6% Specimens collected
31 Not tested for HIV in laboratory
3034 97.6% Deliveries tested for HIV
2527 Cord blood HIV-negative
507 16.7% Cord blood HIV-positive
37
Cord blood HIV-positive 
specimens not tested for ARV
470 92.7% Tested for ARV coverage
346 73.6%












for HIV. Of the HIV-infected specimens (n=507), 470 specimens (92.7%) were tested for 
the presence of ARV regimens (Figure 3.1).  
The median maternal age of women was 24 years (Interquartile range[IQR]: 21-28 
years) and 37.4% of women were primigravid. The median number of antenatal visits was 4 
(IQR: 3-5 visits), with 21.2% of women having 2 or fewer visits and 8.2% of women having 
had no antenatal visits. Overall, 10.5% of women had caesarean sections. Four infants were 
stillborn and were excluded from the maternal-infant coverage analyses. The median birth 
weight of infants was 3100 grams (IQR: 2800-3400 grams), and 10.8% weighed 2500 grams 
or less (Table 3.1).  
Table 3.1 Sociodemographic, maternal and child characteristics,2007-08 
 N n  
All deliveries 3109    
Deliveries with complete laboratory HIV test  3034   
Deliveries with complete HIV and maternal 
antiretroviral coverage test results 
 2997 96.4%  
Primigravid 2979 1115 37.4%  
No antenatal visits 2995 244 8.2%  
Caesarean section 2976 313 10.5%  
    
Median age at delivery 2981 24 years IQR: 21-28 years 
Median number of antenatal visits 2724 4 visits IQR: 2-5 visits 
Median birthweight 2849 3100g IQR: 2800-3400g 
3.4.1 Documented antenatal HIV testing and HIV seroprevalence versus 
maternal cord blood HIV seroprevalence at delivery 
Documented antenatal HIV testing coverage was 79.4% (n=2408, Figure 3.2) and antenatal 
HIV prevalence among these women was 17.8% (n=429). Cord blood HIV seroprevalence 
among all women who delivered was similar at 16.7% (n=507, p=0.53).  
Among women who did not have an antenatal HIV test, 12.3% (n=77/626) had an 
HIV seropositive cord blood result. Based on documented antenatal HIV status versus cord 
blood status at delivery, there were 13 seroconversions (0.7%) and 12 specimens (2.8%) that 














Figure 3.2 PMTCT cascade showing HIV status by antenatal record and 



























































































3.4.2 Documented dispensed antiretroviral prophylaxis and cord blood 
antiretroviral coverage 
Table 3.2 shows that among the women who were documented to be HIV seropositive in 
service records, 65.8% (n=275) received AZT and NVP; 16.9% (n=71) AZT only; 2.4% 
(n=10) NVP only, and 7 women were documented to have received no intervention. 
Although CD4 cell counts were not extracted from the antenatal data and eligibility for 
cART could not be ascertained, a further 13.2% (n=55) of women were documented by 
patient record to be on cART. Hence according to service records, documented ARV 
coverage for receiving the standard of care including cART was 78.9% (n=330/418), and 
documented ARV coverage for all women who received any form of ARV drug was 98.3% 
(n=411/418). 
Table 3.2 ARV regimen coverage per antenatal record and cord blood 
specimen, 2007-08 
 Recorded ARV 
coverage 
Cord blood ARV coverage 
 Known HIV-positive Known HIV-positive, 
confirmed on cord blood 
All cord blood 
HIV-positive 
 n % N % n % 
AZT1 & NVP1 275 65.8 215 55.4 217 46.2 
cART1 55 13.2 55 14.2 56 11.9 
AZT 71 16.9 34 8.2 35 7.4 
NVP 10 2.4 37 9.7 38 8.1 
Standard of care 330 78.9 270 69.6 273 58.1 
Any 411 98.3 341 87.9 346 73.6 
None  7 1.7 47 12.1 124 26.4 
Total 418  2 388  470  
Notes: 1: AZT:azydothymadine; NVP: nevirapine; cART: Combined antiretroviral therapy 
 2: Recorded prophylaxis was not available in any record for 11 of 429 women 
known to be HIV-infected 
 
In comparison, of the 470 HIV seropositive women for whom cord blood specimens 
were available, 46.2 % (n=217/470) had AZT and NVP in their cord blood; 15.5% 
(n=73/470) had either AZT or NVP, and 11.9% (n=56/470) had 3TC, indicating that they 
were on cART. A further 26.4% (n=124/470) of HIV seropositive cord blood specimens 
had no trace of any antiretroviral regimen. In summary, 58.1% (n=273/470) of women 











(dual therapy or cART), while 73.6% (n=346/470) of women were found to have received 
some form of ARV prophylaxis (Table 3.2).  
3.4.3 Accuracy of routinely recorded coverage data 
When restricting the analysis to women who were documented by the services to be HIV 
seropositive, as well as cord blood HIV seropositive and in whom documented coverage 
could therefore be verified on cord blood (complete results on n=388), estimates of 
coverage were lower for dual therapy and AZT monotherapy, but higher for NVP on its 
own (55.4%% vs. 65.8%, 8.2% vs. 16.9% and 9.7% vs. 2.4% respectively, Table 3.2). 
Combined estimates for standard of care regimens or any regimen were consequently lower 
on cord blood analysis than reported by the services (69.6% vs. 78.9% and 87.9% vs. 98.3% 
respectively, Table 3.2). 
Kappa statistics measuring agreement beyond chance among the mothers for whom 
data was available from both sources for cART, AZT and NVP were 0.60, 0.14 and 0.32 
respectively, indicating reasonable agreement for cART, but limited agreement for the 
individual drugs, especially AZT. Of 242 mothers with AZT detected in their cord blood and 
for whom clinical record data were available, 236 (97.5%) had this recorded in their charts, 
whereas there was no evidence of AZT in the cord blood of 61/297 (20.5%) of mothers 
who were reported to have received AZT antenatally. Discrepancies between those reported 
to have received NVP peripartum and the detection of NVP in cord blood were comparable 
in both directions, with 15.3% (39/255) of those recorded to have received NVP not having 
it detected in their cord blood, and similarly 14.6% (37/253) of those with evidence of NVP 
in their cord blood not having any record of having received this (Table 3.3).  
Five out of 72 women who were documented as not having tested and who were cord 











the 12 women who were documented as being HIV seropositive but were HIV seronegative 
on cord blood testing were evaluated for antiretrovirals in their cord blood.  
 
Table 3.3 Measure of agreement between recorded ARV dispensing and 
cord blood specimen, 2007-08 
AZT 
 Dispensed     
  No Yes TOTAL       
In Cord Blood No  9 61 70  Agreement: 0.7853 
 Yes 6 236 242  E(Agreement): 0.7491 
 TOTAL 15 297 312  Kappa: 0.1440 
        
NVP 
 Dispensed     
  No Yes TOTAL       
In Cord Blood No  33 39 72  Agreement: 0.7662 
 Yes 37 216 253  E(Agreement): 0.6585 
 TOTAL 70 255 325  Kappa: 0.3152 
        
cART 
 Dispensed     
  No Yes TOTAL       
In Cord Blood No  293 16 309  Agreement: 0.9030 
 Yes 19 33 52  E(Agreement): 0.7593 
 TOTAL 312 49 361  Kappa: 0.5972 
 
3.4.4 Documented and cord-blood comparison of combined maternal-
infant ARV coverage  
Two infants born to HIV seropositive women were stillborn, and these mother-infant pairs 
were removed from this sub-analysis. According to service records, 68.6% (n=293) of 
infants born to HIV seropositive mothers (n=427) received ARV prophylaxis and 58.3% 
(n=249) mother-infant pairs received combined maternal standard of care and infant 
prophylaxis. When examining documented infant prophylaxis coverage among women with 
an HIV seropositive cord blood specimen (n=468), 62.6% (n=293) of infants were reported 
to have received ARV prophylaxis, and combined mother–infant coverage (seropositive cord 











exposed newborns who did not get ARV prophylaxis were missed because their mothers had 
not tested for HIV in pregnancy (72/175, 41.1%). 
3.4.5 Factors associated with maternal coverage 
In multivariable analysis that included maternal age, facility location as metropolitan or peri-
urban, and mode of delivery as possible confounders based on a priori assumptions, having 
five or more antenatal clinic visits was the only measured association with maternal coverage 
(defined as receiving either dual prophylaxis or cART, adjusted odds ratio [AOR] 2.47; 95% 
CI 1.19-5.15, Table 3.4). 
Table 3.4 Multivariable model of predictors of being on the standard of 
care at delivery, 2007-08 
    
Maternal 
coverage 1 
OR 95% CI AOR 95% CI 
Maternal age (n=466)      
 15-19 years 13/24 1  1  
 20-24 years 90/156 1.15 (0.49-2.74) 1.15 (0.43-3.03) 
 25-29 years 93/155 1.27 (0.53-3.01) 1.22 (0.46-3.25) 
 30 years or more 75/131 1.13 (0.47-2.72) 1.06 (0.40-2.83) 
Facility location (n=470)      
 Metropolitan 189/339 1  1.00  
 Peri-urban 84/131 1.42 (0.94-2.15) 1.24 (0.78-1.96) 
Number of antenatal visits (n=414)     
 1 or fewer 19/39 1  1.00  
 2-4 visits 147/234 1.78 (0.90-3.52) 1.73 (0.87-3.45) 
 5 or more visits 98/141 2.40 (1.16-4.94) 2.47 (1.19-5.15) 
Mode of delivery (n=466)      
 Caesarean section 33/58 1  1.00  
 Vaginal 238/408 1.06 (0.61-1.85) 1.46 (0.80-2.64) 
Note:  1 Number of women receiving the standard of care or cART/Total number of 
women with an HIV-positive cord blood specimen 
3.4.6 Missed opportunities 
Based on these results, PMTCT coverage appears near-complete in programme reporting, 











Figure 3.3 Missed opportunities for testing and antiretroviral coverage, 
2007-08 
 
However, Figure 3.3 shows that, according to cord blood surveillance, a substantial 
proportion of mothers (16.4%) identified as cord blood HIV seropositive did not receive 
prophylaxis because they had not tested for HIV (Figure 3.3, black shading). A further 7.9% 
(Figure 3.3, diagonal-lined section) of known HIV seropositive mothers had no ARVs 
detectable in their cord blood. Assuming differential vertical transmission for mothers 









No HIV test 16.4% 46.2%
Seroconverted 2.1% 10.5%
Known seropositive, no therapy 1.7% 7.9% 22.2%
AZT or NVP 19.4% 15.5% 21.0%
Standard of care































intervention (0.35 versus 0.20)294 and for mothers receiving standard of care (0.04 for dual 
therapy and 0.02 for cART) versus other maternal ARV prophylaxis: 0.12 for NVP and 0.07 
for AZT294), the most frequent missed opportunities for preventing transmission were the 
result of incomplete antenatal HIV testing and failure to administer any prophylaxis or to 
ensure adherence in women known to be HIV seropositive. 
3.5 Discussion 
As the international focus shifts towards the global elimination of paediatric HIV, effectively 
monitoring the coverage of PMTCT programmes is imperative to determine their strengths 
as well as to address the missed opportunities for identifying HIV infection and for 
delivering treatment during pregnancy. Our results show that just over half of women 
identified as cord blood HIV seropositive received the standard of care (dual therapy or 
cART), and about three quarters of women testing cord blood HIV seropositive had 
received some form of ARV. Maternal cord blood ARV coverage was significantly lower 
than that suggested by maternal coverage in routine data. Identifiable programme gaps 
included incomplete HIV testing and a failure to administer ARVs or ensure adherence. 
3.5.1 Concordance of reported versus cord-blood maternal HIV 
seropositivity 
Compared to other studies, seroconversion in this study was low (0.7%), assuming that all 
were true seroconversions and not documenting or reporting errors. Another study in the 
Cape Town metropole found no seroconversions among 532 pregnant women in 2004.177 
With an estimated transmission probability of 0.35,294 seroconversion in pregnancy may 
account for a small, yet significant proportion of transmission in many settings. As 
programme coverage improves, so the relative contribution of seroconversion will increase, 











3.5.2 Concordance of routine versus cord-blood maternal ARV 
prophylaxis coverage 
Results from the cord blood analysis suggested appreciably lower maternal ARV coverage 
than the near-complete coverage suggested by service data, even when restricted to patients 
who were definitively known by the services to be HIV seropositive. The largest discrepancy 
was found between reported and cord blood AZT coverage. Due to the short plasma half-
life of AZT and reported variability in concentrations between subjects elsewhere,296-299 we 
cannot assume that all women without AZT in their cord blood did not receive any AZT 
prior to delivery. However, guidelines at the time of this study recommended AZT from 28 
weeks gestation as well as 3-hourly during labour. Evidence from other settings has 
demonstrated the presence of therapeutic concentrations of AZT in cord blood when oral 
doses were administered within three hours of delivery.300 Hence in our setting, AZT 
concentrations should have been reflected in those women who received PMTCT according 
to protocol during labour. Furthermore cord blood results of AZT coverage at delivery 
cannot be extrapolated to infer adequate antenatal coverage.301 There is also a possibility that 
regimens may not have reflected in women who delivered too quickly after presenting in 
labour. 
3.5.3 Missed opportunities 
Our results show that one in five women did not test for HIV in pregnancy and 12% of 
these women were HIV seropositive at delivery. Several studies have shown regional 
variation in antenatal testing coverage in South Africa,302,303 with the national antenatal testing 
average estimated to be 92.7%.246 This is thought to be an overestimate, as testing coverage is 
reported to be over 100% in some health districts.248 Routinely collected data from the sites 
at the time of this study report testing coverage to range between 77-100%, suggesting that 
HIV screening in pregnancy could be improved. Modelling exercises have shown that failure 











further along the PMTCT cascade.129 This analysis supports the importance of initial 
antenatal testing coverage as the single largest contributor to missed opportunities for 
preventing transmission, but further highlights substantial missed opportunities, as a result of 
no prophylaxis being taken by women known to be HIV seropositive, suboptimal 
prophylaxis and seroconversion during pregnancy.  
3.5.4 Limitations 
A limitation of this study is the absence of CD4 cell count data which would have assisted in 
the further disaggregation of the standard of care. There is also concern about record 
keeping: clerical errors, antenatal false-positive tests or cord blood false-negative tests could 
have given rise to the 12 women who tested HIV seropositive in pregnancy and had a 
seronegative cord blood specimen at delivery. All antenatal HIV seropositive tests are 
routinely confirmed by a second rapid test in South African service settings, and in our 
laboratory, the same protocol was performed, with an additional 10% of tests being tested 
blind for quality assurance. Our specimen collection rate was high at the sites (98.5%), 
however, logistical challenges resulted in the random loss of 7% of cord blood seropositive 
specimens which could not be tested for regimen coverage. Furthermore, the small sample 
size, particularly reflected by the small proportion of HIV seropositive women may account 
for the lack of statistical power of the reported ARV coverage outcomes. 
3.5.5 Conclusion 
Our results show that even in a well-resourced setting, improving HIV screening coverage 
and ensuring compliance with guidelines for antenatal prophylaxis were the most immediate 
priorities for reducing vertical transmission. As increasing resources are invested in the rapid 
expansion of HIV prevention and treatment programmes there is a need for the 
strengthening of monitoring and evaluation of the effectiveness of these programmes.304 











challenge because the interventions at each step of the PMTCT cascade occur sequentially 
through pregnancy and involve more than one service and provider, as well as crucial 
delivery of treatment at different points in pregnancy. This study, along with evidence from 
other settings305 shows the value of cord blood surveillance as a feasible tool for confirming 
both antiretroviral provision and regimen adherence. Cord blood surveillance could be used 












Paper 2: Initiation of highly active antiretroviral therapy 
among pregnant women in Cape Town, South Africa 
Stinson K, Boulle A, Coetzee D, Abrams E.J, Myer L. (2010) Initiation of highly active 
antiretroviral therapy among pregnant women in Cape Town, South Africa. Tropical 
















To investigate highly active antiretroviral therapy (HAART)1 initiation among 
pregnant women and the optimum model of service delivery for integrating 
HAART services into antenatal care.  
Methods  
We analysed clinic records to reconstruct a cohort of all HIV-infected pregnant 
women eligible for HAART at four antenatal clinics representing three different 
service delivery models in Cape Town, South Africa. To assess HAART 
coverage, records of women determined to be eligible for HAART in pregnancy 
were reviewed at corresponding HIV treatment services.  
Results   
Among 13,208 pregnant women tested for HIV, 3,498 (26%) were HIV-infected 
and 516 (15%) were HAART-eligible based on a CD4 cell count of ≤200 cells/µl. 
Among eligible women, 51% initiated HAART before delivery, 27% received 
another prevention of mother-to-child (PMTCT) intervention and 22% did not 
receive any antiretroviral intervention before delivery. The proportions of 
women initiating HAART between the different service delivery models were 
comparable. The median gestational age at first presentation was 26 weeks and 
early gestational age at first presentation was the strongest predictor of being 
on HAART by delivery. Of the women who did not initiate HAART in pregnancy, 
24% started treatment within two years postpartum. 
Conclusions  
In this setting with clear PMTCT and HAART protocols, services failed to 
prioritize and initiate a high proportion of eligible pregnant women on HAART. 
The initiation of HAART in pregnancy requires strengthened antenatal and HIV 




1This paper was published using the term, ‘HAART’, because at the time of this study, it was the term used for 
antiretroviral therapy. Hence in order to reflect the publication, no changes have been made to this chapter. In 












The use of antiretroviral (ARV) prophylaxis during pregnancy and labour can dramatically 
reduce the risk of vertical transmission of HIV infection. Highly active antiretroviral therapy 
(HAART) has the greatest efficacy in reducing mother-to-child transmission (MTCT) of 
HIV and has significant direct benefits for maternal health.7 Results from recent studies of 
improved regimen combinations, earlier treatment start in pregnancy and continued ARV 
support for mother and infant during breastfeeding in the postpartum period have led to 
significant changes in the recommendations for managing pregnant HIV-infected 
women.30,306-308 In light of new evidence, WHO recently released revised guidelines for the 
management of HIV-infected women in pregnancy which recommend initiating lifelong 
HAART earlier in pregnant women, and raising the eligibility criteria from a CD4 cell count 
threshold of ≤200 cells/µl to ≤350cells/µl or WHO clinical staging 3 or 4, irrespective of 
gestational age.44 
Despite the importance of HAART during pregnancy, there are significant patient- 
and service-related challenges to the implementation of HAART services as part of antenatal 
care. In many settings, high HIV seroprevalence among women of reproductive age results 
in a sizeable proportion of HIV-infected pregnant women accessing limited antenatal and 
HIV care services 60. Patient-driven barriers include lack of knowledge of serostatus prior to 
conception; reluctance to test in pregnancy; fear of disclosure and denial post-diagnosis, and 
under-utilization of antenatal care during pregnancy.16,24,25,309 Service delivery approaches 
impact on the accessibility and availability of treatment services for HIV-infected pregnant 
women. Prevention of mother-to-child transmission (PMTCT) services for women who do 
not have advanced HIV disease, but who require short course prophylactic regimens, are 
generally integrated within routine antenatal health services managed by midwives. Presently 











As a result, these women may need to access antenatal care and stand-alone doctor-driven 
HAART services that may be geographically separate. The integration of HAART into 
antenatal services has been proposed and is underway in selected settings, yet little is known 
about the operational experience of different models of service delivery in resource-
constrained contexts.24 
Cape Town health services were among the first in the region to offer both PMTCT 
(1999) and HAART (2001), with protocols providing for universal access to HAART for 
eligible pregnant women since 2003.219,291 A number of service models for delivering 
HAART to pregnant women developed during this period, providing an opportunity to 
explore the relationship between these models and the uptake of HAART. Although 
HAART has been available for eligible HIV-infected pregnant women in Cape Town since 
2003, little is known about HAART coverage in pregnancy. The objectives of this study were 
to describe HAART coverage in a cohort of eligible women accessing antenatal services and 
to evaluate different service models for providing HAART.  
4.2 Methods 
4.2.1 Study setting 
This study evaluated three different service models for HAART referral and initiation in 
pregnancy at four primary care antenatal clinics in Cape Town during 2005. The sites were 
selected to highlight the differences in the proximity of the ARV service to the antenatal site 
and the service model offered. One antenatal clinic incorporated an “integrated” HAART 
service, offered once per week by two outreach doctors. The second antenatal clinic referred 
eligible women to a stand-alone ARV service in a separate building on the same premises, a 
“proximal” model of care. The third, the “distal” model constituted two antenatal clinics, 
and eligible women were referred to ARV services within a five kilometre radius, accessible 











All four clinics operated according to identical midwife-driven care protocols with the same 
procedures for all aspects of antenatal care311,312 including PMTCT. At each antenatal clinic, 
HIV counselling and opt-in testing was offered as part of routine care. After group and 
individual counselling, a rapid HIV test was performed and results were given with post-test 
counselling on the same day. For newly diagnosed HIV-infected women, specimens were 
sent to external laboratories for CD4 cell count enumeration and results were available at the 
service within 2 weeks. In the proximal and distal models of care, women eligible for 
HAART were given a referral letter to each ARV service linked to the antenatal service, 
where treatment initiation occurred. At all sites neonatal prophylaxis was administered at 
birth for HIV-infected women in the delivery room.  
4.2.2 Study design and data collection 
This retrospective cohort included all women who presented at the four antenatal facilities 
between 1 January and 31 December, 2005. Antenatal data including demographic 
information, HIV status and CD4 cell count were extracted from PMTCT registers kept on-
site using a standardized data extraction tool (Appendix 3). Field workers fluent in local 
languages searched paper-based and electronic data sources for patient name variations and 
supplemented this with other personal identifiers, such as date of birth where needed, to 
maximise follow up. Missing data, including CD4 cell counts were obtained from the 
National Health Laboratory Services patient database. 
The subset of HIV-infected women eligible for HAART based on a CD4 count ≤ 200 
cells/µl was identified through patient registers and then traced through antenatal care and 
HIV care and treatment programme records to determine HAART initiation and obstetric 
and newborn outcomes. HAART coverage was defined as evidence of initiating HAART 
during pregnancy, or evidence of being on HAART at delivery. Patients with missing 











through the records and data bases of each relevant health facility, including secondary and 
tertiary referral hospitals as well as every clinic providing HAART in the city. 
Data were analysed using STATA 9.0 (STATA Corporation, College Station, USA). 
Proportions were estimated for each step of the PMTCT cascade and HAART coverage was 
calculated both for the entire cohort and separately for the integrated, proximal and distal 
service models. Bivariate associations were calculated using χ2 tests for categorical variables 
and one-way ANOVA models or the Kruskal-Wallis test for continuous data. Multiple 
logistic regression was used to examine the independent predictors of HAART initiation in 
pregnancy. The inclusion of the dependent variables was based upon a priori knowledge, their 
significance in univariate analyses and model fit in the regression analysis. Approval for the 
study was obtained from the University of Cape Town Research Ethics Committee and local 
government health authorities (Appendix 4).  
4.3 Results 
4.3.1 Patient and pregnancy characteristics  
A total of 14 987 women presented for antenatal care at the four sites (Table 4.1, overleaf). 
The mean age was 25 years (standard deviation, 6 years). Overall 88% of women were tested 
for HIV and 26% were HIV-positive (Figure 4.1, on page 93). Uptake of testing and HIV 
prevalence varied between service models: the proximal model had the lowest coverage of 
79% and the integrated model had the highest seroprevalence of 30% (p<0.001 for both 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Overall, 97% of women who tested HIV-positive had a CD4 test completed by 
external laboratories; 15% (n=516) had a CD4 cell count of ≤ 200 cells/µl and were eligible 
for HAART. Twenty-nine percent (n=986) of HIV-infected women had a CD4 cell count 
>200 cells/µl but ≤350 cells/µl. The proportion of women eligible for HAART did not vary 
between the service delivery models (p=0.09, Table 4.1). The median gestational age at time 
of first presentation among HAART-eligible women was 26 weeks (Interquartile Range: 21-
31 weeks) and varied significantly by service delivery model (p=0.02, Table 4.1), with women 
in the distal service model presenting earlier than those in the other two models. Fewer than 
14 987 Women booked for 
antenatal care
1 751 Declined testing
28 Not offered testing
13 208 Tested 88%
9 694 Tested HIV 
negative
16 No test result 
recorded
3 498 Tested HIV 
positive 26%
3405 CD4 > 200 cells/µl
93 CD4 test not done


















25% of HAART-eligible women presented for their first antenatal clinic visit by 20 weeks 
gestation, 71% by 30 weeks, and 89% presented by 35 weeks.  
Of the HAART-eligible women, 391 (76%) had complete delivery information 
available. Of these women, 70% had normal vaginal deliveries and 30% had caesarean 
sections. Of the 404 resulting babies born, 6% ended in perinatal loss (stillbirth or early 
neonatal death). Data on birth weight were recorded for 367 live infants, of whom 20% were 
under 2500 grams. 
Figure 4.2 HAART coverage by service delivery model, 2005 
 
4.3.2 HAART initiation 
A total of 51% (n=262) of all women with a CD4 cell count of ≤200 cells/µl had initiated 
HAART by the time of delivery (Figure 4.2). The proportion of eligible women initiating 
HAART was 55%, 48% and 47% in the integrated, proximal and distal models, respectively 
(p=0.29, Table 4.1). The median gestational age at first antenatal clinic attendance was lower 
(19%) 















among women who initiated HAART in pregnancy (24 weeks) compared to those who did 
not (29 weeks, p<0.001). For women who were on treatment by delivery, the median 
gestational age at initiation was 32 weeks (IQR: 28-36 weeks). Of these women, 48% had 
more than 8 weeks of HAART; 32% had between 4 and 8 weeks of HAART, and 20% had 
less than 4 weeks of HAART. The proportion of women who received more than 8 weeks 
of HAART versus those who received 8 weeks or less of HAART did not vary by service 
model (p=0.96, Table 4.1). Of the 254 women who did not start HAART before delivery, 
24% (n=61) went on to initiate HAART in the ensuing 2 years postpartum, half of whom 
started within 7.5 months after delivery. 
In a logistic regression model to predict HAART initiation during pregnancy, there 
was no association between the model of care and whether HAART was started in 
pregnancy (p= 0.19, Table 4.2). However, women who presented for their first antenatal visit 
in the third trimester of pregnancy were 75% less likely to be on HAART at delivery than 
those who had presented in the first or second trimester (Adjusted Odds Ratio: 0.25, 95% 
CI: 0.17-0.39). 




Ratio P-value   
95% Confidence 
Interval 
Age (Ref ≤27 years)     
 Age >27 years 1.09 0.68  (0.72-1.66) 
      
Service Model (Ref: Model 1- Integrated)*    
 Model 2 - Proximal 0.77 0.30  (0.48-1.26) 
 Model 3 - Distal 0.62 0.07  (0.37-1.04) 
      
Gestational age at booking (Ref: < Trimester 3)    
  Trimester 3 0.25 <0.001   (0.17-0.39) 
 *Wald test for global p-value: 0.19   
 
A further 27% (n=141) of women who were eligible for HAART were recorded as 
receiving some form of PMTCT prophylaxis, usually zidovudine with single dose nevirapine 











in pregnancy, according to either their antenatal clinic records or HAART initiation registers 
across the city. The proportion of patients receiving other forms of ARV-based PMTCT 
interventions, versus no intervention at all, also did not differ by service model (p=0.88, 
Table 4.1). Gestational age at first presentation was a strong predictor of PMTCT coverage: 
among women who presented in the second trimester 70% initiated HAART and another 
23% received ARV prophylaxis, while among women who presented in the third trimester 
39% started HAART and another 48% received prophylaxis.  
4.4 Discussion 
This analysis demonstrates substantial missed opportunities to initiate HAART among 
pregnant women with advanced HIV disease within public sector antenatal care services. 
Only 51% of HAART-eligible women initiated treatment before delivery, while another 27% 
received a short-course PMTCT regimen and more than one-fifth of women received no 
intervention. Importantly there were no significant differences in these proportions between 
the integrated service in which antenatal care and HAART were co-located, the proximal 
service with separately run services on the same premises and the distal model with off-site 
antenatal HAART provision.  
Recently, the WHO revised its ARV treatment guidelines to recommend the initiation 
of HAART in all adults including pregnant women with CD4 cell counts ≤350 cells/µl.44 
Our study showed very high CD4 cell count testing coverage, and based on our data, shifting 
to a CD4 cell count threshold of ≤350 cells/µl would have raised the proportion of eligible 
HIV-infected women from 15% to 44%, amounting to a threefold increase in women 
eligible for life-long treatment. While this change in threshold for treatment initiation is likely 
to yield significant improvements in maternal health outcomes, as well as reduce perinatal 
transmission, our study points to the challenges of implementing these guidelines and 











Part of the challenge is likely due to the difficulty in initiating HAART in a midwife-driven 
antenatal care service and the subsequent logistical demands of coordinating HIV and 
antenatal care. As doctors are not routinely available in antenatal clinics in this setting and 
midwives are not certified to prescribe HAART, eligible women must attend separate HIV 
services or return to the antenatal clinic when a HAART prescriber is available. Furthermore, 
at the time of this study, it was reported that the duration of treatment adherence 
preparation in patients eligible for HAART was 4-6 weeks. The possibility of ‘fast-tracking’ 
eligible women onto HAART during pregnancy has been suggested but there are few reports 
of such an approach in practice, and its impact, given that the availability of appropriate 
providers is static. Particular concerns may exist around how patient preparation before 
HAART initiation influences long-term outcomes, although there are few data evaluating 
this possibility. The availability of appropriate clinical personnel to initiate HAART in 
antenatal care has been raised as an additional concern. One option that has been suggested 
to address this is nurse-driven HAART initiation which has proven effective and feasible in 
African settings;313 in the context of pregnancy, midwives are a potentially valuable human 
resource for HAART initiation and the possibility of midwife-driven HAART services 
deserves consideration.3141 
Meanwhile, the challenge of starting HAART in newly diagnosed pregnant women 
should not be underestimated. Unknown HIV serostatus in pregnancy and labour has been 
described as an important factor hindering PMTCT scale-up.16 In this setting where 
utilization of antenatal care services is high, universal HIV screening was not achieved, with 
a substantial proportion of women not testing for HIV. Attrition at this point contributes to 
the pool of infected women of unknown serostatus who will not receive PMTCT 
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 Subsequent to the publication of this article, nurse administered and managed ART (NIMART) has 











programme support in pregnancy, and who are consequently at increased risk of MTCT. The 
integrated model achieved 98% testing coverage, which was most likely due to individual 
provider influences at this site, as the opt-in guidelines were consistent across the sites at the 
time of the study. By modelling the collective data on 100% testing coverage, it is predicted 
that a further 70 HAART-eligible women would have been missed due to failure at this step 
in the cascade. In addition, recent evidence suggests that services are failing to identify 
HAART-eligible HIV-infected women through clinical and immunological assessment. 257,315 
Furthermore, the psychosocial impact of HIV infection on pregnancy has been documented 
in women with both pre- and post-conception HIV diagnosis, and anxiety during pregnancy 
is commonly associated with disease-related stigma and fear of the risk of vertical 
transmission.147,316-318 In addition, among non-pregnant adults psychosocial barriers to 
HAART uptake and adherence have been reported to include fear of treatment side effects, 
stigma and a lack of belief in the efficacy of HAART,319 However, little is known about the 
psychosocial challenges to initiating HAART during pregnancy, particularly among women 
who are diagnosed with HIV while seeking antenatal care. It is plausible that the combined 
psychosocial effects of an HIV diagnosis and HAART initiation during pregnancy may be 
particularly problematic, but this possibility requires further research.  
We found no difference in HAART initiation during pregnancy between the 
integrated, proximal and distal models of antenatal HAART delivery. A priori our hypothesis 
was that the integrated model would be associated with a significantly greater proportion of 
women starting HAART during pregnancy through increased access to combined antenatal 
and HAART services. The fact that the integrated model, which had a higher disease burden 
and more women eligible for HAART, initiated HAART in more women in absolute terms 
could be demonstrative of a better model. Other authors have also suggested that the 
integrated model of antenatal HAART services may be expected to facilitate HAART 











increase of HAART uptake in pregnant women from 46% to 71% in one urban South 
African hospital.320 While our data suggest that in this setting the specific service delivery 
model may not be a major determinant of HAART initiation in pregnancy, the failure to 
observe this could be related to the fact that the integrated service was limited to one day a 
week. Since it was not available to pregnant women during all antenatal service hours, it may 
not have been optimally “integrated,” and it is likely that the frequency of the service offered 
may have impacted on coverage. Despite limited capacity, it is impressive that this model 
performed as well, if not better than models where the referral service was operating every 
day. Clearly, health systems need to shift from disease specific programmes towards 
strengthening approaches to integrated maternal and child health and HIV services, to 
increase the uptake of HAART in pregnancy.  
This study focused on HAART initiation during pregnancy; it does not address the 
issues of long-term follow-up of HIV-infected mothers. It is unclear whether a specific 
model of antenatal HAART initiation may be associated with better long-term retention of 
mothers in HIV care services postpartum. Specifically, it is plausible that an integrated model 
of HAART initiation during antenatal care leads to more women starting HAART during 
pregnancy, but the transition to routine adult HIV services postpartum is more difficult, 
compared to an antenatal HAART model where pregnant women are referred immediately 
to routine HIV care services. The postpartum follow-up of women who initiated HAART 
during pregnancy appeared problematic in one study 321 but another suggested that initiation 
during pregnancy is not associated with outcomes that are worse than in non-pregnant 
women; 322 clearly this possibility requires further investigation. 
We found that gestational age at first antenatal visit was a major determinant of 
HAART initiation during pregnancy, with women making their first antenatal visit during the 
third trimester 75% less likely to start HAART while pregnant. At the time of the study, the 











gestation, and this guideline in conjunction with late presentation may have impacted on 
providers’ decisions to initiate treatment close to the time of delivery. However, discussions 
with local service providers (not presented here), suggested that this guideline was not fully 
implemented. Furthermore, as duration of HAART is an important factor in achieving viral 
suppression and in turn preventing vertical transmission of HIV, late presentation is a 
significant concern. Our study suggests that of those women who received HAART, less 
than half received more than 8 weeks of treatment before delivery. Data from the European 
Cohort Study suggest that at least 8 weeks of HAART are required to achieve viral 
suppression in women with advanced HIV disease 128 and one study in South Africa 
demonstrated that in women initiating HAART during pregnancy, every additional week of 
treatment reduced the odds of transmission by 8%. 323 Efforts to encourage women to seek 
antenatal care earlier in pregnancy are likely to face a host of patient- and health service 
related barriers.144,324 Continued progress towards achieving universal HIV testing, 
particularly in pre-conception care, could ensure that more women are aware of their 
serostatus prior to conception. Furthermore, moving towards the adoption of provider-
initiated counselling and testing, CD4 cell count enumeration and improved systems of 
expedited HAART initiation should be explored.16  
These data should be interpreted in light of several limitations. This research was 
conducted in a high HIV prevalence urban setting within well-established maternal and child 
health care services. We may anticipate that the proportion of eligible women initiating 
HAART during pregnancy may be lower in settings with less robust antenatal care systems. 
These data are from retrospective reviews of clinic records, rather than purposively collected 
prospective data. However, the system of clinic registries for antenatal care and HAART 
services that served as the primary data sources is well established and is frequently used for 
HIV-related research in this setting, 325 and hence unlikely to be an appreciable cause of 











context-specific differences between facilities and since we selected only four sites to 
represent the three service delivery models, inter-clinic variability, rather than inter-model 
variability may be an explanation for the observed findings. The small sample size may have 
also contributed to the lack of statistically significant associations, due to lack of power. 
Furthermore, these data come from 2005 when the local public sector HAART programme, 
and its links to antenatal care and PMTCT, was still being established. However, the situation 
of relatively new HIV care and treatment programmes that are exploring the options of how 
to interface with more established antenatal care structures, particularly in light of recent 
WHO policy developments, is likely to be closer to the norm across most of sub-Saharan 
Africa.123 Thus these results are valuable in highlighting the significant hurdles facing health 
care services and HIV-infected women starting antenatal HAART. 
In summary, this study illustrates that in this setting with clear PMTCT protocols, a 
high proportion of eligible women did not initiate HAART before delivery. A range of 
important health service and patient-level challenges may be associated with initiating 
HAART in pregnant women. Further research into specific models of care is needed to 
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Pregnancy is an important time for identifying HIV infection in women to 
prevent mother-to-child transmission. Antenatal services can also identify 
women with advanced disease and link them to lifelong antiretroviral treatment 
(ART). ART services have more often been established outside of antenatal 
care, however, emerging research supports calls to strengthen service linkages 
to promote improved maternal and child health outcomes. To investigate the 
effect of service linkage between antenatal care and ART services, this study 
evaluated treatment initiation in three different service delivery models in a 
cohort of women accessing antenatal care in Cape Town during 2008.  
Results  
Of 14 617 women who presented at the three selected antenatal services in 
2008, 94% tested for HIV. HIV prevalence was 29% and 698 (17%) were 
eligible for ART. Of these women, 11% had initiated ART prenatally, and a 
further 46% initiated ART before delivery. Overall ART coverage was 52%. A 
service delivery model in which ART was integrated into the antenatal service 
performed significantly better than both the proximal and distal models of 
separate services (62% vs. 49% and 44% ART coverage, respectively, global 
p=0.001), with women presenting at separate services being almost half as 
likely to be on ART at delivery (Adjusted Odds Ratio: 0.54, 95% Confidence 
Interval: 0.34-0.85; and AOR: 0.47, 95% CI: 0.28-0.79 respectively). Late 
antenatal presentation impacted significantly on failed coverage. 
Conclusions 
Although ART initiation in pregnancy remains a challenge, this research 
suggests that integrating ART services within antenatal care may help lead to a 
larger proportion of women starting treatment during pregnancy. More research 


















The effectiveness of antiretroviral (ARV) regimens administered to pregnant women and 
exposed infants during pregnancy and postpartum to prevent mother-to-child transmission 
(MTCT) and improve maternal health is well established.7 Prevention of mother-to-child 
(PMTCT) programmes have been implemented in most countries in Africa, where the 
highest proportion of HIV-infected pregnant women live.11,14 Yet in comparison to well-
resourced settings, progress in the scale-up and subsequent coverage of PMTCT 
programmes has been slow, in spite of the fact that 70% of HIV-infected pregnant women 
in these settings access antenatal services at least once in pregnancy.15 Estimates of 
programme coverage in 2008 reported that 53% of HIV-infected pregnant women and 35% 
of exposed infants received antiretroviral drugs in 2009.15,17 
Antiretroviral therapy (ART) to treat maternal infection and prevent vertical 
transmission has become the most important component of PMTCT programmes to date.257 
Historically, simple regimens for PMTCT have been integrated within antenatal services 
successfully in resource-constrained settings. Current PMTCT guidelines developed by the 
WHO recognise the value of initiating women with higher CD4 cell count thresholds earlier 
in pregnancy on lifelong ART.36 Yet HIV care and treatment services for adults with 
advanced stage disease have more often been established as stand-alone services, potentially 
compromising care for pregnant women who are eligible for ART.24 There have been calls to 
integrate antenatal and HIV care and treatment services, given the importance of providing 
ART to eligible women.83,115 
 Several studies have explored innovative service delivery models to strengthen the 
continuity of care for these women. In Zambia, Killam et al. report that introducing ART 
once to twice weekly within the antenatal setting doubled the uptake of ART within 60 days 











intervention did not have any effect on the time to initiation or retention in care outcomes.123 
Evidence from a South African study found that weekly provision of providers to identify 
and facilitate referral of eligible women to participating ART services reduced median time 
to initiation, with intervention coverage of 75%.125 Another study in Rwanda, demonstrated 
that pregnant women who attended facilities offering integrated ART services were almost 
twice as likely to enrol at the ART service as women who attended stand-alone antenatal and 
ART services. Yet there was no significant difference between these two service models in 
terms of ART initiation, which was 83% overall.124 
While these studies demonstrate the feasibility of integrating ART within ANC 
services, their results also suggest challenges to rapid uptake of interventions before delivery 
and suboptimal treatment initiation in pregnancy. In turn, there is a clear need for more 
operational research to ascertain the optimal models of service delivery for ART in 
pregnancy. We have documented similar challenges in Cape Town, South Africa in 2005 (as 
shown in Chapter 4) when ART for pregnant women was becoming available. At that time, 
we found that 51% of ART-eligible women commenced ART in pregnancy. We also 
reported that there was no significant difference in uptake between three different service 
delivery models designed to link women to ART care in pregnancy, each defined by the 
proximity of the antenatal service to an ART service.245 The objectives of this study, 
conducted in 2008, were to ascertain whether initiation of ART in pregnancy had increased 
over time in this population in the same services studied during 2005, and whether any 














Antenatal and obstetric primary care in the Cape Town metropole is midwife-run, with 
referral to secondary and tertiary care when indicated.311,312 We identified retrospectively a 
cohort of pregnant women who presented during the 2008 calendar year at three antenatal 
services. PMTCT services were available in this setting from 1999. 218 In 2004, Western Cape 
PMTCT protocols were redrafted to include referral of pregnant women who were identified 
as ART-eligible to ART sites.214 Satellite clinics were set up within the antenatal service or in 
close proximity to the service to facilitate referral.219 National guidelines at the time of this 
study recommended ART initiation in women with CD4 counts ≤200 cells/µL.212 During 
2008, the selected sites began to roll-out ART to women with CD4 counts ≤250 cells/µL in 
advance of the release of updated PMTCT guidelines for the Western Cape in June 2009.326  
5.2.2 Setting design 
The three sites each implemented a different service model for delivering ART to eligible 
pregnant women. The first consisted of an ‘integrated’ approach in which women were able 
to initiate ART within the antenatal clinic on specific days when community obstetricians 
with an HIV specialisation were on site (Site 1). The second we denoted a ‘proximal’ 
approach in which women were referred (by letter) to a separate ART service located within 
100m of the maternity unit (Site 2). The third service model, the ‘distal’ approach, delivered 
ART at another primary health care facility within five kilometres of the antenatal service, 
also using a referral letter (Site 3). Each of these sites was assumed to be the designated site 
for initiation in ART-naive pregnant women, as stipulated by the service delivery model 
provided. At the time of the study, there were 31 other primary health services which were 












HIV counselling and testing coverage, HIV status and CD4 cell count result were 
determined from antenatal service registers. A folder review of all HIV-infected women who 
presented with a CD4 cell count of ≤200 cells/µL was conducted to incorporate antenatal 
and obstetric history. The labour ward registers of each site, as well as those of secondary 
and tertiary referral sites, were also reviewed. Details pertaining to sociodemographic 
characteristics, antenatal and obstetric history, and PMTCT or ART coverage were captured 
(Appendix 5). In instances of missing data, electronic sources for CD4 cell counts and 
obstetric information were accessed. To ascertain ART initiation and coverage among 
women with CD4 cell counts ≤200 cells/µL, an on-site electronic data base search was 
conducted in conjunction with a matching paper-based folder review at all 31 ART clinics in 
the metropolitan area by fieldworkers fluent in local languages. Following this, all remaining 
ART eligible HIV-infected women with missing ART data were searched for in the 
electronic Western Cape ART monitoring database. 
5.2.4 Measures 
The primary outcome of this study was the proportion of women with a CD4 count≤200 
cells/µL who initiated ART during pregnancy, stratified by service delivery model. Antenatal 
initiation was confirmed by a date which fell between first antenatal presentation and 
delivery date, or in the event of no available initiation date, evidence from the antenatal 
folder or labour ward register indicating ART coverage. Among women who were confirmed 
to have initiated ART after first presentation, but for whom a delivery date was missing, 
antenatal ART initiation was assumed to have occurred within 90 days of antenatal 
presentation, and postnatal initiation >90 days after antenatal presentation. This assumption 
was based on a calculation of the average time between presentation and delivery in the 











counts ≤200 cells/µL, those either documented as not being on ART antenatally, or those 
who were not found in any of the available data sources, were coded as not having initiated 
antenatal ART.  
ART coverage was defined according to pre-pregnancy and antenatal initiation. Pre-
pregnancy coverage was determined by evidence of an ART initiation date prior to antenatal 
presentation. Postnatal coverage was confirmed by a postpartum ART initiation date which 
was searched for up to August 2011 in women who were classified as having received no 
antenatal ART. The ART treatment site was noted where possible for each woman who 
initiated in pregnancy. Where this information was not available, the ART treatment site was 
assumed to be the service linked to the specific model of service delivery. Where information 
on gestational age at presentation or delivery date was not available, an assumption of a 39 
week gestation period was made.  
5.2.5 Analysis 
The data were cleaned and analysed in Stata 12 (STATA Corporation, College Station, USA). 
In women who appeared in the antenatal register twice, the date recorded for the first HIV 
test was retained. Proportions for each step of the PMTCT cascade were estimated 
according to service delivery model. Bivariable associations were tested using statistical 
methods for categorical and continuous non-parametric data (Pearson’s Chi-squared test and 
Kruskal-Wallis test, respectively). Kaplan-Meier estimates were calculated to determine time 
to treatment initiation among eligible women with available information, and a log-rank test 
was performed to assess the significance of differences in time to treatment between sites. 
Logistic regression modelling was used to test the association between ART initiation and 
service delivery model (integrated/Site 1 vs proximal/Site 2 vs distal/Site 3), adjusted for 











obtained from the University of Cape Town Research Ethics Committee and local 
government health authorities (Appendix 6). 
5.3 Results 
5.3.1 Cohort description 
In 2008, 14617 women presented for antenatal care at the three antenatal services. Nine 
women were identified as having early miscarriage or had a false-positive pregnancy test and 
were excluded from the analysis. The median age at presentation was 25 years (Interquartile 
Range [IQR]: 22-30 years), with the median age of women at Site 1 being 2 years higher than 
women at the other sites. HIV counselling and testing uptake was high, but varied 
significantly between the sites (p<0.001), with Site 1 achieving near universal coverage (99%) 
and Site 3 testing the fewest women (89%). Site 3 had the lowest HIV prevalence among 
those who tested (18%), while Site 1 had the highest, with 32% of women testing HIV-
positive. Three per cent of women did not have a CD4 cell count result recorded either in 
paper or electronic sources. The median CD4 cell count among all HIV-infected women was 
373 cells/µL (IQR: 240-542), and 17% (n=698/4107) of all women had a CD4 cell count of 
≤200 cells/µL, up from 15% reported in 2005.245 These proportions varied significantly 
between the three sites (p=0.037) with Site 2 contributing the highest proportion of ART-
eligible women (39%, n=277/698), followed by Site 1 (36%, 252/698) and Site 3 (24%, 
169/698). A further 9% of women presented with CD4 cell counts of 201-250 cells/µL; 
18% of HIV-infected women had a CD4 cell count of 251-350 cells/µL, and just over half 
















14,617    Women booked 
for antenatal care
9 Identified false 
pregnancy/early 
miscarriage 0.06%
494 Did not test 3.4%
13,841    Tested
94.7%
273 Did not test, 
known HIV-
positive status 2.0%
9,995    Tested HIV-
negative 72.2%
12 No result 0.1%
4,107      
29.7%
2,159 CD4 > 350 cells/µl
52.6%
756 CD4 251-350 
cells/µl 18.4%
368 CD4 201-250 
cells/µl 9.0%
126 CD4 test not 
done 3.1%
698 CD4 ≤200 cells/µl 17%























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.2 ART initiation among eligible women with CD4 cell counts ≤200 
cells/µL 
Of the 658 women with a CD4 cell count ≤200 cells/µL, 11% (n=81) were already on ART 
at presentation. This varied significantly between the sites (p=0.04) with Site 1 representing 
the highest percentage (14%) and Site 3 representing the lowest percentage (8.3%). When 
excluding the 81 women with a CD4 cell count ≤200 cells/µL who were on ART at 
presentation, the percentage of eligible women who were initiated on ART during pregnancy 
was 46% (n=284/617). There was a significant difference in the proportions of women who 
initiated between the sites (p=0.003): Site 1 initiated 55% of women; Site 2 initiated 38% of 
eligible women and Site 3 initiated 45% of eligible women, respectively. The remaining 333 
(54%) women had no documentation of antenatal ART initiation. Among the women 
initiating ART during pregnancy, 5% of women presenting at Site 1 initiated at another site, 
while 14% of women from Site 2 initiated at a different site and 22% of women from Site 3 
initiated at another site not designated as the referral site.  
5.3.3 Gestational age at first presentation 
The estimated median gestational age at first presentation among all women with a CD4 cell 
count ≤200 cells/µL was 28 weeks (IQR: 24-32 weeks, n=698). After excluding the 81 
women who had already initiated treatment and a further 117 women for whom data could 
not be retrieved, the median gestational age of the remaining 500 women eligible to initiate 
ART, was 26 weeks (IQR: 21-31 weeks), varying significantly between the sites (p<0.001) 
with women from Site 3 presenting at 23 weeks and women from Sites 1 and 2 presenting at 
26 and 27 weeks respectively. Maternal age was not significantly associated with gestational 
age at presentation (p=0.601). 
There was a significant difference in median gestational age at first presentation 











gestational age at presentation among women who were on ART at delivery was 23 weeks, 
compared to 29 weeks for women who were not on ART at delivery (p<0.001;  
 
Table 5.2). Among 164 of 284 women who initiated ART in pregnancy and for whom 
gestational age at antenatal initiation was available, the median gestational age at initiation 
was 31 weeks (IQR: 28-34), which did not vary significantly between the three sites 
(p=0.946). When modelling gestational age at initiation as a continuous variable, no 
significant differences between sites were observed (p=0.967 for Site 2 and p=0.764 for Site 
3, Site 1 as reference).  
5.3.4 Time to treatment initiation 
Half of women starting ART did so within 49 days of presenting at the antenatal service. The 
median time to treatment initiation varied significantly between the three sites (p<0.001), 
with 50% of women at Site 1 initiating within 36 days of presentation, 50% of women 
initiating within 54 days at Site 2 and within 59 days at Site 3 respectively. Across all the sites, 
75% of women had initiated within 9 weeks of presentation. However, the proportions of 
women initiating by 9 weeks after antenatal presentation varied by site. By 9 weeks after 
presentation, Site 1 had initiated 85% of women, while Site 2 had initiated 71% and Site 3 
had initiated 62% of women. Kaplan-Meier estimates of time to treatment (restricted to 
189/284 women with a date of ART initiation and 244/333 censored women who did not 
start ART but who had a recorded delivery date) showed significant differences in time to 
ART between sites (p<0.001, Figure 5.2). Overall, Site 1 initiated 36% of all eligible women 
in the cohort who presented up to 31 weeks gestation (104/284), while Site 2 initiated 27% 
(77/284) and Site 3 initiated 20% (56/284) of these women respectively. After 31 weeks, 











Sites 1 and 2 both initiating 6% of women respectively and Site 3 initiating the remaining 5% 
of women (p=0.435).  
 
 
Figure 5.2 Kaplan-Meier failure estimates of time to treatment in 
pregnancy, 2008 
 
Note:  Among women with CD4≤200 cells/µL (n=433/617) 
 
 
When comparing time to treatment across CD4 cell count percentiles (CD4 cell count ≤100, 
101-169 and ≥170 cells/µL) there was no significant difference in time to treatment 
initiation (p=0.419). A further 20% of women (125/617) who did not receive ART in 
pregnancy went on to initiate up to 3 years postpartum. The median time of initiation after 
delivery was 34 weeks and the time to postpartum initiation was not significantly associated 
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5.3.5 Coverage of ART among women with CD4 cell counts ≤200 cells/µL 
Overall ART coverage (defined as the proportion of women who were on ART by delivery) 
among women with a CD4 cell count ≤200 cells/ µL, was 52% (n=365/698), this comprised 
284 eligible women initiating ART during pregnancy and 81 women who were already on 
ART at first presentation. There was significant variation in coverage between the three sites 
(p=0.001), with 62% coverage at Site 1, 49% coverage at Site 3 and 44% coverage at Site 2, 
reflecting the trend in initiation between the sites. 
5.3.6 Characteristics of women who did and did not initiate ART 
Table 5.3shows that significant bivariable associations were found between ART initiation 
during pregnancy and service delivery model and gestational age at presentation. However, 
maternal age at presentation, gravidity and parity were not significantly associated with 
initiating ART (Table 5.3).  




ART   
Did not 
initiate ART     
   n     n   p-value 
Total number of women (n=617)  284   333   
Median age at presentation (years) 28 283  27 329  0.104 
        
Site 1 (%) 56% 120  44% 95  0.001 
Site 2 (%) 39% 94  61% 153   
Site 3 (%) 45% 70  55% 85   
        
Median gestational age at presentation (weeks) 23 256  29 244  <0.001 
Median gravidity 2 235  2 228  0.752 
Median parity 1 235  1 227  0.315 
 
In a logistic regression model predicting antenatal ART initiation (Table 5.4), women 
who attended Sites 2 and 3 were at most only half as likely to initiate ART in pregnancy 
when compared to women attending Site 1, with the odds of initiating decreasing with each 
service delivery model (Adjusted Odds Ratio (AOR): 0.54, p=0.008 for Site 2 and AOR: 
0.47, p=0.004 for Site 3, respectively). In addition, increasing gestation at first antenatal 











presenting between 25 and 28 weeks’ gestation were less than half as likely to start ART 
compared to women who presented before 20 weeks’ gestation (AOR: 0.42, 95% CI: 0.24-
0.73, p=0.002). Women who presented between 29 and 32 weeks’ gestation were almost 
70% less likely to initiate ART that women who presented in the first 20 weeks of pregnancy 
(AOR: 0.29, 95% CI: 0.16-0.53, p<0.001, Table 5.4).  Women between the ages of 29 and 31 
years were more likely to initiate ART (AOR: 1.91, 95% CI: 1.07-3.38, p=0.027, Table 5.4). 
Table 5.4 Logistic regression showing predictors of ART initiation in 











Service delivery model 
   
 
Site 1 (Integrated) 
 
Reference 
   
 
Site 2 (Proximal) 
 
0.54 0.008 (0.34-0.85) 
 
 
Site 3 (Distal) 
 
0.47 0.004 (0.28-0.79) 
 
       
 
Maternal age 



















1.40 0.228 (0.81-2.40) 
 
       
 
Gestational age at presentation 





























0.05 <0.001 (0.01-0.20) 
              
 
5.4 Discussion 
We evaluated treatment initiation and coverage for HIV-infected pregnant women eligible to 
initiate ART in three public sector antenatal care services in Cape Town during 2008. 
Although overall ART initiation was sub-optimal, these findings suggest that an integrated 











greater degree of separation between antenatal and ART services. Also, women who present 
to services at late gestational age are dramatically less likely to initiate ART before delivery.  
Our evaluation of different approaches to delivering ART in pregnancy demonstrates 
that an integrated approach in this context may lead to the highest percentage of women 
initiating antenatal ART, as reported in another African setting.123 Site 1 demonstrated a 55% 
uptake of ART among pregnant women, and 62% overall treatment coverage through an 
integrated service model, which was significantly better than the other two models both in 
bivariable and multivariable analysis. The ‘proximal’ approach to initiating ART by referring 
women to treatment services within the same complex both had the largest proportion of 
treatment eligible women and the poorest coverage outcome of 44%.  
These findings also show that in spite of service linkages or integration, late antenatal 
presentation is a persistent barrier to timely treatment initiation and optimal ART coverage. 
Our results indicate that women in this setting present for care in pregnancy well into the 
second trimester, decreasing the opportunity for rapid ART initiation. The median 
gestational age at first presentation among ART-eligible women in the 2008 cohort described 
here was 26 weeks, which did not deviate from our 2005 findings.245 Furthermore, women 
who initiated ART in pregnancy presented at services up to six weeks earlier (23 weeks’ 
gestation) than those who did not initiate, underscoring the contribution of late antenatal 
presentation to failed ART coverage. Women who presented after 26 weeks’ gestation were 
significantly less likely to be on ART at delivery. This evidence is consistent with two other 
studies of ART initiation in pregnancy in addition to our 2005 results, where late 
presentation compromised ART uptake.126,127 In an observational study in Botswana which 
reported 37% uptake of ART in pregnancy, it was found that women who presented for 
antenatal care at 20 weeks gestation or more, were less likely to initiate ART.126 Another 
study from South Africa reported that late presentation and subsequent late diagnosis was a 











Pregnancy provides a limited period for ART initiation, and with successful uptake, the 
risk of vertical transmission in utero and the peripartum is decreased with every week of 
antenatal ART.128 Hence it is imperative to initiate women as soon as possible after they have 
been identified for treatment. Our results suggest that the integrated service initiated a higher 
proportion of women more rapidly after first presentation than other models, however, the 
median gestational age at ART initiation (31 weeks) did not vary significantly between the 
three sites. This finding is similar to that found by Killam et al., who reported that while an 
integrated approach increased the percentage of women initiating antenatal, it has little 
influence on time to ART initiation in Zambia.123 This may again underscore the impact of 
late presentation which compromises time to treatment, regardless of service delivery model.  
The superiority of the integrated service delivery model was further confirmed by the 
fact that 95% of ART-eligible women at this site initiated treatment on site, with the balance 
seeking treatment initiation elsewhere. This proportion was lower at the other sites (86% at 
Site 2 and 78% at Site 3), suggesting that with the increasing distance between antenatal and 
ART services, so the choice of referral services may become less important to women and 
possibly factors such as convenience or desire for privacy may come into play. For example, 
a qualitative study from Malawi has suggested that pregnant women have a preference for 
integrated ART services over access to ART in general primary level services where they 
would be required to mix with HIV-infected men and non-pregnant women, as well as those 
with other communicable diseases such as tuberculosis.327 
Since initiating women at CD4 cell counts ≤250 cells/µL was not uniformly carried 
out, our outcome reflects national guideline recommendations in 2008. Overall treatment 
coverage in women with a CD4 cell count of ≤200 cells/ µL was 52%, reflecting a poor 
increase in coverage of 1%, when compared with 2005 coverage results reported 
previously.245 It seems implausible that this sub-optimal coverage can be attributed to a 











services: according to our data, this increase was 2% between 2005 and 2008. In our study, 
few HIV-infected pregnant women presented at antenatal services having already initiated 
ART (11%). It is possible that ART-eligible women are either not being identified or retained 
in care at other primary health care services prior to pregnancy, thus supporting the 
contention that antenatal services provide a crucial gateway to HIV treatment and care.24  
Low ART initiation and coverage among pregnant women in this study may be interpreted 
in light of several factors. First, the psychological wellbeing of newly diagnosed HIV-infected 
women is a neglected area of service provision in this setting.328 While little is known about 
the psychosocial needs of women who are diagnosed HIV-positive in pregnancy and who 
urgently require lifelong ART both for their own health and for the prophylactic benefit to 
their unborn children, we have previously described in qualitative research conducted in this 
setting that women struggle to accept diagnosis and a lifelong commitment to treatment 
within the context of pregnancy.329 Second, it is possible that a healthy physiological status 
during pregnancy has the potential to mask advanced stage disease, resulting in women 
refusing treatment. Furthermore, the impact of haemodilution in pregnancy has been known 
to lead to decreased CD4 cell count, leading to healthier women starting ART at the same 
cut-off as their non-pregnant counterparts.330,331 In a recent study of adults accessing HIV 
testing and treatment services in Johannesburg, 20% refused ART initiation on the grounds 
of ‘feeling healthy’.199 This suggests that supportive efforts may be required to mitigate the 
risk of treatment refusal.  
Finally, the integrated service approach led to the highest proportion of women 
initiated on ART. However, uptake at this service was still sub-optimal. These findings call 
into question the definition of integration, and whether ART services provided by outreach 
doctors based in the antenatal facility once per week are sufficient. Such services illustrate a 











certain days of the week, and task-oriented work which is delivered by different levels of 
health care provider.332  
We found that 20% of eligible women who did not start antenatal ART, initiated 
treatment within 3 years of being identified for initiation in pregnancy. The median initiation 
time of three months among postpartum women could suggest that women are being 
identified through well-baby services when presenting for immunization and PCR testing. 
The high postpartum uptake of ART in this cohort may further support anecdotal evidence 
that service providers, upon identifying women for ART in advanced pregnancy may prefer 
to initiate treatment postpartum out of concern for loss to follow up and poor postpartum 
retention in care, which has been previously associated with women ho are fast tracked 
onto ART during pregnancy in this setting.333 It is also plausible that many women are only 
identified in a subsequent pregnancy for ART, and this possibly required further 
investigation. 
Our results raise concern around the potential increased burden on antenatal services 
to initiate treatment in a greater proportion of women as required by the updated national 
PMTCT guidelines, which require initiation at CD4 cell count thresholds ≤350 cells/ µL.279 
Given the proportion of women presenting with a CD4 cell count ≤350 cells/ µL, antenatal 
services would have needed to ensure coverage in 48% of HIV-infected women should these 
guidelines have applied in 2008. 
The interpretation of these data comes with several limitations.334 The greatest 
limitation of this study is that it is difficult, if not impossible, to attribute causality directly to 
the different service delivery models alone. Unobserved (and unobservable) heterogeneity 
between the models may play a role too. Given our results, this should be a focus of further 
research. This research was conducted in an urban setting with a high prevalence of antenatal 
HIV (16.1% provincial prevalence in 2008),335 and may only be applicable to similar contexts 











Furthermore, these data are from retrospective clinical records and electronic registries and 
hence lack the accuracy and completeness of purposefully collected prospective data. There 
were no significant differences between the proportions of missing data on variables of 
interest from each service delivery model.  
We estimated gestational age at presentation and treatment initiation in women who 
started antenatal ART assuming delivery at 39 weeks in all women, as information on 
estimated due date and gestational age at birth was limited. Hence we may have 
overestimated the gestational age at ART initiation in women who delivered preterm, 
resulting in women initiating ART closer to delivery than deemed optimal in the PMTCT 
guidelines, though it is unlikely that such misclassification could have occurred differentially 
by site. Despite this, our data calibrate well with data from another study in this setting 
which suggest that women presented at 26 weeks gestation and received a median duration 
of 7.6 weeks antenatal therapy. 
With the efficacy of drug regimens for PMTCT well-established, PMTCT programme 
impact is substantially dependent on sufficient infrastructure and the implementation of 
appropriate and effective service delivery models. Evidence of weak linkage between HIV 
prevention and treatment services within the maternal health programmes fuels the 
complexity behind defining optimised approaches to care for pregnant women with 
advanced stage disease.34 Furthermore, it has been shown that the best PMTCT outcomes 
are in women who conceive on ART, suggesting that more needs to be done outside of 
antenatal services to identify women of reproductive age for treatment and to retain them in 
care.127,128 Despite this, specialised management of ART in pregnancy is important in order to 
prevent potential adverse pregnancy outcomes, including teratogenicity associated with the 
use of Efavirenz in the first trimester of pregnancy;336 preterm birth and/or low birth 
weight;337 infant resistance to ART,338 and hepatotoxicity associated with the use of 











supports and disputes the frequency of occurrence of adverse events, there is still a need for 
a continuum of care which extends both pre- and postnatally in HIV-infected women of 
reproductive age.341 Given the separate administration of services, and in some cases, distinct 
funding streams and the capacity of services to deliver specialised training and expertise 
across programmes, this may prove challenging to implement.24 Continued efforts are 
required to ensure that new approaches to increasing early pregnancy presentation and timely 
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Despite the rapid expansion of antiretroviral treatment (ART) programmes, 
uptake of ART in pregnancy remains suboptimal. Little is known about the 
barriers to initiating lifelong ART in pregnancy and the challenges to 
postpartum retention in care, particularly in sub-Saharan African contexts with 
a high burden of disease. In this qualitative study, 28 HIV-positive pregnant or 
postpartum women who had either initiated ART or who were eligible for ART 
and 21 service providers were interviewed to explore the barriers associated 
with initiating ART in pregnancy in Cape Town, South Africa. Prevention of 
vertical transmission was often the primary motivation for starting treatment. 
Key challenges included late first presentation; denial of diagnosis; fear of 
disclosure and treatment side-effects. Women expressed difficulties in 
accepting a lifelong commitment to treatment for maternal health. Pregnant 
women who require ART face a triple burden of transition into pregnancy, HIV 
diagnosis and the urgent requirement to start lifelong ART before delivery. 
Focused interventions are needed to address the psychosocial barriers of ART 












Prevention of mother-to-child transmission of HIV (PMTCT) programmes have long been 
recognised as a gateway to HIV treatment services with pregnancy serving as a crucial period 
to identify and treat HIV-positive women, and to deliver comprehensive care to their 
families. 24,27 The WHO advocates a two-tiered approach to PMTCT programmes in order to 
optimize both infant and maternal health in low- and middle-income settings.44 Lifelong 
antiretroviral therapy (ART) is recommended for women who require treatment for their 
own health, while short course antiretroviral (ARV) prophylaxis is recommended during 
pregnancy, labour and breastfeeding for infected women who do not require treatment for 
their own health.21 The effectiveness of PMTCT programmes, which aim to reduce the 
burden of paediatric HIV and provide treatment and care for HIV-infected women and their 
families, is contingent on comprehensive coverage of HIV-infected women in pregnancy and 
postpartum. This may be achieved through the early identification of HIV-infected women 
in pregnancy, the timely uptake of appropriate ARV interventions before and during 
delivery, continued postpartum follow up of the infant until cessation of breastfeeding and 
retention in care for women on lifelong ART.60  
Considerable progress has been made toward the scaling-up of PMTCT programmes 
in sub-Saharan Africa.14 Yet in this region only 53% of all pregnant women eligible for 
antiretroviral prophylaxis received treatment in 2009, raising concern over sub-optimal 
coverage in pregnancy.15,17 Barriers to PMTCT programme uptake include fear of an HIV-
positive diagnosis and subsequent death; denial, fear of disclosure and stigma, and poor 
emotional support and insufficient counselling.158,342,343 Socioeconomic factors, including 
younger age and lower educational status, as well as the lack of partner support have been 
linked to poor testing uptake and postpartum loss to follow-up.204,344,345 Research into the 











in pregnancy and further informed the models of counselling and treatment preparation used 
in PMTCT programmes.179 Yet, service-related barriers stemming from health system 
weaknesses are still prevalent, amounting to the limited reach of antenatal HIV counselling 
and testing and delays in the return of test results in some settings.23 Continuity of care is 
frequently compromised by the lack of linkage between maternal and child health and HIV 
programmes, leading to poor uptake of ART in pregnancy.24,346 Poor integration of antenatal 
services with ART services is further compounded by the dearth of infrastructure for 
laboratory testing and programme monitoring.34 
Much of the literature on PMTCT effectiveness pertains to programme uptake in 
general and few distinctions are drawn between women who require different regimens 
according to the WHO two-tiered approach in different settings. Little is known about the 
experience of pregnant women who are eligible for ART and the challenges they experience 
regarding initiating lifelong treatment, particularly in developing country contexts where the 
burden of HIV is greatest. One study from Uganda has cited stigma, non-disclosure, as well 
as poor access to services with limited human resources capacity as barriers to ART access in 
pregnancy.198 Yet it is these women with advanced disease who are at greatest risk of vertical 
transmission and mortality, and who stand to benefit the most from rapid initiation of ART 
during pregnancy.119,322,347 
Pregnancy provides a limited period to optimize treatment initiation, and the risk of 
vertical transmission in utero and the peripartum decreases with every week of antenatal 
ART.128 In South Africa, which employs the two-tiered approach to PMTCT programmes, 
guidelines at the time of this study recommended that women with a CD4 count of ≤200 
cells/µL be initiated on ART. While it is imperative for ART-eligible women to be identified 
early in pregnancy in order to provide sufficient time for treatment initiation and to optimize 
treatment efficacy, attrition seems particularly pronounced among women eligible for ART 











lifelong ART during pregnancy in order provide a clearer understanding of the experience of 
South African women with advanced stage disease. 
6.2 Methods 
6.2.1 Study setting 
This study was conducted between August 2007 and March 2008 in four Cape Town public 
sector primary health care facilities as well as two referral hospitals which offered antenatal 
and delivery care and/or ART services for pregnant and postpartum women. A sample of 28 
HIV-positive ART-eligible or ART-initiated pregnant or postpartum women, and 21 health 
care providers was purposively derived using a snowballing technique. The primary author 
worked through clinical staff and support group facilitators to identify participants 
representative of the target group. Participants were considered to be suitable for inclusion if 
they were pregnant or < 6 months postpartum, and if they had either initiated ART in their 
current or most recent pregnancy; or if they were deemed ART-eligible in pregnancy, but 
had not initiated treatment. Service providers were sampled from different antenatal and 
HIV care services attended by the pregnant and postpartum women. Participants were 
sampled to saturation, and fieldwork was concluded once no new data arose from the 
interviews. 
Approval for the study was granted by the Human Research Ethics Committee of the 
University of Cape Town and local government (Appendix 2). The study instrument 
comprised a structured questionnaire with a combination of open and closed questions 
(Appendices 7 and 8). Socio-demographic information relating to pregnancy was also 
requested. Written informed consent was obtained for all participants, and each interview 
lasted approximately 1 hour. One participant and two providers declined to be interviewed 
for reasons of privacy. Participant interviews were conducted in the participant’s mother 











author respectively, both of whom were trained in qualitative techniques. Role plays and a 
pilot of the instrument were undertaken prior to fieldwork. All interviews were digitally 
recorded, transcribed verbatim in the mother tongue and translated into English with the 
assistance of a linguist who worked with a mother tongue speaker to ensure congruence in 
thematic interpretation.  
A thematic content approach was used in analysis. Data from the interviews were 
reviewed and categorised and salient themes were identified from early commencement of 
the fieldwork. A coding scheme was developed from the key themes by the two authors. 
Transcripts were loaded into a qualitative analysis software package (Atlas ti 5.2, Scientific 
Software Developments, Berlin) for text management and coding. Pertinent themes 
concerning barriers to initiating ART in pregnancy were identified and categorised. Verbatim 
quotations were selected if deemed to support the thematic interpretation and represent the 
balance and depth of feeling among the participants. Trends in the data were reviewed and 
consensus was reached between the two authors on the reporting of the themes in the 
results.  
6.3 Results  
Among the 28 women who were interviewed, 17 were pregnant and 11 had delivered in the 
past 6 months. All postpartum women were on ART, while 4 of the 17 pregnant women had 
not yet initiated ART. The mean maternal age was 27 years, and 10 women lived with a 
spouse or partner, 15 women lived with close or extended family and three women lived 
alone. All but 5 women were unemployed. A range of clinicians was interviewed, including 9 
doctors specialising in obstetrics, HIV care or paediatrics, 3 nurses specialising in PMTCT 
care, 3 service managers and 1 HIV counsellor. Different referral patterns were observed 
between antenatal and ART services. Two institutions offered an integrated antenatal and 











week, while other antenatal and ART services were more remote, either housed in a separate 
building on the premises or at a different facility. In all cases, counselling and testing 
protocols comprised an opt-in approach with group counselling, followed by individual 
counselling and testing, with post-test counselling at the first visit. Midwives at the antenatal 
service supplied women with referral letters for treatment initiation at the nearest ART 
service, where they were to be seen by doctors with a specialisation in HIV care. All but one 
antenatal service had an NGO-based lay counsellor presence on site for women enrolling on 
the PMTCT programmes. These lay counsellors assisted women with referral to ART 
services and hosted support groups which covered a range of topics pertinent to antenatal 
and postpartum care for HIV-positive women. 
6.3.1 First presentation in late pregnancy  
Presentation in advanced pregnancy was highlighted by providers as an obstacle to timely 
enrolment of newly diagnosed HIV-positive women on the PMTCT programme, as well as 
referral for, and initiation of, ART. When asked about the optimal time to present for 
antenatal care, all women agreed it was better to present early in pregnancy. Of the 8 women 
who could recall their first visit, timing of the visit ranged between 2 and 8 months, with the 
most common gestational age for first visit being cited to be around 4 months. The 
motivation for coming to services was to check the health of the foetus and to ensure 
registration at the labour ward. Some women suggested a few socio-economic and cultural 
factors which influenced the timing of the first pregnancy visit. Barriers to early presentation 
included unaffordable transport fares and the fear of job loss due to time off work and 
subsequent disclosure of the pregnancy. Hence a personal cost of pregnancy care was 
evident: one respondent mentioned that she was not paid for the hours she took off to 
access antenatal care. Another described how her life had become “really difficult” because 











her child had “run away.” Another woman suggested that ensuring an adequate daily food 
supply took precedence over seeking early pregnancy care.  
Furthermore, providers and women alike described that women perceived the need to 
have evidence of the pregnancy externally visible – to be ‘showing’ – before they went to 
have their pregnancy confirmed at a clinic. One woman explained: 
I think it is because maybe [women] don’t really feel pregnant. They 
want to see that they are really pregnant or not ... If it is your first 
time in pregnancy, you don’t really think you are pregnant. 
(Participant [P] 26, pregnant woman, 31 years) 
Providers felt that women were also more likely to present late in cases of an 
unplanned pregnancy due to denial. One provider mentioned that delays were caused by 
fragmented reproductive health services which offered pregnancy diagnosis and termination 
of pregnancy at primary health care services but not antenatal services themselves. Women 
might go to one facility for a pregnancy test, but take weeks to act on it by booking an 
appointment for antenatal care at a separate service. 
6.3.2 Denial of HIV diagnosis 
Another barrier to swift initiation of ART in pregnancy was the women’s capacity to accept 
their HIV diagnosis and need to start lifelong treatment at the time of accessing antenatal 
care. Many women interviewed had not tested before presenting in pregnancy, and they 
recalled shock and disbelief when being diagnosed HIV-positive. One woman explained: 
I wasn’t aware enough about AIDS, I never thought it was a serious 
disease … I knew there is AIDS, but I never thought deeply about it 
… I never thought that I might be [infected] … There was no need 
to [test] - I was not sick - there were no symptoms. I never thought 
that I could march into the clinic saying, “I’m here for testing.” (P6, 
pregnant woman, 34 years) 
Providers agreed that the most challenging aspect of HIV testing in pregnancy was 











difficulty in acceptance of diagnosis. These factors provided little motivation for initiating 
ART. Women concurred, suggesting that the difficulty associated with acceptance of being 
HIV-infected arose from the fact that frequently there were no visible signs or symptoms of 
disease. One woman described that: 
You see I will believe if could see signs. Here on the body, or if 
something could itch on the body, or if I could vomit or have 
diarrhoea - but I never had any of these things. (P 27, postpartum 
woman, 25 years) 
Providers also believed that women newly diagnosed with HIV struggled to accept an 
HIV-positive diagnosis in the context of antenatal care. They suggested that the impact of an 
HIV-positive test result, in combination with pregnancy and news of advanced stage disease, 
which required swift work up to life long therapy, was too much for some women to 
manage. Providers speculated that this burden was compounded by unplanned pregnancy in 
some cases, although this was not volunteered by any women in the interviews. One service 
provider suggested that: 
With a woman who is diagnosed in pregnancy on account of an 
attendance at antenatal clinic – it is as though she hasn’t really 
thought, “I think I might have HIV and I think I had better go and 
get tested because maybe I’ll need ART.” It hasn’t happened like 
that. She’s pregnant and she’s gone to an antenatal clinic, and 
suddenly someone tells her she’s HIV-positive. She might be very 
well … and suddenly she’s told that she needs ART. So the 
commitment, the buy-in and the person’s belief in the need for ART 
is much less. (Provider [Pr] 19, HIV specialist) 
Denial of illness was an important recurrent theme for providers and women alike. 
One woman reported that after testing HIV-positive at the antenatal service, she retested 
elsewhere because she did not believe the result. Providers felt that women who could not 
accept their status seemed less likely to present at services for ART initiation in pregnancy. 
Providers empathized with their participants, saying that there were too many issues a 











It’s denial, because if they are in denial, they don’t accept that they 
are sick or that they must take this kind of test while pregnant. 
Secondly, when the counsellors counsel them - they tell them, “If 
your CD4 cell count is less than 200 (cells/µl), then you’ll have to 
start ART” - and that it is for life, and then they say, “For life?” 
They cannot take treatment for life. So they would rather not start 
ART if they have to take it for life. So they don’t come back. (Pr 21, 
midwife) 
6.3.3 Disclosure of HIV status 
The time needed to accept and disclose their HIV diagnosis in order to commence treatment 
represented a barrier to ART initiation in pregnancy for many women. Most respondents 
preferred to wait between a week and a month to disclose their HIV status to a partner, 
relative or close friend. Some mentioned that they waited until they had no option but to 
disclose in order to start treatment, while others would return for antenatal follow-up and 
report that they had not found someone to disclose to, or that they were not ready to 
disclose. A service provider noted: 
Disclosure is a huge problem, the only problem usually that keeps 
them from not accessing ARVs. Because when they come, the 
counsellors tell them, “Please bring a treatment partner.” Usually the 
treatment buddy is a partner and then we lose them … They don’t 
come back …They don’t start because of a treatment buddy 
problem. (Pr 15, HIV specialist) 
Internalized stigma was central to the fear of disclosure. Women anticipated that the 
confidant would be “disgusted” and unsupportive, or spread information about their status. 
While most women disclosed their status to a partner, many women chose to disclose first to 
a female relative or friend. Fear of disclosure due to the threat of abandonment was a 
recurrent theme for women in partnerships. Despite this assumption, many women 
subsequently disclosed to their male partners and described that their partners had been 
accepting and emotionally supportive. A woman noted: 
I asked him what was going to happen and he told me that nothing 
was going to happen, that he was not going to get rid of me because 











you have it. That means that I have it, as we are still continuing even 
now.” (P 22, pregnant woman, 24 years) 
For two women, however, partner disclosure resulted in negative consequences 
ranging from derision and disbelief to abandonment. One woman described: 
The father of the child ran away and changed his phone number. 
No one came to see me at the hospital, the person who came to see 
me was his brother-in-law. His family cursed me, saying that I 
brought AIDS to their brother. (P 12, postpartum woman, 30 years) 
6.3.4 Fear of initiating lifelong ART 
All women interviewed were eligible for lifelong ART in pregnancy, and most were started 
on PMTCT regimens while waiting to initiate ART as stipulated by treatment guidelines. For 
some of the women who were on ART, treatment initiation was n t perceived to be difficult; 
they “accepted” that they had to start treatment, and felt “comfortable,” or “happy” in the 
knowledge that they were going to be “protecting” their babies. Other women suggested it 
was difficult to initiate ART because it required a life-long commitment. Particular 
reservation was expressed by those who were asymptomatic. One woman mentioned that 
women who were eligible for short course treatment could envisage treatment as a means to 
an end in pregnancy, whereas lifelong ART post-delivery was harder to justify in the absence 
of physical evidence of disease. Most women felt that they had no choice but to start lifelong 
treatment because they were pregnant and they needed to protect their children. One woman 
explained: 
It was difficult. I got home to the house with them and I had to start 
them. I had never taken any [pills] before that day, it had been my 
way. I am not a person who takes things hard, but then I realized … 
yhuu!! I am very scared about taking pills for my whole life! What 
would I be doing to myself if I didn’t take them? I had to take them 
because I am thinking about that person I am carrying - so then I 












Providers concurred that women found it challenging to accept that they needed to initiate 
lifelong treatment in pregnancy. One provider described: 
She accepted the fact that she was HIV- positive … but for her to 
take ART, especially when she was told that you have to take [it] for 
the rest of your life, she said if it was just for the baby, she would 
have taken it and then just left it afterwards. (Pr 9, midwife) 
The fear associated with ART side-effects was raised as another factor which delayed 
or prevented treatment initiation. Fear was associated with imagined negative consequences 
of treatment, often derived from community perceptions rather than based on fact. A 
woman commented that she would have refused to start ART if she had not been pregnant, 
despite her CD4 cell count being low, due to her concern over side-effects. Her main motive 
for initiating treatment was “to protect my child.” Other women described that they were 
afraid that ART would affect their unborn child or lead to miscarriage. Providers suspected 
that participants who refused treatment might be seeking traditional or religious alternatives. 
They felt that the fear of side-effects was sufficient for some participants to delay treatment 
initiation. One provider noted:  
We find out that sometimes the participant doesn’t even come [to 
the ART service]. They stay with their referral letters at home ... By 
the time they come through it’s already almost too late. “Why didn’t 
you come early?” – “I was afraid of taking the medication, it might 
affect me and my baby,” they say. Then once you explain everything 
to them and the risk they’ve taken by not coming through, they’re 
willing to try afterwards. It’s fear. Most of the participants don’t 
want to start the medication because they fear side-effects, which 
people who have taken the medication have exaggerated. (Pr 20, 
nurse trained in HIV care) 
6.3.5 ART beyond pregnancy and retention in care 
Even though women were motivated to start treatment to benefit their children, by the time 
of the interviews most women who had initiated ART believed that treatment would be 
advantageous to both themselves and their offspring. Women who were taking ART 











and death if they were to stop. One woman mentioned that by taking ART postpartum, she 
was ‘protecting’ herself. Another pregnant woman associated continuing ART with the 
benefit of remaining healthy in order to care for her children: 
It is my problem; my life. I have to be healthy to raise my children. 
I’m concerned about my children. If I’m healthy, my children are 
healthy. (P 6, pregnant woman, 34 years) 
 Providers were more sceptical about postpartum retention in care. They expressed a 
concern that a mother’s care of her infant continued to take precedence over her own health 
and this, combined with poor disclosure and the absence of signs and symptoms of disease, 
was a likely cause of losses in postpartum retention in care among wome  newly initiated on 
ART. 
I found that some people default after they start - they default a 
month later. I don’t think it is service related. Part of it is that they 
don’t need the medication for the baby anymore. They start the 
medication because they want to protect the child, and then they test 
the child; they still feel well because they were well to begin with, so 
they feel that they can actually stop this medication … I still feel that 
they’re not ready to start - to c ntinue for the rest of their lives with 
medication when they’re really feeling well. (Pr 16, HIV specialist) 
6.4 Discussion 
This study highlights several barriers which may prevent or delay initiation of ART in eligible 
pregnant women. First, our research suggests that multiple factors influence a pregnant 
woman’s decision when to present for antenatal care, this often being after the first trimester 
once there is physical evidence supporting a pregnancy. Despite strong utilization of 
institutional antenatal and obstetric care, late first presentation in pregnancy has been 
documented in other South African settings139 and other developing countries144 and has 
been cited as a challenge to PMTCT programme success.127,348 Women in this setting 
perceive antenatal services as a means of ensuring registration for the labour ward, hence 
accessing services closer to the time of birth makes sense to them. Late presentation has also 











Our results suggest that women who screened for HIV in pregnancy frequently felt clinically 
well and found it hard to accept an HIV diagnosis in the absence of signs and symptoms of 
disease. Providers concurred by reporting that women did not expect an HIV-positive 
diagnosis when testing in pregnancy. A woman’s rationale for HIV testing in pregnancy may 
be different to that of a non-pregnant individual voluntarily testing in mainstream HIV 
services, in that the decision to test is commonly made in context of the potential benefits 
accrued to the child.23 Patient perceptions of wellness, despite advanced stage disease have 
been documented elsewhere, where ART initiation has been refused, even after up to 2 
months of counselling, due to reasons of “feeling healthy.” 199 
It is well documented that women undergo severe emotional stress when confronted 
with an HIV-positive test result.179 Furthermore, pregnancy is a life event accompanied by 
hormonal changes, and as with HIV diagnosis, places women at risk of depression.180 
Evidence from sub-Saharan Africa suggests that HIV-positive women suffer greater levels of 
psychological distress than non-infected women during pregnancy 181 and it is possible that 
women who diagnose HIV-positive in pregnancy may be more at risk of depressive and 
somatic illness than women of known HIV-status who become pregnant.182 One South 
African study suggested a high background prevalence of depressive disorders associated 
with unplanned pregnancy and poor socio-economic circumstances in rural women enrolling 
for PMTCT services, regardless of HIV status.183 Thus it is likely that a woman diagnosed 
HIV-positive in pregnancy is faced with a process of complex and pressing decisions when 
she may already be vulnerable to, or experiencing psychological distress. Denial of the need 
for treatment has been shown to be associated with pregnancy, lower educational level and 
greater age, as well as advanced stage disease and poor ART adherence.349 Shock emanating 
from a positive diagnosis frequently arises from feelings of betrayal of a partner.350 
In light of this evidence, we argue that women who are eligible for ART face a triple 











lifelong ART before delivery. In turn, it is plausible that this combination of life events, 
which requires complex psychosocial reorganization and adjustment, may be too 
overwhelming to contemplate, subsequently leading to a lack of acceptance, denial and loss 
to follow up either in pregnancy or postpartum. Denial, a recognized coping mechanism for 
HIV diagnosis in pregnancy,351 was also seen to prevent or delay ART initiation in pregnancy 
in this study. It would seem according to the women and providers that both denial of HIV 
status and fear of committing to lifelong ART in the context of asymptomatic disease could 
be areas of focus for future interventions.  
At the time of this study, disclosure was a widely used psychosocial criterion for ART 
initiation,352 with some treatment services requiring the participation of treatment supporters 
prior to initiation. Disclosure, however, is particularly challenging in the context of 
pregnancy. 147,316Concern about disclosure of HIV status is linked to perceived stigma 
associated with infection. Although disclosure is advocated by both the WHO and CDC as a 
means to decrease anxiety, garner social support and to decrease risk of transmission through 
uptake of preventive interventions and behavioural change,165 evidence suggests that fear of 
abandonment, discrimination and rejection by partners or family members are common 
barriers to disclosure of HIV status in pregnancy. Fear of partner rejection was of particular 
concern to women who were economically dependent on their partners.147 A recent study of 
women from Tshwane, South Africa, portrays women as balancing the risk of abandonment 
with the desire for support and to raise transmission risk awareness within their intimate 
relationships. Few women experienced adversity as a result of disclosure, as has been 
documented elsewhere.147,166 While our study did not examine relationship dynamics with 
intimate partners, nor explore the impact of unplanned or unwanted pregnancy, evidence has 
shown that the decision to disclose in this setting is often based upon the nature of a 
couple’s relationship, and the interplay of dependency and economic factors.317 As illustrated 











women experienced loss of support and emotional abuse as a consequence. The promotion 
of partner testing in antenatal care and linked family-based ART services could address social 
barriers to disclosure and treatment for both pregnant women and their partners.24,204,353 
Our findings suggest that women may need time to accept and disclose their HIV 
status. Given that many women are predisposed to presenting late in pregnancy, delays in 
accepting and disclosing diagnosis may further decrease the window for initiating ART 
before delivery. This points to the need for focused interventions to support HIV-infected 
pregnant women that ensure successful referral and rapid ART initiation. Such interventions 
require a structured approach to address the issues faced by pregnant women, including 
those highlighted here, to strengthen the uptake of ART. For instance, integration of 
antenatal care with ART services can facilitate women’s access to both antenatal and ART 
services during pregnancy.125 Although not fully explored in this study, service integration 
has shown to increase initiation of ART in pregnancy,123 however, late presentation can still 
comprise integrated services by allowing insufficient time for treatment uptake and 
suboptimal treatment duration in pregnant women with advanced disease.127  
Knowing someone who is on ART has been associated with higher uptake of testing 
and treatment adherence in pregnancy,131 and there is preliminary evidence pointing to the 
role of peer-driven support groups for HIV-infected pregnant women facilitating PMTCT 
uptake.354 Other research has shown the benefits of family and group–based psychosocial 
support in assisting HIV-infected pregnant women with adjustment and coping.354,355 These 
models have the potential to complement stretched public health services which frequently 
lack the resources to offer psychosocial care, however, more research is required to identify 
the optimal design and eventual impact of different types of interventions. 
Of note in these findings is the pervasive sentiment among women that any 
antiretroviral intervention started in pregnancy (whether short-course PMTCT or lifelong 











providers’ concerns that women who initiated ART in pregnancy often perceived treatment 
to be episodic and pregnancy-bound. While all the postpartum women interviewed did not 
believe that they would default, providers suggested that women who felt clinically well had 
the greatest potential to be lost to care postpartum because there was no longer an incentive 
to continue with treatment. This assumption may provide insight into existing quantitative 
data from this setting, which suggest that women who initiate ART in pregnancy may be at 
elevated risk of loss to follow-up postpartum.333,334 
A limitation of this study is that only women who were either on ART or waiting to 
initiate ART were interviewed. Hence the views of those who either refused treatment 
initiation or who were lost to follow up are unknown and the experiences of this sub-
population may be different to those of our respondents. Yet the inclusion of providers may 
serve to provide a more holistic view of the challenges faced by all women who access the 
services regardless of treatment status.  
It is possible that women who are identified as ART-eligible and who start treatment 
before pregnancy may be more likely retained in care (compared to women who initiate ART 
only during pregnancy) because the rationale for treatment is not associated with child 
outcomes. The most favourable paediatric outcomes are observed in women who conceive 
once established on ART.4,323 In this case, identifying women of reproductive age, and 
linking them to ART services before they become pregnant and providing strengthened 
preconception screening and care, could dramatically reduce the challenges associated with 
late antenatal presentation.356 
6.5 Conclusion 
This study suggests that HIV-infected women face considerable challenges when initiating 
ART in pregnancy. Major barriers exist for many women concerning coping with a new 











therapy. Although much progress has been made to close the gaps in PMTCT programmes 
across sub-Saharan Africa, services can be further strengthened through interventions that 











Chapter 7  
Paper 5: HIV-infected women’s experiences of pregnancy 
and motherhood in Cape Town, South Africa 
 
Stinson, K., Myer, L. (2012) HIV-infected women’s experiences of pregnancy and 
















Antenatal services provide a valuable opportunity for the uptake of prevention 
of mother-to child transmission (PMTCT) of HIV interventions and antiretroviral 
treatment (ART) for maternal health. While knowledge of HIV status during 
pregnancy is beneficial to both the mother and child, PMTCT programmes may 
focus more on prevention and the physical aspects of health than the 
psychosocial impact of HIV on pregnancy and motherhood. The objective of this 
study was to examine South African women’s perceptions of HIV infection in 
pregnancy and how they related to motherhood in the context of HIV infection. 
In-depth interviews were conducted with 17 HIV-positive pregnant and 11 ≤6 
month postpartum women to elicit perspectives on HIV-positive pregnancy and 
motherhood. For most women who tested in pregnancy, the primary rationale 
for testing stemmed from a concern for their children and anxiety around the 
risk of vertical transmission was highly prevalent. Women did not perceive any 
superficial differences between themselves and non-infected pregnant women 
and they compared HIV to any other chronic condition. However, they voiced 
anxiety about being infected and were preoccupied with keeping their children 
safe, both in pregnancy and postpartum. They described a diminished sense of 
pride about motherhood, and an additional burden of guilt associated with 
carrying a vulnerable child, which made pregnancy different for them in 
comparison to uninfected women. Feeding posed a particularly difficult issue 
because by choosing formula feeding, women were protecting their children, 
yet this seemed to diminish their status as a mother, while at the same time 
publicising messages about being infected with HIV. While women identified 
externally with the social value of motherhood, the burden of HIV infection was 












Across sub-Saharan Africa, antenatal services provide a valuable opportunity for the uptake 
of prevention of mother-to child transmission (PMTCT) of HIV interventions and 
antiretroviral treatment (ART) for maternal health.24 While knowledge of HIV status during 
pregnancy is beneficial to both the mother and child, PMTCT programmes may focus more 
on the clinical benefits of interventions than the psychosocial aspects of HIV diagnosis and 
disease management in pregnancy.318 Women who test HIV-positive during pregnancy may 
not only face emotional adjustment and the simultaneous requirement for treatment 
initiation, they also may experience challenges concerning disclosure, the perceived threat of 
stigma and fear of future disease impact for themselves and their children.179,351,357,358 
Evidence suggests that the psychosocial burden associated with HIV-positive motherhood 
necessitates much work by these women to maintain and protect their maternal identities 
and to preserve maternal and child health.196,197 
 PMTCT programmes comprise a comprehensive strategy that promotes both 
maternal and infant health through the prevention of vertical transmission and the treatment 
of maternal HIV, starting with maternal testing and diagnosis.105 Yet, acceptance of HIV 
testing in pregnancy and the uptake of PMTCT interventions may be motivated more by the 
need to protect the unborn child than the perceived benefit to the mother of knowing her 
status.23,359 It has been documented that many women in sub-Saharan Africa, including 
women in South Africa, present at late gestational age for antenatal care136-140 and there may 
be little time to consider the effect that a lifelong chronic illness may have on motherhood.  
In most parts of Africa, motherhood is highly valued. Childbearing in South African 
society is considered the norm among married and co-habiting couples.184-186 Motherhood is 
laden with social meaning: reproduction is viewed both publically and privately as 











on social connection and acceptance that are shaped by greater political processes.189 Women 
are exposed to paradoxical social messages: while pregnancy is socially desirable and is seen 
to elevate a woman’s status, HIV infection is a stigmatizing condition that may raise a 
punitive social response.190,191 In the context of maternal identity, HIV infection is commonly 
perceived as deviance from the norm.190,191 Previous research has suggested that while faced 
with this paradox, HIV-infected pregnant women, either whose HIV-positive status is 
known prior to pregnancy, or who are diagnosed in pregnancy, may experience a conflict 
between social constructs of motherhood and the stigma associated with HIV infection, 
leading to internalized negative attitudes towards motherhood.192 While HIV-infected 
women experience and internalize stigma, motherhood still remains a priority, and decision-
making processes around pregnancy care and the avoidance of vertical transmission entail 
counterbalancing the social risks of HIV infection with the benefits of motherhood.194  
Despite the public health significance of pregnancy and HIV, little research into their 
intersection with motherhood exists. Few studies have evaluated women’s perceptions of 
HIV-positive motherhood, and much of this evidence describes the experience of women in 
Western countries, where the burden of HIV and the social context of pregnancy differ from 
sub-Saharan Africa.190,316,318,357 While the values assigned to motherhood may be universal, in 
Western societies HIV infection is linked to minorities and is associated with behaviours 
outside of social norms. In contrast, resource-poor contexts experience a higher burden of 
HIV through heterosexual transmission, fuelled by multiple factors including poverty and 
gender power differentials.360 Hence the burden of HIV may impact on women’s perceptions 
of HIV-positive motherhood differently in this setting, compared to the perceptions held by 
their counterparts in resource-rich countries. We investigated the experience of pregnancy 












The objective of this study was to examine South African women’s perceptions of HIV 
infection in pregnancy and how they related to motherhood in the context of HIV infection. 
In-depth interviews were conducted to elicit perspectives on their reaction and coping with 
HIV-positive pregnancy and motherhood.  
Table 7.1 Characteristics of women interviewed, 2007-08 
  
Characteristics  n Interquartile range/% 
 Pregnant  17 61% 
 Postpartum 11 39% 
     
 




     
 Parity    
  No children 6 22% 
  1 child 12 43% 
  2 children 6 22% 
  3 children 2 7% 
  4 children 2 7% 
     
 Lives with   
  Husband/partner/boyfriend 10 36% 
  Parents/other relatives 13 46% 
  Alone 5 18% 
     
 Work    
  Employed 6 22% 
  Unemployed 18 64% 
  Unknown 4 14% 
 
Twenty-eight women who were either pregnant (n=17) or six month’s postpartum (n=11), 
were purposively sampled between August 2007 and March 2008 from four public sector 
primary health clinics and two referral hospitals in Cape Town, which offered either 
antenatal and delivery care or antiretroviral services. Four women tested before pregnancy, 
and one pregnant woman tested before she knew she was pregnant. Four of these women 
tested due to clinical manifestations of opportunistic infections, and one tested due to 
suspicion of disease. At the time of the study, PMTCT guidelines offered antiretroviral 











were on ART. Ten women lived with a spouse or partner and the median age of the women 
was 26 years (Inter Quartile range: 23.5-31.5 years, Table 7.1). 
In this setting, women characteristically present for antenatal care in the second 
trimester, and most antenatal and delivery services are provided by midwives at primary care 
clinics. Prior to the interview, written informed consent was obtained from participants and 
to protect privacy and confidentiality, no names were used or recorded during the interviews. 
Interviews were conducted in the participant’s mother tongue (isiXhosa) and recorded; 
transcribed verbatim and translated into English for analysis (Appendix 7). A thematic 
approach to narrative analysis was applied. This approach seeks to reveal aspects about 
trends existing in a wider social context through the recounting of individual personal 
experience 361. Women’s stories relating to their experiences of testing for HIV both among 
those who tested prior to pregnancy and those who tested during pregnancy, as well as their 
perceptions of motherhood while pregnant or postpartum were conceptually grouped. 
Common themes were compared and interpreted in light of current evidence from PMTCT 
research and theories of motherhood. 
7.3 Results 
7.3.1 Experie ce of HIV testing in pregnancy and perception of HIV 
infection 
In the interview, the 23 women who tested in pregnancy were asked to describe the 
circumstances around their HIV test. Most women tested because they were pregnant and 
they wanted to know their HIV status for the sake of their children. They recalled that they 
had not considered the possibility of HIV infection prior to pregnancy because they did not 
have any disease symptoms and believed that they were not at risk.  
For these women, an HIV-positive test result came as a substantial shock. Some 











rash or diarrhoea, it would have been easier for them to believe that they were infected. 
There was general acknowledgement of the association between HIV, morbidity and death, 
and while some women mentioned that they had no choice but to accept their status, others 
mentioned that acceptance was linked to less anxiety, making treatment initiation easier. A 
respondent reflected that, “After it was explained to me that I mustn’t think I am going to 
die, I just put the thought away; I relaxed and it doesn’t bother me anymore.” Among the 
five women who had tested prior to pregnancy, diagnosis had also come as a shock, with one 
woman suggesting that she had not acknowledged her diagnosis or ‘followed it up’ until she 
was pregnant. With pregnancy, she realised that she had to accept her HIV-positive status in 
order to protect her unborn child. One woman said she tried not to think about HIV when 
she became pregnant and another said that she felt it would have been better if it were her 
alone, and not her unborn child who was exposed to HIV: 
It would be much easier if it was me alone … like trying to fight it, 
to protect the child, it is much more difficult. 
Among both those who tested prior to and during pregnancy, a significant number of 
women drew parallels between HIV and other manageable chronic diseases. HIV infection 
was perceived to be “common” and “the same as other diseases.” One woman remarked: 
It is like other sicknesses and even if you have got it, you can live, 
and a person who hasn’t got it could still die before you from an 
accident. You should not tell yourself that you will die because you 
have it. 
7.3.2 Perception of being pregnant and HIV-infected 
Women were asked to discuss whether they perceived themselves to be different from HIV-
negative pregnant women. Some women drew superficial comparisons, noting that all 
pregnant women “looked the same,” and that “no person can see if you have the virus.” 












It can’t be the same, possibly it could be nice, I don’t know ... There 
is this thing at the back of my mind that I am HIV-infected. Now 
you see [without HIV], I would be living cleanly, just living without 
worrying that maybe I should be taking the pills, I should be going 
to the clinic - those worries would not be there. 
Preoccupation with health status and a personal concern around wellness postpartum 
were also prevalent. Respondents felt that HIV-infected women were not able to make 
“mistakes,” and that they had to take “special care” regarding their health, particularly 
because they were “made sick by something small.” Yet uninfected women could afford to 
be more lenient with their lifestyle choices during pregnancy. A respondent noted that she 
perceived HIV-infected women as “giving birth and then dying.” Even among women who 
viewed HIV as a manageable chronic disease, fear of advanced disease and death resulting in 
orphanhood was an additional emotional burden which set them aside from uninfected 
women in pregnancy. A woman stated. 
If you are pregnant and you don’t have the virus it is nice for you, 
but if you are pregnant and HIV-infected, you think about the child. 
What will happen to the child? You also think again about the 
possibility of getting sick and maybe dying after the delivery, if 
maybe it was really difficult, you see, your child has to grow up 
having been left alone. 
Women also expressed anxiety about the wellbeing of their unborn children. In spite 
of the availability of effective prophylaxis and treatment, they were preoccupied with the fear 
of transmission. A woman remarked, “You see, you cannot be 100 per cent sure that your 
child will not come out with the germ if you have it.” She described that not only did an 
HIV-infected woman have to ensure that she took ART “to protect herself and the baby,” 
but she feared an adverse event during labour could increase transmission risk. Other 
women discussed that they were “always worried” about their unborn children. HIV-infected 












You can still get sick - you the parent. Then the main thing that sits 
on your conscience is that the child should not get infected. It just 
must not get infected, and it must grow well. And me too, I must 
not get sick so that I can look after the child. 
While most women suggested that they were hesitant to initiate lifelong treatment, they 
saw ART as a source of hope to prevent transmission. The prospect of bearing an HIV-free 
child provided the impetus for many to initiate lifelong therapy in pregnancy, although some 
women were also motivated to initiate treatment to preserve their own lives to ensure that 
they would be able to look after their children. 
I didn’t want to start on ART, the reason being that I was afraid. 
Then it was imperative that I start them because my CD4 count was 
low, and the main advice I got was that I should accept myself and 
take the pills … It is fine when they are taken by some other person, 
but when it was going to be me – and that I was going to have to be 
on treatment for my whole life! But there was no doubt that I must 
prepare myself that if they [CD4 cell count] didn’t increase, then I 
would be putting my child in danger and my own life in danger. 
 A postpartum woman mentioned that the fear of having an HIV-infected child was 
the most challenging aspect of her pregnancy. She felt relieved when her infant tested HIV-
negative, and expressed that, “At least I feel I can have a child … in this situation it would be 
hard if I live and the child dies.” One pregnant woman expressed anxiety around child care 
and safety: 
You have to be careful with your hands. Everything you touch you 
must make sure there is no cut ... Like if you were doing something 
and you cut yourself, [you must] immediately find something to 
clean it and cover it - don’t do anything else. So you can’t say you 
know you have a cut and you are bleeding when the baby is busy 
crying. You rush to the baby and although your blood is running, 
you must make sure that you cover that before you touch anything 
and the baby.  
7.3.3  Perceptions of HIV-infection and motherhood 
Most women did not think that their feelings around motherhood had or would be changed 











them when compared to HIV-negative mothers. One woman stated, “I will feel like other 
mothers …I will always be the same mother.” However, while it was believed that 
uninfected women could be “proud” of their pregnancies and motherhood, infected women 
felt “more guilty to bring a new life.” One woman described: 
You don’t feel proud like a normal person you just feel like 30 per 
cent proud. You feel less than a person who is not HIV-infected. 
Women’s perceptions of HIV-related stigma in pregnancy and postpartum were 
mixed. Some believed that people “gossiped” about women who were pregnant and 
infected. Many women, however, felt that their diagnosis was private and not externally 
visible. One woman mentioned that it was easier for women to cope with prevailing social 
attitudes of HIV by coming to terms with the diagnosis, and through this, “You don’t hear 
what other people say, especially if it is negative.” A few women believed that other people 
felt “disappointed” or “ashamed” of women who were HIV-infected and pregnant and that 
HIV-infected women should not have children. 
The complexity of balancing motherhood with HIV infection manifested prominently 
during the postpartum period, primarily around feeding choice. Women were most likely 
assumed to be HIV-infected if they were seen to be formula feeding, yet there was a mixed 
reaction to the perceived stigma associated with this choice. Some women felt that fetching 
formula at the clinic identified women as HIV-infected, while others defended this 
assumption by saying that there were many reasons for women choosing not to breast feed, 
for example, needing to go to work or having another health condition which prevented 
breastfeeding. One woman suggested 
It’s obvious that many people already know now. I don’t know how, 
because for a long time children who cannot breast feed have been 
given formula from the clinic. But now most people just know that 
if you are holding [the formula], it is obvious you are [HIV-]positive. 
I don’t mind because the person who looks down on you perhaps 
does not know her status, and then when she does know, it will be 











Feeding choice was clearly an important aspect of motherhood which made most of the 
respondents feel differently about their identity, with one woman describing it as making her 
feel that motherhood was ‘incomplete.’ One woman described that mothers who breast fed 
could feel ‘proud’ and another mentioned that she was sad that she would never experience 
breastfeeding because she chose to formula feed. Although they wished to breast feed, all 
but one mother reported that they would or did formula feed. Feeding choice was predicated 
on the desire to ensure that the exposed child remained uninfected:  
I will bottle feed because I am not going to do anything else apart 
from protect my child. I am not going to have time for[paying 
attention to] people [who may judge me]…I will be happy because I 
have told myself there is no other way in which I can protect my 
child. I would never forgive myself if I breast fed because I didn’t 
want people to see that I am HIV[-positive], so let them just talk 
and finish.  
7.4 Discussion 
The results of this study show that many women in this setting are motivated to test for HIV 
in pregnancy primarily for the benefit of their children. Most women of unknown HIV 
status prior to pregnancy had not expected a positive HIV result, because they felt physically 
well. Just as the primary rationale for testing in pregnancy stemmed from a concern for their 
children, fears around vertical transmission were foremost. Women who had been diagnosed 
prior to pregnancy shared the same concerns for the wellbeing of their children in spite of 
knowing their HIV status prior to pregnancy. While women did not perceive any superficial 
differences between themselves and uninfected pregnant women and they compared HIV to 
any other chronic condition, they voiced anxiety about being infected and were preoccupied 
with keeping their children safe, both in pregnancy and postpartum. Linked to this was an 
attenuated sense of pride about motherhood, and an additional burden of guilt associated 
with carrying a vulnerable child, which made pregnancy different in comparison to 











women were protecting their children, yet this seemed to diminish their status as a mother, 
while at the same time publicising messages about being HIV-infected.  
These data suggest that while respondents did not feel superficially different from 
uninfected pregnant women and mothers, women believed that uninfected women did not 
experience the pervasive underlying anxiety they associated with being HIV-infected and the 
guilt of an HIV-positive pregnancy. Previous approaches have suggested that social 
representations of HIV-infected women present them as threatening and ‘bad,’ even when 
associated with the positive construct of motherhood.362 Representations of HIV-positive 
motherhood further extend to the social stereotype of the deviant or ‘bad’ mother, a societal 
scapegoat who is identified as one who is unable to or fails to protect her child from harm, 
juxtaposed against the ‘good’ mother who is revered as nurturing and self-sacrificing.193 HIV 
infection and motherhood place a woman in a ‘double-bind’ such that while social 
expectations dictate reproduction, so society condemns HIV-positive motherhood.190,191 
Teetering on the brink of failure while trying to maintain the identity of a ‘good’ mother, 
HIV-infected pregnant women report elevated levels of emotional distress: they envision a 
future threatened by loss through vertical transmission and maternal or child illness and 
death.318,357,358 Through their narratives, respondents hinted at these characteristics of the 
‘good’ mother, who was free of the burdens associated with living with HIV, and who was 
able to take pride in motherhood. Hence while they identified externally with the social value 
of motherhood, these women acknowledged that life as a mother without HIV would have 
been less burdensome. 
Our study shows that the preoccupation with preventing vertical transmission was a 
prevailing mental and physical task. Discourse on experiences of HIV-positive motherhood 
has described a typology of ‘work’ that HIV-infected mothers engage in to preserve their 
identities as ‘good’ mothers as well as to protect their children.195 One previous analysis 











transmission and stigma; they engage in information and accounting ‘work’ to make 
decisions on care and to weigh up benefits and risks associated with illness-related activity. 
Among other types of ‘work’, they manage hope and worry ‘work’ when contemplating the 
impact of HIV on their children.196,197 The emotional aspects of this ‘work’ have also been 
described as ‘defensive mothering’, suggesting the mental effort required to protect against 
discrimination.363 
In our study, women suggested that they were driven to protect their children “under 
any conditions”. In applying the above discourse, ‘work’ to achieve this was undertaken, 
including surveillance and safety ‘work’ in postpartum care. Similar findings have been 
described in a study of women in another African setting, where fear of contagion went so 
far as to alter the daily patterns of infant care.364 As found elsewhere, participants in this 
study also engaged in hope and worry work concerning infant testing outcomes 365 and ART 
was associated with the hope of reduced transmission risk and prolonged life in the absence 
of advanced disease.366 
Choices regarding infant feeding highlighted in the narratives are particularly 
suggestive of the predicament faced by HIV-infected women and the ‘work’ they faced in 
terms of accounting for ben fit and risk and the preservation of positive maternal identity. 
While breastfeeding was aligned with the social representation of the ‘good’ mother, it was 
also seen as a risk for transmission, and women were forced to balance replacement feeding 
interventions to prevent HIV with personal desires and social expectations to breast feed. 
Replacement feeding, while presented as a choice, was more a requirement that sought to 
transform the identity of the ‘bad’ mother to ‘good’ mother, by protecting against vertical 
transmission.191,196 In South Africa where breastfeeding is the cultural norm, the women in 
this study felt set apart from others not so much because they were HIV-infected, but 











Among these women, the duality of the ‘good’ and ‘bad’ mother was maintained privately in 
much of pregnancy, yet it became public postpartum when these women confronted their 
choices about infant feeding. With the introduction of new South African infant feeding 
guidelines which advocate the support of exclusive breastfeeding for the first six months of 
life and extended postpartum maternal and infant prophylaxis regimens.280 It is possible that 
the negotiation of this choice will be easier in future. However, while these interventions are 
evidence-based, little is known of their effectiveness in operational settings, particularly those 
with high seroprevalence and sub-optimal ART coverage.  
While mothers may work to maintain their maternal identity within the context of the 
psychosocial burden of HIV, their illness in conjunction with situational factors has the 
potential to influence the long-term physical and mental health, as well as the social and 
behavioural outcomes of their children.367 The physical health of an HIV-positive mother is 
known to influence child mortality, with children of mothers who have died of AIDS having 
a 3 to 4 fold increased mortality risk, regardless of HIV status.19,20 Compromised maternal 
physical health has also been associated with poorer development of self-concept and higher 
depression risk in children.368 Furthermore, studies from the United States have reported a 
negative relationship between increased maternal stress, poorer parenting skills in HIV-
positive mothers and child problem behaviours.369 Formative evaluations of interventions 
which address the psychosocial stressors of HIV-positive motherhood and enhance 
parenting skills and social support are promising.370 These interventions need to be integrated 
into postpartum PMTCT care in order to address the psychosocial needs of mothers and 
enhance early childhood development. 
Our hypothesis was that while perceptions of motherhood are universal, the 
contrasting epidemiology of HIV in South Africa may have resulted in different perceptions 
of HIV-positive motherhood among the women interviewed in this setting when compared 











themes of deviance and the psychosocial burden of HIV-positive motherhood were 
expressed. Our findings further suggest that like women from other settings,196,197 these 
women also performed much ‘work’ to protect and maintain their maternal identities in the 
context of HIV infection. Hence despite these women describing HIV as a manageable 
disease, more is required to address their psychosocial needs in motherhood.  
Our study has several limitations. First, snowball techniques led to the identification of 
women who were attending services, most of whom had accepted treatment initiation and 
who were part of the PMTCT programme. Hence their perceptions regarding HIV-positive 
motherhood may have been different from those women who were lost to services either 
through their own volition or for reasons of poor access. Our sample was small and from an 
urban setting with established PMTCT services, hence these results may not be generalizable 
to less resourced settings. Furthermore, during our data collection and analysis, we did not 
distinguish between pregnant and postpartum women, and hence we may have overlooked 
potential differences or changes in attitudes towards HIV-positive motherhood between 
these women. We also did not examine the impact of parity on perceptions of motherhood. 
More research is needed into the impact of timing of diagnosis, parity and the changes over 











Chapter 8 — Conclusions 
 
This thesis sought to detail the coverage of the PMTCT programme in Cape Town, both in 
terms of prophylaxis to women who required interventions for prevention, and more 
specifically, to examine ART initiation in pregnant women who required treatment for their 
own health. This thesis also investigated the barriers to ART initiation and women’s 
perspectives on the lived experience of HIV in pregnancy and HIV-positive motherhood. 
Three research projects were undertaken, each of which has covered questions posed at the 
start of this thesis. These questions explored the proportion of women who were identified 
by services as requiring PMTCT interventions, and the coverage of these interventions; the 
uptake of ART among eligible pregnant women; and whether there was a difference in this 
uptake between different models of service delivery. The research questions also focused on 
the barriers to ART initiation, as perceived by HIV-infected women and health care 
providers, and investigated women’s perceptions of HIV-positive pregnancy.  
Prior to this research, little was known of the operational effectiveness of PMTCT 
programmes in Cape Town, and PMTCT coverage estimates were for the most part limited 
to reported routine service data. In particular, qualitative research into the challenges to 
ART initiation and women’s perceptions of HIV diagnosis and initiating ART in pregnancy 
were unknown in this setting. The conclusions here present a synthesis of these findings, 
and put forward the reasons for suboptimal programme coverage in this setting. 











8.1 Summary of findings 
The first research project, set out in Chapter 3, investigated PMTCT programme coverage at 
three delivery sites in Cape Town during 2007-2008, using cord blood surveillance. This 
manuscript provided evidence for suboptimal programme performance in terms of 
coverage, demonstrating that just over half of the women identified as cord blood HIV-
positive received the standard of care (dual therapy or ART), and about three quarters of 
women testing cord blood HIV-positive received some form of ARV. Furthermore, cord 
blood ARV coverage in mothers was significantly lower than the coverage documented in 
routine data. Two reasons for suboptimal coverage were gleaned from this study. First, one 
in five women did not test for HV in pregnancy, 12% of whom had an undocumented HIV-
positive status. As a consequence of not being identified as HIV-infected by the services, 
they did not receive an intervention, which was confirmed by no evidence of ARV coverage 
in the cord blood surveillance. This finding represents a missed opportunity for prevention. 
Second, this study demonstrated that there was a difference between clinical record coverage 
and adherence to ARV regimens according to cord blood surveillance. This occurred even 
when the analyses were restricted to patients who were definitively known to be HIV-
infected. This finding suggests that treatment adherence may be another barrier to coverage 
and hence, may impact on programme effectiveness. Through the use of cord blood 
surveillance, missed opportunities in prevention that would have not have been identified 
with the use of service data alone, were exposed. Similar finding have been reported in other 
settings.371 
Chapters 4 and 5 examined ART initiation in eligible women in selected Cape Town 
clinics in 2005 and 2008 respectively, within the context of different service delivery models. 
Poor coverage was documented in both evaluations, raising concern about the effectiveness 
of PMTCT programmes for women with advanced stage disease. While the 2005 data did 











proportion of women who were on treatment by delivery, the 2008 analysis showed that 
integrating ART within the antenatal service setting was significantly more effective than 
service delivery models demonstrating separate services. It is possible that improvement in 
the integrated model over time reflects early challenges around the co-ordination of ART 
for pregnant women in 2005, where there may have been limited availability of personnel 
and resources to support this approach, as well as subsequent improvements in service 
delivery through the maturation of the programme. These findings support global PMTCT 
strategy which underscores the importance of promoting linkages between services over 
verticalised models. 
In both evaluations, late antenatal presentation was a significant factor influencing 
ART initiation. As evidenced elsewhere, women who presented at earlier gestational age 
were more likely to have initiated ART by delivery. Furthermore, the results suggested that 
women needed time to initiate ART, and many women went on to initiate postpartum. 
While not directly investigated in these two analyses, it is possible that psychosocial barriers 
which were examined in Chapter 6, may have played a role in either treatment refusal or 
delays in initiation.  
The findings in Chapter 6 confirmed that late antenatal presentation compromises 
ART initiation in eligible women, giving limited time for treatment start before delivery. 
These findings which were supported by HIV-infected women and service providers alike, 
suggested that in combination with late presentation, women require time to accept HIV 
diagnosis - this acceptance possibly being compounded by a pre-existing need for 
psychological adjustment to pregnancy itself. Shock and denial are common reactions to 
HIV diagnosis and the findings in this chapter suggested that women who are found to be 
eligible for ART in pregnancy face a triple burden of pregnancy, HIV diagnosis and the 












This chapter also documented further reasons for delayed initiation or treatment refusal 
including the lack of symptoms and signs of disease. This phenomenon has been reported in 
non-pregnant populations elsewhere.199 Fear of partner disclosure was another treatment 
disabler to ART initiation in this study.  
The results in Chapters 5 and 6 both suggest that women’s primary motivation for 
testing for HIV in pregnancy centres around prevention of vertical transmission. This has 
implications for women who require lifelong ART because the motivation for continued 
therapy after delivery may subside. As described in Chapter 6, the preoccupation with 
preventing vertical transmission was translated into psychological ‘work’ for such women, a 
phenomenon documented in resource-rich settings. Furthermore, the findings in Chapter 6 
suggested that HIV-infected women experience the paradox of both “good” and “deviant” 
mothering identities, which contribute to an attenuated sense of maternal pride and an 
additional emotional burden of living with HIV. Adherence to PMTCT interventions were 
challenged particularly in the postpartum period when women were confronted with infant 
feeding choices. 
8.2 Limitations 
Study-specific limitations are discussed in each chapter, and these include the potential 
impact of missing data associated with the use of routine service data. As noted, sensitivity 
analyses showed no significant differences between records with missing data and those 
which were complete, suggesting that missing data were missing at random. Furthermore, 
there are several cross-cutting limitations to this thesis which require mention. First, this 
evaluation specifically focuses on Cape Town services and hence these findings may not be 
wholly generalizable to other settings. As detailed in the literature review in Chapter 2, Cape 











available funding resources led to service expansion which was unique in the early years of 
the programme in South Africa.  
As a result, the challenges to coverage faced in this setting may be different from 
those in other parts of South Africa or the continent. For example, Chapters 4 and 5 which 
cover ART initiation in pregnancy, show high CD4 cell count testing and return of results, 
which has been reported as problematic in other South African settings, for example 
KwaZulu-Natal.372 However, the results from Chapters 6 and 7 which cover the barriers to 
ART initiation and women’s experience of HIV-positive motherhood, share similarities with 
findings in other settings, for example, women’s motivation for ART initiation, their fear of 
stigma and their perceptions of HIV-positive mothering.  
Second, these data are a reflection of the PMTCT programme as it was implemented 
between 2005 and 2008, hence the findings presented in this thesis may be construed as out 
of date. PMTCT programmes undergo rapid change as new evidence from trials and 
observational research becomes available. While protocols are frequently updated, there is a 
recognised implementation lag in these protocols. Despite this, Cape Town has always been 
at the forefront of implementing the most up-to-date interventions. As illustrated in the 
local PMTCT guidelines which were being implemented at the time of data collection for 
Chapters 3, 4 and 5, these services were ahead of the rest of the country in the 
implementation of dual and triple therapy for pregnant women, which came into effect 
nationally in 2008. 
A weakness of this thesis is that it does not evaluate the guidelines implemented in 
2010. As already described in Chapter 2, the latest guidelines incorporate a strong focus on 
earlier ART initiation at higher CD4 cell thresholds and emphasise postpartum interventions 
to prevent breastfeeding transmission. Despite this limitation, the findings from this 
research may well still be applicable regardless of updated guidelines. For example, the 











in Chapter 3 is a challenge independent of guideline change, and requires further 
investigation and intervention. Late antenatal presentation which resulted in a higher risk of 
failed ART initiation in Chapters 4 and 5 remains a pertinent finding, particularly in light of 
the promotion of earlier treatment start for ART-eligible pregnant women, as well as those 
requiring dual therapy from 14 weeks gestation. Since more women will be requiring ART at 
higher CD4 cell count thresholds, a greater volume of women requiring these interventions 
may only serve to exacerbate these existing weaknesses, suggesting the need for further 
evaluation and intervention to ensure optimal programme coverage. 
While from the outset, the aim and scope of this thesis was never to examine 
postpartum services, the papers presented here provide valuable insights into ART initiation 
in this setting which have not been previously documented. Future areas of operations 
research would include evaluations of postpartum maternal adherence to ART and retention 
in care, infant feeding practices and adherence to infant prophylaxis and child outcomes. 
8.3 Recommendations 
The findings in this thesis have provided insight into the reasons influencing sub-optimal 
PMTCT programme coverage in Cape Town antenatal services. Based on this evidence, the 
following recommendations are put forward to improve service coverage. First, on a service 
level, more women need to be identified for PMTCT interventions in pregnancy, in order to 
increase the reach of the programme. Working towards universal testing is an area where 
operational effectiveness could be improved. Modelling exercises have shown that failure to 
achieve near universal testing has a greater impact on vertical transmission than attrition 
further along the PMTCT cascade.129 While repeat testing is advocated in current PMTCT 
guidelines, little is known of the extent of the implementation of repeat testing, or its 
effectiveness. Approaches such as cord blood surveillance could be used to assist in the 











Second, integration of maternal and child health with ART services is critical in improving 
service coverage for women who require ART in pregnancy.132 Novel approaches to 
strengthening the linkages between antenatal and ART services need to be tested at the 
district, regional and national levels to gain insights as to how integration may lead to 
enhanced programme outcomes.373 However, there are several limitations to integration. On 
a service level in many instances these approaches will be incorporated into facilities in 
which fragmentation is already inherent. At district and regional levels, the vertical structure 
of programmes becomes even more apparent through their administration and funding 
streams. 
There is also a lack of a common conceptual framework for service linkage and 
integration, it being understood and implemented in multiple ways within health services.374 
Even services which claim to be integrated are subject to degrees of ‘functional separation,’ 
illustrated by the limited provision of specific services on certain days of the week, or the 
separation of services by consulting room or different service locations.332 This has also 
resulted in negative patient perceptions of ‘segregated’ services for HIV-infected and 
uninfected pregnant women.375  
Furthermore, health services are predominantly task-oriented, and these tasks are 
frequently divided between different service providers, according to specialization and for 
the benefit of streamlined patient flow.332 These features were found to be operating in the 
integrated service delivery model for ART initiation in pregnancy in Chapters 4 and 5. While 
the integrated model supported in-service ART initiation at the antenatal site, this was not 
available every day of the week. Furthermore, it was delivered by specialised doctors who 
had no other involvement in pregnancy care. On both a programme and service level, 
challenges such as these should be closely examined.  
It is also believed that integration may jeopardise existing service operations. This has 











excessive strain on resources and health care providers.376,377 Overloaded services in turn 
may lead to increased patient waiting times and poor quality of care. 367,368 Therefore, feasible 
approaches which allow the development of service linkages are required.  
Task shifting has been identified as a valuable means of broadening the reach of HIV 
treatment and care services, and may potentially smooth over structural challenges inherent 
in vertical services that are driven by task-oriented and specialist practices. Emerging 
research has suggested lay health worker and expert patient programme assistance in 
PMTCT services has increased referral and programme uptake, and provided important 
educational and psychosocial benefit to HIV-positive pregnant women.354,378,379 Decentralised 
delivery models which utilize nurse-initiated management of ART (NIMART) are part of 
the current South African accelerated AIDS plan and have been shown in a pragmatic trial 
to be feasible in this setting.380,381 NIMART may assist the strengthening of integrated 
approaches to antenatal ART initiation and training midwives in NIMART could provide a 
natural extension to the exiting doctor-based initiation model in antenatal services, described 
in Chapters 4 and 5. In Cape Town, NIMART is currently being rolled out through a joint 
partnership between local and provincial health authorities. However, to date primary health 
care clinics, rather than dedicated antenatal services (midwife obstetric units), have been the 
target of this strategy, and the feasibility of training midwives in NIMART at these services 
has yet to be tabled for discussion.382  
Third, continued mobilisation of efforts to implement improved PMTCT 
interventions which have been shown to be effective in resource-rich settings need to be 
embraced at policy level. For example, universal ART provision for all HIV-infected women 
for the duration of pregnancy through breastfeeding cessation is a recent approach which 
has been tabled for resource-constrained settings.13,36 Through universal ART in pregnancy, 











ART may lead to more streamlined services, a model resulting in higher treatment coverage 
and improved effectiveness.  
This ‘test and treat’ approach to initiating all pregnant HIV-infected women on ART, 
through pregnancy and breastfeeding, is outlined as Option B in the current WHO PMTCT 
guidelines,36 and has been proposed for high burden countries with resource challenges, 
particularly where CD4 cell count testing technologies are lacking.13,383 Furthermore, 
“Option B-Plus” is an innovative approach to universal ART which was developed in 
Malawi in 2011. Due to the lack of availability of service infrastructure to perform CD4 cell 
count testing, Malawi places all pregnant HIV-infected women on lifelong ART, as per the 
‘test and treat’ model proposed by Granich et al. 283,384 Option B-Plus promises to improve 
PMTCT coverage in Malawi; eliminate the need for treatment tapering during breastfeeding 
cessation, and minimize the associated risks of viral rebound, and will contribute to 
reductions in heterosexual transmission.385,386 By relaying the simple message that lifelong 
ART is beneficial for the mother, Option B-Plus also addresses the underlying challenge of 
motivation for treatment initiation that is predominantly associated with direct benefits 
during pregnancy. 
The benefits of the Option B ‘test and treat’ approach, however, need to be weighed 
up against the risks of drug resistance, foetal exposure to multiple drugs, the long term 
impact of treatment interruption and the cost.34 While some of these limitations also apply 
to Option B-Plus, resource allocation to, and management of, this approach may be the 
most challenging aspect of this strategy. The application of the ‘test and treat’ approach may 
have different implications in resource-constrained settings where there is a higher HIV 
disease burden, more widespread prevalence of opportunistic infection and a more 
advanced immunological stage at which they occur.387 Furthermore, poorer nutrition and the 
availability of sufficiently resourced maternal and health services which are integrated with 











Nonetheless, this novel approach needs to be explored at both a policy and programme 
level in South Africa, as it would increase programme coverage and accelerate progress 
towards the virtual elimination of paediatric HIV. 
Fourth, HIV-infected women need to be identified timeously for ART. While this 
may be underscored at programme level, more needs to be achieved in terms of 
improvements at the service level for women attending antenatal or HIV care services. Viral 
load is the strongest predictor of vertical transmission40,388 and ART can reduce viral load to 
undetectable levels, hence the timing of ART initiation in pregnancy is an influential factor 
in effective care.389 Early findings from the European Collaborative Study suggested that the 
median time to achievement of undetectable viral load among pregnant women of West 
African origin was 4.4 weeks for women on NVP-based ART and 6 weeks for protease 
inhibitor-based ART. Median time to undetectable viral load in non-African women was 
longer; being 7.1 weeks for women on NVP-based regimens and 9.8 weeks for women on 
PI- based regimens.128 Findings from a recent study in Zambia suggest that women with less 
than 4.4 weeks of ART prior to pregnancy had more than a five-fold increased odds of HIV 
transmission. Regression analyses showed that the additional prophylactic benefit of more 
than 13 weeks of ART was limited.390  
Even if a threshold effect at around 13 weeks of ART is apparent, this threshold 
pertains to vertical transmission risk alone and the consideration of the benefits of 
prolonged ART for maternal health still remain a priority. There is a strong argument for 
identifying women for treatment prior to pregnancy. While fertility is decreased in women 
with advanced stage disease, studies have shown that ART initiation is associated with 
increased fertility intentions in HIV-infected women391 and the incidence of pregnancy 
increases in women who are on ART.392 The most successful paediatric outcomes are 
observed in women who conceive once established on ART. 4,323 Hence, by providing 











reproductive age, and linking them to ART services before they become pregnant, the 
challenges associated with late antenatal presentation could be mitigated.356 This is possible 
given the new evidence supporting highly effective regimen combinations which have the 
potential to be safely utilized by women both during and outside of pregnancy, thus 
sustaining the continuum of care.336 
Recent guidelines have been proposed by the Southern African HIV Clinicians 
Society for conception care in HIV-infected couples. These guidelines underscore the need 
for holistic approaches to the support of decision-making around treatment and conception 
and have the potential to further promote linkages between HIV treatment services and 
maternal and health care.393 Identifying and linking ART-eligible women of reproductive age 
to ART services and providing them with adequate knowledge and psychological support in 
this way would afford them the opportunity to make informed decisions about conception 
and pregnancy. This would reduce the risk of dealing with the triple burden of simultaneous 
HIV diagnosis, pregnancy and the need for lifelong treatment.  
Furthermore preconception ART initiation would decrease the urgency attached to 
initiation in pregnancy and reshape the motivation for initiating lifelong treatment. It is likely 
that women who initiate ART prior to conception would be more ready to acknowledge the 
direct treatment benefits to mothers themselves, before perceiving ART as a means of 
prevention of vertical transmission. This could ameliorate the high losses in postpartum 
retention in care reported in this setting.333 
Fifth, women need more psychosocial support. It has been suggested that HIV-
infected women look to health care providers not only for clinical advice, but for comfort 
and counselling during pregnancy. However, the management of their mental health is 
frequently neglected.328 Evidence from evaluations of peer support group interventions have 
shown improved adherence in pregnant women.394 Again, through task shifting, the 











through support group initiatives run by trained peer counsellors who provide information 
regarding HIV in pregnancy, disclosure, ART and PMTCT regimens and safe infant feeding. 
In some cases, support groups are run by women who are HIV-infected mothers themselves 
and these encounters are enriched through shared personal experience.354 
A support group intervention study in this setting for HIV-infected pregnant women 
showed promising findings, including increased disclosure rates, and improved adaptive and 
coping behaviour during pregnancy and the peripartum. Long term benefit, however, was 
reduced, pointing to the need for the development of more sustained approaches to 
psychosocial interventions over time.395 Support services such as these are commonly the 
result of partnerships between non-governmental organizations and the Department of 
Health. More work towards formalising psychosocial support services for pregnant. HIV-
positive women on a programme level as well as their evaluation in order to inform best 
practice, needs to be done. Furthermore, the promotion of family-based approaches which 
not only provide treatment and care for mothers, but extend services to their partners and 
children, need to be implemented to improve PMTCT outcomes.204,396 
Sixth, ongoing improvements in monitoring and evaluation of PMTCT programmes 
are required in order to measure progress accurately. While surveillance systems such as the 
annual antenatal survey provide useful data on the burden of disease in pregnant women, 
this methodology could be expanded to provide data on treatment needs in this population. 
Furthermore, early infant diagnosis surveys promise to provide data on perinatal 
transmission,252 yet more operational research is required to ascertain the impact of the 2010 
PMTCT guidelines on late postpartum transmission in light of changes to infant feeding 
strategy. Strengthened data collection systems which combine relevant indicator data need to 
be developed, and appropriate staff training needs to be given in the collection and 
interpretation of routine data to ensure completeness and accuracy. Recognition of the value 











achieved through regular feedback of data which could be used for immediate programme 
improvement. Routine data reporting could be supplemented with findings from periodic 
cord blood surveillance to shed light on aspects of the PMTCT cascade not covered by 
routine data. 
Improvement in PMTCT programme coverage cannot be achieved without national 
level leadership and accountability. The role of the National Department of Health in 
ensuring that the latest PMTCT evidence is operationalised through iterative policy change 
and careful spending is crucial in achieving virtual elimination of paediatric HIV. 
8.4 Conclusions 
This thesis demonstrates that, as documented in other low-and middle-income African 
settings, PMTCT service coverage in Cape Town is sub-optimal, and that there are missed 
opportunities for identifying HIV-infected women for PMTCT interventions to prevent 
peripartum transmission. In particular, this thesis shows low uptake of ART in pregnant 
women with advanced stage disease, among whom the greatest gains in prevention could be 
made.  
Political will and the availability of adequate resources, combined with a low burden 
of HIV and a rapid response to the management of maternal infection, gave rise to very low 
rates of MTCT and the virtual elimination of paediatric HIV in developed countries. There 
is no denying that the challenges faced by health services to implementing PMTCT 
programmes in resource-constrained settings are different and more complex, leading to 
many factors which compromise progress towards an HIV-free generation. Yet it has been 
demonstrated that treatment and prevention interventions for pregnant women and their 
children are feasible in developing countries, leading to lives saved and improved health 
outcomes. While it was initially believed that this would not be possible, much ground has 











and ART for pregnant women were implemented. There is no room for complacency and 
continued improvements at policy, programme and service level are required to ensure that 
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Appendix 7 – Chapters 6 and 7 (Patient interview guide 


























































































































































Appendix 8 – Chapters 6 and 7 (Provider interview guide 





























































































Appendix 1 - Chapter 3 (Surveillance form) 
PE3 - SURVEILLANCE FORM Study numbe1 
IPART A) ComD/ete form w/rh a Clue or black pen 
1. Date of delivery QP-O_O 
2 Mother's age (yeatS) 00 
3. GraviditY· CJ 410(11 numtwr of pref"lnclft Ineludln, mit ootI.Itd.n)' pasr jIIllOlrtn .... ",lsc.flUl,..."..DOrtIon$ 
.4 Where dId mother have her first prenatal vlsrt?ONo ANC vilits o This facilitY OOtner 
S. T0\81 number of ANC visits D 
e. Oat. of lasl ANC visit 00-00 - -
7. HIV te.!1 before lhia praanency? OVes, whfl? 00-00 ON. QUnknown - - """'''~SWP'' __ ' 8. Praliious F'e5ult? OPOSIItYe ONeptlve r IM@termlnate 0 Not applicable 
DURING THIS PREGNANCY: 
9 Was mother prates1 counseled fOf HIV? OVes, when? D-P· O_D ON. OUtlltnown 
10.Was HIli tlSt performed? DYes, wnen? 0_0 -D_D ON. OUnknown 
lL If test perform~, HlV lest result QPosIUve ONegallv. Olndetermlnatt! OUnknown 
12. Maternal NVP d1spensed1 OVes ON. QUnknown 
13. p.zr dispensed? OVes, momll.ttned: O_O-O,.p ON. OUnknown 
14. HMRT therapy dlspenaad1 OVes, mOIItII".IUd: 0 0 . D 0 - - ON. OUnknown Staff name Sianatule 
IPART S) 
15 Mode of deHvery:OIJaKinal OCaesarean 
18. Hours aher delivery the mother was dlsch8raed.D 17.Hours IIher delivery the baby was diSchllrgl!'d; D 
18. Not yet dISCharged (tick in the boll) 
D 
19. Old the baby receive AfN prOphylaxIS? O No 20. Reason; 
OMothll1 we. not tested QBaby died or was stillborn 
QMother tested HIV-neI8Uve QBaby wa.!! transferred 
OMoth.r was tllln~"erred QBaby tNP liven In ANC 
Oather 
OV" 21. Number of hours after delIvery D 
22. Whlc:h /oJNs? QNVP only Om only OAlT -t NVP 
001"", 
23. Was mother dlscharaed with replacement feedln&? DYes ONo QUnknOYrn 
24. Birth welgnt of baby (In grams) CJ 
'25.1n case of twins, birth weight of baby 2 {In grarn5)CJ 
SteN name S'ln.lure 











PE4 - LABORATORY TEST 
Study number I 
Lebor.tory facility. 
IPART AI To be filled In by mldwlvas and nurses from malem/tyward 
DSample collected. Date and lime: 011 we, not poaJbr. to collect a simpl • . Tick the primary teason: 
D"'OO-OO-OO . - -
nrn·OO 'OO 
OMaea,.ted stlllbh11'1 (MSB) 
OFresh stJlltMr1h (FSB) 
OCard snllpped I broke 
OBom before arriYai at clinic 
OMother transferred 
QForaO\ to t8ke sample . .. 
Write dele .nd rime sample collected 
on Ihe blood tube 
OSemple spilled/ broke 0 Other reason,lpec/1y: 
Opteeentll/ cord unheatlhy I too thin 
Stiff neme SI.natut. Olle 
[PART 8) To be filled In by 18bOralOt)l Da" .. m ...... "" 0 0 -0 0 -0 0 




ONot done. Reeson:, 081000 clotted Olnsufflc:lent sample QSampielPUIed I broke OCMer reaaon, apeelfy: 
2. Dried Blood Spot sample. Pre~te when Delll,,"'ne lest b positive. 
O Preptsted 
ONat prepared, Reason''-_____________ -------------- -








llberatOf)' staff name _____ ___ _ 
p£~ . tA8OflATORYT£ST FORM . 112.0 23 OCT 01 











Appendix 2 - Chapter 3 (Ethics) 
lJl..'1VERsn"Y OF CAPF. '!OWN , 
09 P~bruary 2007 
REC REF, 038/2007 
Dc D Coeaee 
lIDMM 
Public He1lrh and Fuuih Med.clne 
Fll1mouth Bulldlng. Lcv~1 1 
Health Sciences Faculty 
Research Euuc, Comm,juec 
Roam E52 .. :J,.& GIOOtt Sc:bullr HOlpm.1 Old Main eWldlo: 
Oh.erntocy 7~5 
Td·pIIo_/IIllt_4llII· hubolio.pUrollla"'ll 
.... ,., ........ 'nv.n 
PRO,JnCT TITLE: PMTCl' EJlFECl'IVENESS TN AFBICA: RESEARCH AND LINKAGES TO CARE 
PART1: CORD BLOOD SUR VEl.lJ.ANCE PROTOCOL VERSION LD 
n\ank you ror lubmitacg yQ1.u" .lUdy 10 the: Ra~[cb E.dUc. Committ« (or n:yjew. 
[ have p!euure in infotming you thar the: Elklc$ Commlnu h.as fonnally opprovtd the ~boll'C mcndoaed 
lrudy. 
This IC!.I'\'CI to confitm mu the U,uvcr ... ily of C:apc Town R~Clr(h. Ethies ConlUu(tt:c complies to Ike ethic. 
Suodards fOl CliWcal R.escuch with • 'lew drug in p~cienu. bued an Ihe Mcdu:lll RelQrch Council (MRe. 
SA), Food .nd Drug AdminiJI.r.niQn (FD.\..uSAj, International ConVenuull 00 HlrtrlOnlJillUon Goad Ctwal 
Practice (lCH GCf') And Dccillcunn or Hd5ickl "mJelines. 
The Rese:&rc:h ElhiCJ Cctnnuth:'c gtanuug mi. appronl i. JO compliAnce VoIteh the rCH HtauonUcd Tap.nite 
GuiddiueI E6: Note fOf GUld~ncC' 011 Good Clinl,,1 Pt:l.cticc (CPMP/ICI-f/!lS/9S) ri nd rot\. Code- Federal 
Regutaaon Part SO, 56 lad 312 
PJeau DOrc riul [be ongoing cthk:l.l conducl of the lnld)' temAlns Ihe rcspoo.ibJ1iry or Ihe prinCIpal 
imresog.lIOf. 
Plu.le quote the Me. REF in all yow cOtrcspondeac~ . 
YUUtS siuc.crdy 














.e Illv..,,,,,, CHC 0 """""",MOll 0 
c::::r:=J 
I IS I d I In I "I I 'f 1 y I" '/ I 






.c IINHSlOlllbese U Dele oIliboralory T8It 
Comlnn CO< """" 
f d I II 1111 I m Lv I J I r ! ) I 
o Honn.nQURId 0 
YIN Fm1 d!C1I'I'I)'l! .. ] , I ., j .. 1 
1...Il tl l m l m l " I 'I~ 
Kha)'llilShl (SfIa B) MOU D 
MIMe!'. date 01 buth 
Parily 
GeslaVor.I. (Weeks) 
False Bay Ho!Ipilai o 
I 
EDO ! ,l ldllr l.-,-I ! '/ I .. ] .,I., 1 
PIIMnI receiYes,esuu YIN 
01. .. palief11 ~ .nUII 
Aekmal made YfN 
II vee, data reh,."al nolo 
Khay.~1Sha Slle B (MSF) o 
Weeks gottBlfon ART 1ni1la18d 
S <1\C ni l ni l ·,", I ~ I ,. I ~· I 
hf!H JiC 11 1 I II'! I '! I v I ., I \' I 













o G"OUieUuJ MOU 
Hospital o "'-....... 
I d l d l ml m l v l y l v l yl 
o 
o 
Khayelitaha (Site B) MOU - o 







I d l d l m l ", I , I , I , I , 1 
I I I -I 
HaManc..-~ 
D False Bay HD5pItaJ 
lost 10 follo\lrt up 
















14 Fcb"",,), 2007 
REC REF, 054/2007 
Ms Kl.. Stlll~D 
lDEU 
Appendix 4 - Chapter 4 (Ethics) 
H .t-plth 5(~e:n(''C8 F llCllhy 
Rtseatcb Btbics Comminec 
Room BS2-24 Gtt"'t. Schuur Ho..pi'a1 Old Main Building 
ObsetYaUl')' 7925 
1'c1cphonc [021]4116 63:l8 • !' ..... imilc 1°21" ~06 MIl 
e-maiJ: prc:tW~"UOe.UCT • .l\C.r.a 
Puhlic Health & Flltmly Mediciot: 
DeAr M, StuuOll 
P.RO]BCf TITI.E, AN EVAJ.,UA '[JON 01' DU'I·'BRENT A!'PItOACHES '1'0 THE lNlTlATION 
0 1' ANTIRET.ROVTRAl. THERAPY AMO G H1V-INfflCTEJ) WOMEN O{JRING 
PREGNANCY IN CAPE TOWN 
l'bnnk you (or submitting your $tudf to dlC .Rea~t(;h E lhial Commiu'ee for rtNi~. 
11m prot(lCot U: .pptiyvcd using: lUI exre<lited t<:\-ltw procedure ( .... S CPR46.11 0). 
It U I miuirnAl ri:!k prognmmc:. cvalt.t:LtiQn (catq}Ory 7) of cxUung sc.r.-1a:s (or HN -lr.a:f"ected. womell dl.lriJll?: 
ptegnanq.', Although dlCtf" II:' I smuU risk. or bttKL or confi(k:nrilllity in t~ rtUosf>ecUve componenl or the 
mldy, the ,tudy includes tnel.AU'f:$ ro counter. th.r:eaal to potet')uaJ bteachat. Rc:AC1f'Cb~ will ohwn in(pmiCd 
corucnl frotrl pArticiptulS and ~lth seMen providca. 
l'bia IIClVtIf 10 confirm char [he Univetsity or .pc Town ke:seorm Ethics uJtOJl1Jttee cumpliCl' 1'0 th( Educs 
$1>"''''''' ro, Oinicol Roses".h with • new drug in p"tiools, based 00 ,Il<: Medical R=.rch Council (MIte-
SA)~ Food 000 Drug, Administr'.Ition (IDA-USA)~ ItllWl.tioUN Collvention OD 
lla~n Good CHnit':ll Pnctic:c (lCH GCt» ~Ild Declsr.oltlon of Helsinki l,ouirldint::$, 
111~ Rt'$t'Udl Ethia Committet granting Wi! approval u. in compliance: wu.h tbe JeB Jlstlll)(m.lsed TtiplJ.rtile 
G";e1clines E6. NolC for Gulcbnce on Good O!nical P",etice (CPMP/lO-1/1l5/95) .00 FDA Code F.dera! 
R<gWtion """ SO,.16 Mel 312 
'Pleu".note chat rhc:: ongoing crhkul conduct of tl,C tltlldy 1:t'11'\"in." the l<~(1l,1n:Jbmty O{ Ult. prindpal 
i~t.or, ' 












Appendix 5 - Chapter 5 (Data extraction form) 
PMTcr~ b:tt'lctlon ANC 'old" 'O""d~ QeD Clplure .<NC§ QeD HAAItT o!llalblf! ., H ARvfolMrfound ., H HMRT 
Babv realner' Prj S,by 
ANC $h.. FW code form number 
I H H I I i i Olt!!l· i. i. i. i 0 i9 i N., B' HIY POt elM 0 
Not ttst~ 
On HAAAT I yiN I ? I "~~ I~ I. I. I. I. I. I 1M''''", I I 
PMTCT re,lslD 






Con'~ £USA IMTT"" CD' , I ~ Y N ffi Pos Ne rn IpoIINe'1 Y N I 
OnHAART ~ 
Anttfllg! patient fold., · ANe c.lrd/CRADLE 
RoUtlon.::§ oos 0 Parltv MIo/'IIIIHOI_ T6 Ml!dlCltlon I. I. I. 1.1. I. I c:::J C::=J D I I M ...... Scabl. 
NotH 
SF meuurement VORl!RPIl. tlDt Isvphllll'l Hb ART Y § I I I lem I I c:::J,,~ Rrf\lled H 
lNMP .00 Future contraception ,- ..... -
I. I. I. 1.1. I. I I. I. I. I. I. I. I I - I .... I """ I •• I - I '~-I I I I Oru: 
I,n.,,, r'O! I Gutlbon c:::Jweeks ProtMeml1Jt I .. ~ ....... , 1"1;11" 
Date I~ I. I. I. I. I. I 3 ,0. ..... " '" .. , .... , I 
, 
5 
AnI~.tIi' p.tlvn fold.r . HIV c:Ot.InnlUn,lnd lutln, 'aeotd NOlet 
H'IIUled~ "-lplH INe'llllawl"I1IIIIrioI'offi T'"'"'I I. I. 1.1. I. I I I 1Ie'-- Itltlll IIlqnetICy 1--.14 
Antenltl' padent folder/oth.r · PMTCT ptl)9hyf •• Is/HAART PMTCT I.bour ward rill st., 
In I.bour 
A2T~"·1 I. l- I. I. I. I ~;:,rIYINlll rn Child NVP I Y I N I "" dispensed l~rtH. '" OnHAART~ Ill" I I. I. I. I. I. I I yiN I ' I ChlldAZT I y I N I On HAART st.-I,d ~ 
ARV iltt 
Anlln.tJlI p.tient foider/CRAOl£. Oenvery outcomes .. " NVD ,/5 "'" 51 NN ... W h. I S.1I1M/FI PAWC folftr nr 
D~. I. I. I. I. I. I ~"~§ 1 Twins , 












HMRT Inltlltiott In pnepncy 
AftV Oink dill b ••• 1 ARV p.tl'nt folder 
M.dlal AiHSlIM"t· TR!ATMENT RUURAL Folder number ARVOlnk 
I I I I I I I I I I 
HAAIIT mrtftl ,,,:.,E3 ~:14 I. I. I.l l I WHoD tD4D ..... 
"'I!IItIl~ TI'Im~l"l 1 1'1 ' I OIfmrtT'TlIffi T'f't'm9t_1 ~ Tllllldudt:dj 
, 
I N I 
Courts.II", As .... ",.nt 
"v .. , blldonsnlp rn GrOUlirn eou=1 1 I ' I • I OIcdatellj YIN I I .kt~.IIIIP '''arion 
Ikqroll/Mt Informilioft 
._{ I. I. I. I. I, I -- ffi ~~ffi .-.-.~ ,--..... / Po, I N!l1 
..:0 ,.. ... cYoI, ..... tt··O ,.."'~IIIY·D ~·-D -~~ 
Clnkll ."mm.ry • TIUATM(NT IHlTlAnOH 
=b I. I. 1.1. I. I ~T-~rnk"=Dw~'~O co.O ...... 01 ..... 1 I 
lIeih'".". .toIIV, _.
"". 
Male rKIlrlt wit MOSI Ncenl dWcal/\Bt Nu 
.... 1. L I. U I. I -Ow"',fof)D CDOO"--O 
~I~"D ...... u 
- 1' ...... _ ................. ,,' 
I 
B.by cAnle ('lister or NHLS dltl 'XUlct folder number! I I I I I I I I I Nlm. 











Appendix 6 - Chapter 5 (Ethics) 
UNIVERSITY OF CAPE TOWN , 
09 Jun< 2009 
REC REF: 054 / 2007 
Ms K Stinson 
IDEU 
Public Health & Family Mediane 
Dear Ms Stinson 
Health Sciences Pacuhy 
Research Ethics Comminee 
Room ES2-24 Groote SChUUI Hospital Old Main Building 
Observatory 7925 
Td<pbon< [021J 406 6626 • Facsimil< [021] 406 6411 
e·mail: shuretta.thomas@uCl.llc.%a 
PROJECT TITLE: AN EVALUATION OF DIFfERENT APPROACHES TO THE INITIATION 
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Appendix 7 - Chapters 6 and 7 (Patient interview guide 
and informed consent) 
AD. evaluation o f different approaches to the initiation of antire lroviraJ therapy 
during pregnancy among I-DV-infectt:d women in Cape Town 
INfORME D CONSENT FOR PART ICIPATION IN IN-DEPTH INTERVLBWS - CUNIC 
AITBNDEBS - ENGUSH (ALSO AVAJLABLE IN ISIXHoSA) 
We are from the School of Public Hulth and Family Medicine at the University of Cape 
To'Wtl.. We are collecting informacion abom health services for pregnant women, 
specifically the different experiences pregnant women Mve regarding antenatal Care and 
antirctroviral services. We are inte.rested in finding OUt what poccmial factol'l make it 
difficult for these women to attend these clinics, and their percepoom rogarding the 
services, as Mll as how they believe the services could. be improved. 
This research is pan of a study involving the evaluation of different approaches 
to the initiation of ancir<uovinl therapy among HlV-infected women during prognancy 
in Cape Town. The research ~ being paid for by the Doris Duke Olaritable Foundacion. 
Your participation in this study is volunmry. Whether or not you decide to participate in 
this study will not affect )Our right to, or experience of treatme.nt and care at this or any 
ocher clinic now or in the future. 
11' YOU DECIDE TO PAlITlCIPATE: 
• This will involve you answering and discussing questions put to you by the 
imervieMr. for aboul30 minUtes. 
• All of the informacioo chat)'Ou provide will be kept completely priv.te and 
confidential and will only be vie..d wd used by the research.n on this projeCt-
Health ca~ providers and other attendees at this clinic will not see mis 
inforn:grion. 
• We will record the information using a digital audio- recorder so that ~ bave an 
accurate record of what )UU llilve said. bUL we will never record )Uur name or 
anything chat could be used to identify)'Ou. 
• You have the right to decide not co panicipat:C in the study, to refuse to atlSVJCr 
any specific questions. or to end the intervaew at any time without penalty. 
• The information )1)U provide may help us to improve health services for 
pregnant womell living with f-UV in the Cape To'Ml area.. 
Your participation in this srudywill not involve any risks to you. 
If thero is .nything chat is unclear or if )'OU need funher informacion, please ask us and 











PARTIC U'ANT VOLUNTEER DECl..ARATION 
I have understood that the purpose of the study is [0 inves tigate health services for 
pregnant l-llV-infected women, and to understand specificaJly their experiences of 
receiving antenatal care and antiretroviral therapy in order to inform health care 
improvement 
I have ",ad the .bove informacion, or it bas been ",.d to me. I have bad the opponunity 
to ask questions about it, and any questions that I have asked, have been answered to my 
satisfaction. I consem voluntarily to participate as a subject in this srudyand understand 
that I have the right to withdraw from the srudyat any time without in anyway affecting 
my position as olO attendee at this or any other clinic now or in the future. 
P LEASE IND ICATE YOUR CONSENT WITH YOUR SIGNATURE, OR A TICK IP YOU 
WOULD PREFER. 
Signature of participant volunteer [tick optioruJ] Date 

















An evaluation of different approaches to the Inlliallon of anliretroviral therapy during pregnancy among HIV·inlected 
women In Cape Town 
SOCIO·DEMOGRAPHIC INFORMATION FOR PATIENTS. PREGNANT/POSTPARTUM 
Interview Date l tl l (J lml 'I I 1<1 I , I Interviewer Inltial& [TI 
Interview Site I I 
Antenatal service used I I 
PATIENT INFORMATION 
Age [TIyOllfS 
Patlenl recall of CD4 count I I I I I 
Number 01 children alive [TI 
Number 01 previous pregnancies [TI 
Delivery site 
Details 01 previOUS pregnancleslblrths Any compllcatfons 
FOLDER INFORMATION 
Folder number I I I I I I I I I I 
Date of HIV tesl I I " I 11.1 I I I I I 
C04 count I I I I I 
ART Initiated [TI 
If pregnant If postpartum 
Dale of first boCHdng I I II I I I I I I Deflvery dale of last child I I , I I I I I I I 
Gestational age [TIweeka 
ART REFERRAL 
Referral made [TI 
ART service used I I 
Date of referral I I" I I I I I I I 
If prlgnant 
Gestational age [TIweeks 
QUAUTY OF CARE·RELATED QUESTIONS 
How long did II take you to gal to the clinic Irom your house today? 
What mode of transport do you use to gel to the Clinic today? 











An evaluation oC different approaches to the initiation of antirc.lrovi(al therapy 
during pregn.ancy among HIV-inleclcd women i.1l Cape Town 
INTERVIEW GUIDE - pregnan, women 
GENERAL INFORMATION ADOtlT PAR11ClPANT 
1.1 Could )IOu teU me abou, )IOulSelf? How.re )IOu feeling roday! 
1.2 Where do)'Ou live at presenc? 
11.1 Can}'>u leU me .boUl whore}'>u live. and • little .bout )lOur f.mily life? 
11.1 Have )IOu atwa)' lived here? If no~ what made )IOU move 10 the .re.? 
11.3 TeU me who do)lOu live with, how"",)IOu reLned 10 them, '0 whom "'" 
)IOU dependentl 
1.2.4 How many chikln:n do )IOU have? (How old is the )lOunges, one?) 
1.3 How far .way is the clinic from where )IOU "'" living? 
1.3.1 Howdid)lOu get to the clinic ,oday! 
1.3.2 Can }'>U ,eU me wha, brough, )IOU to the clinic ,oday! 
1.3.3 Who did )IOU come to see ., the clinic roday! 
1.3.4 When )IOu arrived, wha, did )IOu have to do in order to see tha, pelSOn, 
and how long did it a.ke? (Find ou, if re.spondent waited a long time or 
not, pick up any negative msponsC3) 
1.35 Wha, would )IOu be do.ing if )IOu wore not here roday! 
2 KNO~GEANDPERCErnoNsoPHUV 
2.1 I would like '0 ask)lOu abou, )lOur unde,,,andings .nd feelings around I-IlV. 
2.1, t How would you de.scn'be or explain HJV? What does it mean to )'Ou to 
be I-IlV+? 
21 Howdid)lOu find out tha,)IOu ,,,,,,, I-IlV+. can)lOu recall whon and where)lOu 
filS, ~ted for HlVI 
(Find OUte>GIcuy whon - independent of pregnancy/ before or during I .... , 
pregnancy/ at .. tenatal service fIlS, booking?) 
2.2.1 CAn you describe your reasons for deciding to teSu 
21.2 If tested in pregnancy: Would )IOu s.y that the f.ct that)lOu were 
pregnant changed )'Jur view on I-DV testing? 
2.2.3 (If yes. how did being pregnant change )lOur view? Wha, were )lOur 
reasons for testing?) 
2.2.4 (If no. why do }'>u think)lOu "",uId not have ,ested?) 
21.5 If tested in pregnancy: Would )IOu have tested for I-IlV if )IOu wen: not 











3 EXPERIENCE OF vcr AND H rvTBST 
3.1 Did)"u ",«ive p~''''' couseUing/VCf? 






Wha, son 01 things did the counselor mention ro )"u abou, being 
pregnant and getting a positive resuJt before )'Qu [e5ledJ 
Did the counselor mention any imponan, things associ.ted with 
pregnancy and HlV?) 
Who gave )"U )"ur 1eS~ and who gave )"U )"ur result? 
How did )UU get )'Dur result? Was it in private, or ~re there other peoplt 
who Mre present? 
How did the health care provider who gave ~u )'Uur result respond to 
your test result? 
4 UNDERSTANDING AROUND H JV DIAGNOSIS 
4.1 TeU me abou, how i, lelt when )"u gOt )"ur HlV test result 
4.1.1 II tested in p"'gnancy. When)"u gOt )"ur HlV resul~ how did it rnakt 
)"u leel about being p"'gnant? 
4.1.2 II tested outside 01 p"'gnancy. When)"u got )"ur HlV result, bow did 
)"u fee~ 
4. 1.3 When you are diagnosed with J-UV, )'Du are [old your CD4 count.) 
4.2 What do )"U undmtand by the CD4 count? 
42.1 'Wh:lt was it? 
4.2.2 Did the health care provider give )"U )"ur CD4 count? 
5 ExrERlENCE OF POST-TEST COtJNS£UNG 
S. t When you got }'Out result, what information were you given about J1'la.rulging 
HlV and pregnancyrogether? 
5.2 What did they say about treatment and management 01 HlV. espec;'llyduring 
early pregnaocy1 
5.3 Do )"U think it is dill""nt being p"'gnant with HlV. than to jus, being 
pregnant? 
SA What son of questions did )'OU have for the health care provider after you gOt 
)'lut resuJt? 
5.4.1 Did)"u leel comlonable asking the health = provider)"Uf questions? 
5.4.2 Were me questions )UU had ann . .oc.red to your satisfaction? 
6 P ERCErTl ONS ABOUT BEING PREGNANT AND H rv+ 












61 How do pregnant women cope with being HlY+? 
6.3 What is difficult for)"u about being pregnant and HlV+? 
6.4 What are the issues)'Ou have ro consider as an HIV+ woman when you are 
pregnant? 
6.5 Do you see )Our ni!eru as a pregnant"M)man with J-nV as different from the 
needs or other (negative) women who are accessing :1m.enaw care? 
(If~, howl) 
6.6 What do most people think about HlV + womeD being p"'g",nr aod having 
children? 
6.7 What are the rtasons a pregnant 'WOman may decide to test for I-HV? 
6.8 Do)"u think that all p ... gnant women should be tes",d for HIV? (If~, why? If 
no, why not?) 
6.9 How do you think women wouW benefit or noc benefit from testing for I-fiV 
when they are pregnant? 
7 DISCLOSURE AND PAJ,ULY·BASED CAJlE 
7.1 Pregnant women may find it difficult to talk to their partners/ the father of the 
child about their sratus. How do )"U think women feel about disclosing their 
SCUllS in a relationship? 
7.1 Have )'OU disclosed to any person about )Our .u:arus? 
7.3 WhO( would make i, "",i.r to ",u the father?) 
7.3.1 If disclosed to partn.r/ father. how Ius )"ur pann.r/ the father of )"ur 
child .... pond.d to )"ur HlV status? 
7.31 If not disclosed to partn.r/ fath.r. what .... the reasons for not telling 
)"ur partn.r/ the father of )"ur baby? 
7.4 What SOrt of rol. do )"U think a fath.r plays regarding )"ur health and the health 
of )'>Or baby? 
7.4. 1 Do )"U think )"ur partn.r would be prepared to be involved in MY 
treaanem programmes with )'Ou? 
7.41 If no, why DOt? 
7.4.3 If~, why- .xplain 
8 PMTCf 
8.1 Do)"u know of anything a woman can do to prevent her unborn baby from 
g.ning HIV? 










8.2.1 How does PMTCT work? 
8.2.2 Who wid )<>u .bou[ PMTCT, and wIu, things did they ,ayabout it? 
8.3 Who do )<>u think PMTCT ben<filS more - )<>ur child or )<>ulliclf? 
8.3.1 What<'" these benefilS? 
9 RllPERRALAND ART 
9.1 Tell me about )'Our experience of Starting on ART. 
9.1.1 How mmy "",eks p"'gnao' ""')<>U when)<>u 'tarted ART? 
9.2 U woman Ius made the ",ferral: What was it lila: w make the n:ferral? Tell me 







9.2.1 Wha, made the n:femJ bard, orwlu, made iteasy1 
(probe uansport issues, time,location of clinic, qualiryof care at the 
clinic, attirude of ,tafQ 
What was i, like to ,tart ART while being p"'gnant? 
What son of side effects did you have to '9.-tI1'T)' about or not have to 'WOrry about 
during )<>ur pn:gnancy, while being on ART? 
[0 your view, wh;lt do other people think about pregnant ~men who take 
ARY,? 
When)<>u think of other people who.." on ART and an: not p"'gnao~ how do 
)<>U think being on ART differs for )<>u? 
RETENTION IN CARE 
When)<>u have had )<>ur baby, how do )<>U think it will be to can: for)<>uneK 
And your child's needs? 
10.1.1 How will )<>u manage feeding )<>urchild! 
(Explore ideas/ knowledge about bn:ast feeding, formula feeding, mixed 
feeding etc) 
10.2 Would)<>u feci differendyabout motherhood if)<>u ""'n: not HJV+1 
(lf~,ho~ 
10.2.1 How do )<>u think other HJV+ moth ... in)<>ur ,i=oon feci? 
1003 Tell me wIu, i[ is lila: for)<>u to take ""acment n:gularly- at the moment wlut 
an: the most challenging aspeCts of being on ART for)<>o1 (Explore .moun' of 
rime off work, clinic opening hours and days, waicing time" financial burden of 
managing l-UV - transpon costs, v.r.tges lost etc). 











(Explore ability to get to clinic, pill.lJ.king regimens, potential for fee.llng ttain 
with I. new child). Explore idea of ART being perceived III Il "chronic" then-py. 
10,5 What do you think would happen if you stopped taking AR17 
10.6 WMt leads some mothers to not continue with their treatment plan? 
11 QUALITY OF CARE ISSUES - ANTENATAL CARE 
11.1 I want to uk you about your experi~ce of llOten2t:al senrices during your 
prcgnmcy. 
11.2 For whAt reasons do pregnant women book for Intenatal ca.ce? 
(Check if early or late hooker) 
11 .3 Why did you book for ant~atal care when. you did? 
11 ,4 Where do you plan to give hinh? What do you t1uck willlu.ppeo ifrou have 
complications? 
11 .5 What do you imagine your bLrth experience [Q be? Do you think anyone you have 
dC21t with in the ameruH:lll services has treated you differ:cndy because you arc 
H!V+? (WhY. or bowl) 
11 ,6 What do women need Ul order to makc their bt.rth e.xpe.riences better? 
Explorc improvements reguding &.cility, staff support, pain manllgemeo[ 
U QUALITY OF CARE ISSUES - H1V TBST J ART REFERRAL AND TREATMENT 
SERVICE 
12.1 1 want to ask you aboulyour expc.rimces relating to your HlV care, How would 
you describe your treatment by the suafr involved Ul youe HlV test It the 
Ilnten2w clinic? 
12, t.l What sort of belp and ca.r:e did they give you? 
12.1.2 Do you fed they had any Attitudes towarw you and your pregnancy 
which they made clear? (Did they comment on the faCt that you were 
1-OV+ and iI. mother? Wbllt did they say?) 
12.2 Where: do you thlnk the best places are to get ARYs? 
12,2.1 Do you think that women have wues with privacy when they go to get 
their MYs? 
12.2.2 What could be done: to make sUte iI. pregnant woman gets onto ART 
quickly? 
12.2.3 How loog did it me you [0 !Wt AR17 
12.2.4 Did anyone teU you why it is hnport2nt for you to start ART quickly 
when you are pregnant? 
12.3 If you could change for the better the WAy in wrucb the health service provides 











12.3.1 In what w>)' do }'>U think • health service could improve the way they 
offer mothers and children access to ART and other health cart needs? 
Do you have any other comments or suggestions you ~uld like to add] 











An evaluation o f differt:nt approaches to tbt: initiation of antire.troviral therapy 
during pregnancy among HJV· infected wome.n in Cape Town 
INTE RVIE W GUIDE - postpartum women 
1 G ENERAL INFOJU.tATiON ABOtrT PARTICIPANT 
1.1 Could you tell me .bout YOUtSell? How are you feeling today? 
1.2 'Where do you live at present? 
1.2.1 Can you tell me about where you live, and • little abou, your family life? 
1.2.2 HLVe you al .... Y' lived here? II noL, what made you roove to the area! 
1.2.3 Tell me who do you live with, how are you related to them, to whom are 
you dependent? 
1.2.4 How many children do you have? (How old is the youngeSL one?) 
lj How far 3v.oay is the clinic from where)Ou an: living? 
1.3.1 Howdid you get to the clinic today? 
1.3.2 Can you tell me what brought you to the clinic today? 
1.3.3 Who did you come to see at the clinic today? 
1.3.4 When ~u arrived, what did ~u have to do in order to see that person, 
and how long did it ",ir.e? (Find out if respondent wai",d a long ome or 
not. pick up any negative resporu:~) 
1.35 What would you be doing if you ""re not here today? 
2 KNOWLEDGE AND PERCEPTIONS Of HlV 
2.1 I would like to ... k you about yourunde"t2Ddings and fee ling' around HIV. 
2.1.1 How would you describe orexplain I-!IV? What does it mean to you to 
be HIV+! 
2.2 How did you (ind Out that )<'U were HIV +, can )<'U recall when and where you 
fint ",,,,d for HIV? (Find nut e .. cuy when - independent of pregnancy/before 
or during lateSt pregnancy/ at antenatal service first booking?) 
2.2 .1 Can you describe your reasons for decicling to ""t? 
2.2.2 II ""ted in pregnancy: Would you say that the fact tha, you were 
pregnant changed your view on HIV ""ring? 
2.2.3 (If yes, how did being pregnant change your view? What Wt:re )<'ur 
reasons for testing?) 
2.2.4 (If no, why do )<'u think you would no' have testedl) 
2.2.5 If ,ested in pregnancy: Would )<'u have tested for HIV if you ""re no, 
pregnant and had not come to the arHenatlli clinic? 
3 ExPERIENCE OF vcr AND HIV TEST 











3.1.1 If }"" wb;.t was th. cous.lling ~ke - wb.t did the couns.lorsay [0 )'OU 
about being prognant aod fmding Out)'OU are HlV-positiv.? 
3.1.2 Did the counselor mention any importam things associated with 
pregnancy and HIV? 
3.1.3 Who gave )'OU )'Our t.n, and who gave )'OU )'Our result? 
3. t.4 How did )'OU get )Our result? Was it in private, or were there other people 
who '\Jt/tre present? 
3.1.5 Howdid the h.alth care providerwbo gav.)'Ou)'Our .... ult respond to 
your test result? 
4 UNDERSTANDING AROUND HJV DIAGNOSIS 
4.1 Tell me about how it felt when)'Ou got )'Our HlV , .. t resule 
4.1.1 If ~ted in pregnancy: When )'Ou gOt )'Our HlV rtsul~ how did it make 
)'Ou f,,1 about being pregnant? 
4.1.2 If teSeed outside of pregnancy: When )'OU gOt )'Our HlV .... ul~ how did 
)'Ouf.el? 
4.1.3 When )'Ou are diagnosed with HlV, )'Ou are [Old )'OUr 0)4 coune 
4.2 What do)'Ou unde .. tlnd by the Q)4 count? 
4.2.1 What was )'OUI>? 
4.2.2 Did the health care provider give )'OU )'Our 0)4 count? 
5 ExPSRlENCB OF POST·TEST COUNSEUNG 
5.1 When)'Ou gOt your resuJl, what lnIonnacioD ~re)'Ou given about managing 
HlV and pregnancy rogeth.r? 
5.2 What did they say about treatment and management of HIV, especiaUyduring 
early pregnancy? 
5.3 Do)'OU think it ~ different being pregnant with HlV, than [0 just being 
pregnant? 
5.4 Whatson of questions did)'Ou have for the health care provider af .. ,)'Ou got 
your resule? 
5.4.1 Did )'Ou f,,1 comfortable asking the health care provider )'Our quescions? 
5.42 Were the questions you bad answered to your satisfaction? 
6 P ERCEPTIONSABOur BBING PREGNANI' AND HIV+ 
6.1 I would like to ask)'Ou about )Our response to being pregnant as well as being 
HlV+. 
6.2 How do pregaant women cope with being HIV+? 











6.4 What were the issues you had to consider as an J-UV+ M:lnun when)Ou were 
pregnant? 
65 Did )<lU see )<lur needs as a pregnant ""rnan with l-UV as different from the 
needs of orner (negative) women who were accessing antenatal care? 
(If yes, howl) 
6.6 What do most people think aboutl-llV + ""men being pregnant and having 
children? 
6.7 What are the reasons a pregnant 'M>man maydecide to teSt for HJV] 
6.8 Do )<lU think tim all pregnant ""men should be teSted for HIV? (If )"s, wh~ 
If no, why notl) 
6.9 How do )<lU think ""men ""uld benefit or not benefit from ",sting for l-llV 
when they are pregnanu 
7 DISCLOSURE AND PAMILY·8ASED CARE 
7.1 Pregnant ""!Den may find it difficult to talk to their partners/ the f.ther of the 
child about their saws. How do ~u think women feel about disclosing their 
Status in a relationship? 
72 Have )<lu disclosed/"",re )<lU able to disclose/ how easy was illo disclose )<lur 
Starus to the father of )<lur child? 
(What ""uId make it e .. ier to teU the fatheli) 
7.3 If yes, how has )<lur partner/ the father of your baby responded to )<lur l-llV 
starus? 
7.3.1 If no, what are the .... ons for not ",Uing )<>Ut partner/ the f.ther of )<lur 
bab~ 
7.4 What SOrt of role do )<lU think a father pia}' regattling )<lur health and the 
health of )<lur bab~ 
7.4.1 DO)<lu think )<lur partner "",u/d be prepared to be involved in MV 
treattnent programmes 'With )OW 
7.42 (If no, why nou) 
7.4.3 (If yes, why- explain) 
8 PMTCT 
8.1 Do )<lu know of anything. "",man can do to prevent her unborn b.by from 
gerting HlV? 
82 What ""rds do )<lU use to describe it (prompt PMfCf, if necess~ 











8.2.2 Who told )<>u about PMfCf, and what things did they say .bout it? (for 
example, bow does it ""rkJ) 
8J Who do you think PMTel' bene firs more - your cbild or youneU? 
8.3.1 Wha"re these benefi,,? 
9 REFERRAL AND ART 
9.1 Tell me about your experience of sarring on ART. 
9.1.1 How lTWly"",ela of treatment did you get before you gave birth? 
9.2 What was it like to make the referral? Tell me the Slotyof how you MOl from 
the antenatal clink to swting on ART. 
9.2.1 What made the refeml hard, or what made it easr. 
(probe transport ~sues, time, loc,cion of clinic, quality of care at the 
clinic, attitude of stafQ 
9J What was it like to san ART while being pregnant? 
9.4 What son of side effects did you have to wonyabout or not have to worry 
about during your pregnancy, while being on ART? 
9.5 Scigma - in your view, what do other people think .bout pregnant women who 
ake ARV,? 
9.6 When you think of other people who are on ART .nd are not pregnan~ bow do 
)<>U think being on ART diff ... for you? 
10 POSTPARTUM ISSUES AND RETENTION IN CA.R.£ 
10.1 Now thAt you have had your baby, how have you found ltWl2gtng your child's 
own health needs? 
10.1.1 How have )<>u managed feeding your child? (Explore whether breast 
feeding. fonnu" feeding, mixed feeding etc) 
10.2 Would )<>U feel dilferendy about motherhood if)<>u 'M:re not HIV +? 
(If )"$. how) 
10.2.1 Howdo you think other HlV+ mothe" in yoursiruacion feel? 
10J Tell me what it is like for you to tlke treatment regularly- at the moment 
what.re the most chalJenging aspeCts of being on ART for you? 
(Explore amount of rime olf work, clinic opening bour> ,nd days, waiciog 
ci~. fUl2ncw burden of managing I-llV - transpon COSts, wages lost etc). 











(Explore ability to get to clinic, pill-taking regimeru, feeling smin of new 
child) 
(Explore ide. of ART being perceived ... "chronic" therapy) 
105 What do )'>U think would happen a )'>u stopped "'king ARTI 
10.6 What leads some mothers (0 not continue with their treatment plan) 
10.7 What could lead you to not take )'Uur treilUJlem? 
U Q UAl.JTY OP CARE ISSUES -ANTBNATAL CARE 
11.1 I want to ask)Uu about j{)ur experience or ancenatl! services during your 
pregnancy. 
111 For wbat reasons do pregnant women book for antenatal care? 
(01eck if early or Llle booker) 
11.3 Whydid)'>u book for an"Datal care when)'>u did? 
11.4 Where did )'>U give binh? Was it at an MOU, or. secondaty hospital or 
other? 




What was good, wbat was bad, particularly in "rms of the quality of 
service )t)u rec:eive& 
How did )'>U find the staff treated )'>W 
Do )'>U think the labour ward staff, or .ny staff who helped )'>U in 
labour, rrea"d )'>U differently because )'>U "",re HIV +? 
11.6 What do 'lVt)men need in order to make their birth experiences better? 
(Explore improvements regarding facility, staff support, pain management 
12 Q UAUTV OF CARl! ISSUBS- HIVTEST,ART REFEIUW.AND TREATMENT 
SERVICB 
12.1 I M t to ask)'t>u about your experienc~ relating to )'Our J-nV care. How 
would )'>U describe )'>ur "".anent by the staff involved in )'>ut J-DV "" at the 
antenaw clinic.? 
12.1.1 What son of belp and care did they give )'>W 
12.1.2 Do)'>u feel they had anyattiwdes towards)'>U and)'>ur pregnancy 
which they made clearl (Did they COlIllD<nt on the fact that )'>U were 
J-DV + and a mother? what did they say1) 











12.2.1 Do)'Ou think that women have ;,sues with privacy when they go to get 
their ARV,) 
12.2.2 What could be done to make sure a pregnant 'WOman getS OntO ART 
quickly? 
12.2.3 How long did it lake )'Ou to SIan ART? 
12.2.4 Did an)'One ",U)'Ou why it was imponant for)'Ou to ,tin ART quickly 
when )'OU _'" p"'gnantl 
12.3 If )'OU could change for the better the way in which the health service provides 
ARVs, what would )'OU do? 
12.3.1 In what wa)'S do)'Ou think a health service could improve the way they 
offer mothers and children access to ART and other health care needs? 
12.4 How many clinics do )'OU have to attend be"",en )'OutSeif and )'Our baby? 
12.4.1 I-Iowdoes managing your baby's cli.nic v15its. as wdlll5 your own visits, 
impact on )'Our everyday life? 
Do you have any other comments or suggescions )'Ou \Wuld like to add? 











Appendix 8 - Chapters 6 and 7 (Provider interview guide 
and informed consent) 
An evaluation of different approaches to me initiation of antir~troviral therapy 
during pregnancy among HIV·infccled women in Cape Town 
H ealth Care provider - Informed consent 
[ am from the School of Public Health ",d Family Medicine at the University of 
Cape Town. I am coUecting infonnation about health services for pregnant women, 
specifically the different expuiences pregnant women lave regarding antenatal cue t..nd 
antiretroviralservlCe5. This research is pArt of a study involving the evaluatioa of 
different approaches to the initi.don of antiretroviral therapy Ilmong HTV-infected 
women during pregnancy in Cape Town. The project, which is Il joinl initiuive between 
ucr IUld PGWC, is being paid for by the Don. Duke Chui .. ble Foundation. 
Your pamcipatioo in this study is voluntuy. Whether or not you decide to 
parocipate in this study will nOl affect your positloo at this or any other clinic now or in 
the future.. 
I r you decide to participate: 
• This will involve you answeting and discussing questions put ro you by the 
interviewer, for about 45 minutes. 
• AU of the infor:mation t.b.a( you provide will be kept completdy private And 
con6denri.al and will oniy be viewed and used by the researcheu on thts 
projecL Oilier: health care providen III this clinic will not ~e thia 
infODnAtion. 
• 1 will record the infoonatio(l using A digital audio-- recorder so Wt I have 
an accurate record of whAt you bave said, but I will (lever record yow 
marne or anything that could be used to identify you. 
• You have the right to decide DOt to participate in the study, [0 refuse to 
an$Wet any specific questions, or [0 end the interview at any time without 
penalty. 
• The infocmatton you provide may hdp us to improve health services for 
pregnant women living with HIV in the Cape Town area. 
Your participation in this srudy will not involve AOY risks to you. 
If thete is anything that is undar or if you need further infonnatioo, please ask me and I 











Participant volunteer declaration 
I have understood that the purpose of the study is to investigate health services for 
pregnant HlV-infecced M>rTlen, and to understand specifically their experiences of 
receiving antenatal care and anuretroviral therapy in order co inform health care 
irnproveIDtnt. 
r have read the above information, or it has been read to me. r have had the 
opportunity to ask quescioru about it, and anyquescions that I have asked, Iuve been 
aIlS-wered to my satisfaction. J consent voluntarily to participate as a subject in this study 
and understand that I have the right to withdraw from the studyal any time without in 
any way affecting my posicion at lhis or any other clinic now or in the future. 
Please indicate your consent with your signature, or a tick if you would pre fer. 
Signature of participant volunteer [tick optional] Date 




Infectious Disease Epidemiology Unit 
School of Public Health and Family Medicine 
University of up< Town 












Interview Guide - PROVIDERS 
04 February 2008 
1. Service delivery approaches to ART Initiation tor pregnant women 
• To get provider [0 de.scn'be service delivery approaches specific to their clinic seru 
the lines of the PMTGr cascade 
• To elaborate upon approaches in terms of patient care and utilization of staff reso 
1. Can you ",n me about the kind of work you do bere? 
Probe: 
• [n terms of pregnant clients, about bow many do you see per day/ week.> 
H antenatal service provider: 
- explore number> of new bookings, follow ups, gestational age 
- explore experience of late bookers and reasons 'WOme:n give for 
booking lat<. 
• rf ARV servia provider: 
explore number of pregnant women secn as new referrals per 'Wt:ck 
Average gestational age of pregnant wol't"le.n who refer 
What proportion of pregnant "WOmen arrive quite late in pregnancy? 
(Do you see a /0, of women who arrive postJO w.:eks?) 
Proportion of ~men seen as J>05t putUm referr.t1s 
How do pregnant women get to you? (source clinics, process of 
referral) 
• Where do most of )'Our pregnant women come from? (Ie catchment ma ys actual area of 
residence, explore cruuporr.uion issues, or other perceived rnsoru for clinic choice) 
2. Can )Uu describe for me how the servi~ process works for a pregnant 'WOman who comes 
to this facility? 
(If amen.tal: What are the steps she goes through from the fi", booking?) 
(If MV service: What bapp<os when she amves as a referral?) 












Present and explain the cascade, bearing in mind where the service provider slots in and the 
description given above. 
3. I VIOuJd like to hear about )'Our experiences and opinioru of service delivery in terms of the 
Steps of the PMfcr cascade. 
Probe: (probe for good and bad aspoctS of each) 
• Booking for pregnanc;y - Miring time,. tn,.tm<nt by,taff, accurac;y and usefulness of 
booking "'g~ttr and folder information 
• vcr - the role of the counselor, privacy, confidentiality, position of testing room, women 
tested in batches! individually. getting me result. 
• Information systems - processing of teSt results (CD4 counts etc), W2iting times. the 
recording of patient infonnauon and its availability across services (folder, patient cards, daca 
bam) 
• Rdernl process - who ~ ""ponsible for the ",ferraJ, the use (elfecoveness) of ",ferral 
letters, feedback "'garoing successful or unsuccessful refem~ communication belMen 
services and individual providers. 
• The role of NGOs in the vcr. refernl and support process 
• AR. V VIOrk up - issues specific to pregnant wo~n (00 conjunc:rion with tho:;:\: who pre5\:nt 
late - explore how ~ ~ handled by both antena"land l-UV service provide,.,). 
• POSt rucal cart and foUowup, lnf'ant testing and foUowup and retention in care 
on in service provision 
4. As a service provider what influences your ability and comfon in providing a service to 
pregnant women? 
Probe: 
• What kinds of obstacles make it difficuh to manage a pregnant woman who has come for 
re1erra.~ or a woman who refers pOst parnun? 
• How well do}Ou think}OW" orne as a professional ~ used in the job that}Ou are doing? 
• How much time: is spent OD \\Ork unrelated ro immediate needs of patients? 












Role playen in treaonent and care.: explou the tole of the midwife, the l-lIV counselor. 
p:acient advocate the HJV doctor, the HN nutse. the obstetricilln, staff involved in post panu.m 
cue, phumacists 
5. What are your ideas 00 the roles of chffereot service providers in the treatment and care of 
pregnant women with HM 
Probe: 
• What is the oarure of the mulci~disciptinaty team? 
• Wbsu are the benefits and pitfalls of having a mult:i~level/ disciplinuy team? 
• Is there communiClltioo between providus? 
• Could/should anything be done to integrate these roles better? 
• What effect do you thtnk this has on refemals? 
I Chent pe.tspectives 
6. From a client's perspective, what constraints and burien do you think she faces in teans of 
accessing and using these health services, partkMlar!! ill itrml of 1M "ftmll prtK'ln? 
Probe: 
• Fatlwe to establish connection between antenatal and ARV fAcilities 
• Waiting rimes, c.lmic hours 
• Socio~econornic 
• Peaonal/domescic/socia.l problems - disc1oswe, child care, stigtrul, residential area 
2. CUrrent models of care for HIV+ pregnant women 
[ Explore undeatandmgs around PMTCT 
7. What do you think a pregnutt woman WIth HIV needs? 
8. What do you unrlerstnnd to be the underlying purpose of iii PMTCT programme? 
Probe 
• Provider's perception of me. prunuy endpoint (tn2tcrna1 or child health or both) 












• Try to elicit ideas about mono therapy vs triple therapy .. what are the obst:acles; in reality, 
who gets what (women with low cd4 CDUm! aD AZT only etc)? 
10. How do you think PMTCT services rcl.c!.te to ART services llt present? 
Probe 
• AIe there. close connections between these services? 
• How do you think these services should relate to each other, ideally? 
• What steps or interventions are needed to support this? 
t 1. What other interventions do you think would help HIV-positive pregnant women? 
Probe 
• The role of the caesarian in the maoagemeOl of HN -positive patients - in light of Don-
advanced vs advanced diseASe 
• Better access to secondary I tertiary ca.re 
• What steps are followed by health cue WOLken In this facility to provide emotional support, 
infODll about follow up cue, and educate women about PMTCI? 
I Explore upaie.nce lUOund refetn1 for ART and fast - tracking 
12 I'd like to know whA.t iJ currently done about women who present for the firSt time in 
pregnancy. with advanced-stage disease? How do they fit intO the PMTCf model? 
Probe 
• How are HIV-infected pregnwt women who require ART i"iria/iQ" managed 10 this facility? 
• What is the avttllge length of the woLk up and how does this impact on women who refer 
late in pregnancy? 
• AIe there any special steps in place to 'fast track' pregnant women onto ART? 
• How does this wade? 
• How could fast tracking be improved? (M.inimising wne to treAtment) 
• AIe there Any ahon comings in this servtce that you are aware of? 
• Do you think the length oC work up lw any bearing on retention in care for pregnant 
women, or aLe there other factors which may influence retention in care? 













14. What are tbe procedures fot the management of HN~m£ected women already on ART who 
blCDI1I' pregnant? Oe after initiating ART earlier) 
• How does this work? 
• 
I For ART Service Providers: ART delivery 
15. I'd like you to tell me about your e.xperieoc~'5' ptovider in delivering ART to pregnaDl 
women who are ART-eligible. 
Probe 
• In your expeOenc~, what do you think mtke.s ART delivery easy/feasible? 
• Ln your opinion, what are the hurdles to e£fectiv~ ART de1tvery? 
• What do you think is the best way to provide .ART to pregnant women who are e1igibl~? 
I For anterullaJ service ploviders: Seconduy/tertia.ry care 
16. How He pregnancy complicatioN mll!lAg~d in AN-infected women? 
Probe: 
• Could you descri be any experiences you have had regarding referral of women to 
sccondw-y or tertiary level obstetric care. 
• Are there any special s teps in p lace to ensure adequate obstetric care? 
17. Where are the gaps/pitI~ in the management of women wbo present at seconduy/tertia.ry 
level hospitals, and bow do you think things could br. improved in te.nm of case 
management of these women? (Access to metis, access to patient b.istory. role of folders, 
access to caesarian sections, better management of complications etc) 
3, Post-partum Iss ues Ind retention in care 
I Post-pa.rrom issues 
18. What IltC the challenges facing specifically postpllttUlll HIV -posiove mothe.n? 
Probe: 
• What kinds of ba..men prevent women from being rCWned in MV cue once they have 
given bLtth? 












19. Whatu your opinion on infanc fceding? 
20. Wlut ate the £SctOD which influence an HIV-positivc mother's choices OD infant feeding? 
Probe 
• Explore provider's views on the logistics uound breast feedmg. formula feeding etc 
I Retention in care 
21 . In yow: mind. what obstacles prevent women from continuing in cue? 
22. What do you think woclc.s. Or doesn't work in term! of ensuring retention in care during 
p'egruulcyl 
Probe 
• For what kinds of retlons are women loS[ to follow up? 
• What could be done to keep women in care? 
4. Conclusions, suggestions, recommendations 
23. What aspects would you add to health services policy or health system design to 
improve m:uemlLl health and ART ucaunent services? 
Probe 
• Lf this cliruc was given R1m, what would you spend it on to make a difference? 
• if this cli.nic was given RSOOO, what would you spend it on to make a dJfference? 
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